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I.1 Overview on Counterfeit Medicines and related consequences to the 
Public Health 
 
I.1.1 Introduction to poor quality medicines 
 
According to the Cotonou declaration against fake medicines, the criminal economy of 
counterfeit medicines is appalling [1]: 
 
 Because it preys on the poorest countries, and within them, on families with no social 
protection and no financial means; 
 Because it involves drugs that are the most vital to individual and public health: 
treatment for malaria, tuberculosis, and AIDS; 
 Because it has spread everywhere, into street markets, on the internet, and because it 
has developed to the point of becoming almost more profitable than the illegal drug 
trade; 
 Because counterfeit medication does not simply dupe the hopes of the ill; they are 
poisons that often kill or handicap. 
 
Indeed, the presence of poor quality medicines (see definition latter) on the market constitutes 
a harmful threat to the Public Health worldwide and particularly in developing countries 
where drug regulatory systems are often weak and therefore cannot ensure good quality of 
medicines on their territories that can seriously affect the efficacy and safety. On the other 
hand, estimations put counterfeit medicines at more than 10% of the global market, and they 
are present in all regions especially in under-resourced countries where they can reach 30% or 
even more alarming proportions associated to serious consequences such as treatment failures, 
development of drug resistance, adverse effects, mortality and morbidity, economic loss for 
patients, families and even governments, etc. [2-3]. Hence, there is need of developing 
simple, rapid, effective, and affordable analytical tools that can be used in drug quality control 
laboratories and proficiently help in detecting and fighting against the spread of poor quality 
medicines. 
 
The circulation of poor quality medicines constitutes a serious threat to the public health and 
socio-economic life worldwide especially in developing countries where the manufacturing, 
4 
 
 
 
importation, distribution, supply and sales of medicines are less regulated and poorly 
monitored [4-10]. 
 
Moreover, any kind of medicine and medical devices can be and has been counterfeited such 
as expensive lifestyle and anticancer medicines, antibiotics, medicines for hypertension and 
cholesterol-lowering medicines, hormones, steroids and inexpensive generic versions of 
simple pain killers and antihistamines, blood glucose test strips and condoms, etc. In 
developing countries the most disturbing issue is the common availability of counterfeited 
medicines for the treatment of life-threatening conditions such as malaria, tuberculosis and 
HIV/AIDS [4]. 
 
As illustrated in Figure 1, poor quality medicines can be classified into three main categories: 
counterfeit/falsified, substandard, and degraded medicines [5]. 
 
 
Figure 1 Categorization of poor quality medicines (adapted from Paul N. Newton et al.) 
 
Note: There could be grey areas between all three main types. For example, both substandard 
medicines and counterfeits can degrade after manufacture; and not all counterfeit 
medicines are out-of-specifications of the required quality standards as there are 
counterfeit organizations that have sophisticated production capacities for 
manufacturing products and labeling strikingly similar to the authentic products [5-6].  
 
Counterfeit / 
Falsified
SubstandardDegraded
Counterfeit that are “true 
copies” of a given medicine 
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The category of “counterfeit or falsified” medicines is defined as products deliberately and 
fraudulently produced without any regard to regulatory and public health concerns.  
 
The category of “Substandard medicines” also called out-of-specification (OOS) products are 
genuine medicines produced by manufacturers authorized by the NMRA which do not meet 
quality specifications set for them by national standards. 
 
The category of “Degraded medicines” sometimes associated with substandard is for those 
which are spoiled and lost their original quality due to poor handling (storage conditions) or 
expiration.  
 
Hence, from the above definitions, poor quality medicines may include [4; 9]: 
 
1. Products containing correct or wrong ingredients;  
2. Products containing overdose, low dose or no active ingredients; 
3. Products with fake packaging and labelling;  
4. Products with poor stability; 
5. Products with unsatisfactory dissolution profiles; 
6. Expired medicines relabeled with the purpose to extend the shelf-life;  
7. Products without the name and address of the manufacturer;  
8. Expired products;  
9. Products with no expiry date;  
10. Products affected by chemical or microbial contaminations containing higher level of 
impurities, microorganisms, etc. 
 
On the other hand, the World Health Organization (WHO) defines counterfeit medicines as 
the “one which is deliberately and fraudulently mislabeled with respect to identity and/or 
source. Counterfeiting can apply to both branded and generic products and counterfeit 
products may include products with the correct ingredients or with the wrong ingredients, 
without active ingredients, with insufficient active ingredients or with fake packaging” [7]. 
 
Note that the WHO has updated in May 2017 the name of “substandard and falsified” (SF) 
medical products that will be used for what had been previously known as 
“substandard/spurious/falsely-labelled/falsified/counterfeit (SSFFC)” medical products. The 
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WHO also agreed a definition of “unregistered or unlicensed medical products”. These have 
not been assessed or approved by the relevant national or regional regulatory authority for the 
market in which they are marketed, distributed or used [8]. 
 
The new terminology aims to establish a common understanding of what is meant by 
substandard and falsified medical products and to facilitate a more thorough and accurate 
comparison and analysis of data. It focuses solely on the public health implications of 
substandard and falsified products, and does not cover the protection of intellectual property 
rights.  
 
I.1.2 Factors facilitating pharmaceutical counterfeiting 
 
Easy Money is the main driver for counterfeiters as the manufacturing costs are very low in 
clandestine places where no quality and safety standards are respected. Then, a variety of 
factors make drug counterfeiting possible [4; 7]: 
 
o Thirst for easy money is the main driver for counterfeiters as manufacturing costs are 
very low for them due to non-respect of quality and safety standards; 
 
o Inadequate legislation, regulations and enforcement result in supply systems 
vulnerable to counterfeit products and extremely low capacity to uncover and punish 
counterfeiters; 
 
o Ineffective cooperation among stakeholders: health authorities, customs, police, 
industry and trade should establish effective cooperation and exchange of information 
in order to detect and stop counterfeiters; 
 
o Lack of awareness: ignorance of the risks of counterfeit medicines among health 
professionals and patients hinders detection and reporting, even when patients face 
treatment failure or adverse reactions; 
 
o Costs of medical products: the costs of legitimate medicines (both original and 
generics) may be too high for patients, and the later unable to afford the costs of 
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legitimate medicines can take high risk to go for cheaper medications in unregulated 
markets such as street markets or the Internet; 
 
o Lack of political will: in some countries authorities are not prepared to recognize the 
existence of the problem or to pursue counterfeiters if there is inadequate appreciation 
of  the public health value of medical products compared to considerations of export 
interests; 
 
o Weak penal sanctions: absence of or lenient penal sanctions for violations of drugs 
legislation may encourage counterfeiting; 
 
o Corruption and conflicts of interest may adversely affect the efficiency of drug 
regulatory authority and law enforcement personnel, resulting in a failure to arrest, 
prosecute and convict those responsible for counterfeiting;  
 
o Transactions involving many intermediaries increase opportunities for 
counterfeiters to infiltrate the regulated distribution system; 
 
o Lack of regulation by exporting countries and within free trade zones: 
Pharmaceuticals made “For Export” (sometimes labelled “For Export Only”) are often 
not regulated by exporting countries to the same standards as those produced for 
domestic use. In addition, pharmaceuticals are sometimes exported through free trade 
zones where drug control is negligent and where repackaging and relabeling take 
place; this can facilitate trade in counterfeit medicines. 
 
I.1.3 Extent of poor quality medicines 
 
It is difficult to obtain precise figures on the extent of counterfeit medicines due to the lack of 
sufficient data across the World. The United States Food and Drug Administration estimates 
that counterfeit medicines represent about 10% of the global pharmaceutical market, while 
many developing countries of Africa, parts of Asia, and parts of Latin America have areas 
where more than 30% of the medicines on sale can be counterfeit [2-3; 10].  
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The map in Figure 2 shows the global repartition of counterfeit medicines as per Sanofi-
Aventis (2008) [11] and the status of the problem is still illustrative for nowadays, while 
Figure 3 illustrates the geographical breakdown of pharmaceutical crime incidents in 2015. 
  
 
Figure 2 Global Repartition of Counterfeit Medicines 
Source: Sanofi-Aventis (2008) [10] 
 
 
 
Figure 3 Geographical breakdown of pharmaceutical crime incidents in 2015 
Source: Pharmaceutical Security Institute, 2016 [11] 
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Note: An incident means that a region has been identified as the origin, point of seizure or 
transit, or destination of illegal pharmaceuticals, and one can notice that counterfeit 
medicines are everywhere in the world. However, note that having recorded few 
incidents in Africa, Middle East and Eurasia do not mean that those regions are the 
ones having fewer counterfeit/falsified products, but having simply fewer reported 
cases. 
 
I.1.4 Consequences of poor quality medicines 
 
The use of poor quality medicines can be harmful to the population at both medical and socio-
economic aspects through therapeutic failures, drug resistance, loss of efficacy, adverse 
effects, loss of confidence in health systems and health workers, increased mortality and 
morbidity, infringement of intellectual property rights, economic loss for patients/their 
families/health systems/producers and traders of genuine products, etc. [2; 4; 6-8].  
 
Moreover, note that in most cases, counterfeit drugs are not equivalent in quality, safety and 
efficacy to their genuine counterparts. Even if they seem to be of correct quality or contain the 
correct amount of active ingredients, their production and distribution are not within the 
purview of the drug regulatory authority of the country concerned. This means that any 
associated defects and adverse reactions will not be easily recognized or monitored and, if 
needed, an effective product recall would not be possible [7]. 
 
I.2 Overview on medicines Quality Assurance in Rwanda 
 
I.2.1 Country profile 
 
Rwanda is located in the Central / Eastern Africa at 1,200 km from the Indian Ocean to the 
East and 2,000 km from the Atlantic Ocean to the West. The surface area of 26,338 km
2
 is 
930 km bordered by Uganda to the North with 172 km of border length, Tanzania to the East 
with 222 km border length, the Democratic Republic of the Congo (DRC) to the West with 
221 km border length, and Burundi to the South with 315 km border length as shown in the 
country map (Figure 4), and some other useful information are given in Table 1 [12-16].  
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Figure 4 Map of Rwanda 
Source: World Health Organization [12] 
 
Table 1 Useful data on Rwanda 
Indicators  Statistics (2013) 
[15] 
Latest (May 2018) 
[16] 
Population 11,777,000 12,501,156 
Population density (people / km
2
) 447 507 
Population aged under 15 years (%) 43 - 
Population aged over 60 years (%) 4 - 
Median age (years) 18 19.6 
Population living in urban areas (%) 27 34.0 
Total fertility rate (per woman) 4.5 4.1 
Population growth rate (average annual %) - 2.4 
Life expectancy                At birth 
                                          At age 60 
                                          Females 
                                          Males 
65 
18 
- 
- 
- 
- 
69.3
*
 
66.0
*
 
World bank income classification Low  - 
 
* Year: 2016 (cf. Reference [17])  
 
On the other hand, according to the Institute for Health Metrics and Evaluation (IHME, 
Seattle, Washington / USA), the top 10 causes of disability and death combined commonly 
known as disability-adjusted life years (DALYs) for Rwanda in 2016 are shown in Figure 5 
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where we can notice that Malaria and HIV/AIDS epidemics are respectively 5
th
 and 6
th
 in the 
ranking [17]; and related medicines were selected for study in the frame of this thesis.  
 
To understand the figure, a DALY can be thought of as “one lost year of a healthy life”, and 
DALYs are used as unit of measurement that combines information about morbidity and 
mortality. For example, ten DALYs correspond to ten lost years of healthy life, attributable to 
morbidity, mortality, or both. Then, DALYs for a disease or health condition are calculated as 
the sum of the Years of Life Lost (YLL) due to premature mortality in the population and the 
Years Lost due to Disability (YLD) for people living with the health condition or its 
consequences [18-19]. In the figure, the red bars indicate the level of percent changes between 
2005 and 2016 per disease; and the negative levels such as -10%, -30%, -50%, etc. indicate 
that the disability-adjusted life years have decreased at those levels, often due to the 
improvement of existing health programs in disease control and prevention, while positive 
changes such as 10%, 20%, 30%, etc. indicate the increase of DALYs due to more morbidity 
and/or mortality that occurred in the studied period.  
 
 
 
Figure 5 Top 10 causes of death and disability combined (DALYs) in Rwanda and percent 
change between 2005-2016, all ages [17]  
 
 
In fact, we selected antimalarial and ARV medicines in our study due to the high priority the 
two epidemics are given in the Rwandan Health Sector Strategic Plans (HSSP - I, II, and III) 
from 2005 to 2018 aligned with the United Nations (UN)-Millennium Development Goals 
(MDGs, 2000-2015), Africa Health Strategy (2007-2015), UN-Sustainable Development 
Goals (SDGs, 2016-2030), etc. [18-21]. Therefore, eight ambitious MDGs were 
internationally committed on, aiming to:  
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 Eradicate extreme poverty and hunger (MDG 1) 
 Achieve universal primary education (MDG 2) 
 Promote gender equality and empower women (MDG 3) 
 Reduce child mortality (MDG 4) 
 Improve maternal health (MDG 5) 
 Combat HIV/AIDS, malaria and other diseases (MDG 6) 
 Ensure environmental sustainability (MDG 7), and 
 Develop a global partnership for development (MDG 8) 
 
Among them, the underlined MDGs (1, 4, 5, and 6) are directly linked to health, and the 
MDG 6 is specific to “Combatting HIV/AIDS, malaria, and other diseases”.  
 
On the other hand, after the UN MDGs period, the latter were replaced by SDGs oriented to 
seventeen goals around five core themes: people, planet, prosperity, peace, and partnership. 
Thus far, in contrast to the MDGs, which were primary focused on progress in developing 
countries; the SDGs aim to support and promote well-being for everyone, and everywhere in 
developing and developed countries. Hence, the consolidated health goal (SDG 3) is at the 
core of the SDG framework, closely linked to each and every other goal. The SDG 3 is to 
“Ensure healthy lives and promote well-being for all at all ages”; for which 13 targets are 
defined including the target for infectious diseases stipulating that “By 2030, end the 
epidemics of AIDS, tuberculosis, malaria and neglected tropical diseases and combat 
hepatitis, water-borne diseases and other communicable diseases” [18]. 
 
I.2.2 Rwanda supply chain network description 
 
Different levels and institutions from public and private sectors are actively involved in the 
network of the supply chain of medicines in Rwanda. The national level supports district 
pharmacies (DPs) and service delivery points (SDPs) to increase access to healthcare 
commodities to clients / patients.  
 
The private sector complements the public sector for the supply of commodities, even though 
the public sector provides the majority of commodities. On the other hand, the information 
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flow through the network provides data and feedback useful for decision making at all levels 
of the supply chain as illustrated in Figure 6 [22].  
 
 
Figure 6 Rwanda supply chain network (adapted from the Supply Chain Management System 
“SCMS” / Rwanda Ministry of Health) [22] 
 
Legend: 
 
 
Such complex supply chain needs appropriate measures including control strategies in terms 
of products “sanctity” through inviolability or security labels, “identification and traceability” 
through barcoding or numbering of labels, data matrix or serialization / products information 
in time and space, and “authentication” through verification of products per internet or mobile 
phone short messages to confirm the authenticity in order to ensure that the products on 
market are good and genuine.  
 
External suppliers 
(manufacturers, intermediate suppliers)
MPPD / BUFMAR
Logistics Management Office / database 
(MoH)
PRIVATE SECTOR 
REGIONAL AND REFERRAL HOSPITALS
DISTRICT PHARMACIES
HEALTH CENTERS DISTRICT HOSPITALS
CLIENTS / PATIENTS
COMMUNITY HEALTH WORKERS
RETAIL 
PHARMACIES;
PRIVATE CLINICS
Internal suppliers 
(manufacturers)(Raw materials)
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It should be noted that today almost all medicines used in Rwanda are imported by both 
public and private sector generally providing medicines, medical consumables, medical 
devices and equipment, laboratory supplies, food supplements and other pharmaceutical 
services needed in the country  The imported products come from several countries from the 
region such as Uganda, Kenya, South Africa, Mauritius Island, etc., and mostly from 
countries outside the continent such as India and China in Asia; Belgium, Germany, 
Switzerland in Europe; and USA, etc.. In fact, the Rwandan market share of locally 
manufactured pharmaceutical drugs is estimated to be less than 1% according to the 
Federation of East African Pharmaceutical Manufacturers Association Chairman [23], but the 
Government of Rwanda is continuously inviting and encouraging investors in local 
pharmaceutical manufacturing. In this context, two big projects have been launched by 
Cooper Pharma (a leading African pharmaceutical firm based in Morocco) and Apex Biotech 
Ltd (a co-owned pharmaceutical firm by Rwandans and Bangladeshi investors). Cooper 
Pharma has launched the construction works of a $USD 6 million plant in January this year 
for the production of beta-lactam antibiotics in the short term, and then will expand to non-
beta lactam antibiotics depending on the local and regional market demands; the factory is 
expected to be completed in 2019 [24]. On the other hand, the Apex Biotech Ltd project 
worth $USD 18 million is expected to open next year too, and the plant will manufacture 
generic pharmaceutical formulations in all major therapeutics in a variety of dosage forms 
including tablets, capsules, powder for suspension, liquid syrups, and oral rehydration therapy 
[25]. 
 
Note that in Rwanda, procurement functions of medicines are mainly fulfilled by the Central 
Medical Store “currently RBC/MPPD”, Referral hospitals, BUFMAR, and Private pharmacy 
wholesalers. Then, the supply chain network across the country can be divided into five core 
hierarchical levels: (i) National, (ii) District, (iii) Health centers, (iv) Health posts and (v) 
Community. For the private sector, there are two levels: (i) Wholesalers, and (ii) Retail 
pharmacies.  
 
Further additional information on different administrative structures and related health 
facilities involved in the supply chain of medicines, approximate numbers of population per 
category, etc. are summarized in the following table.  
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Table 2 Existing administrative structures and related health facilities, HSSP 4 (2018) [26-27]   
Administrative 
level 
Number Health care delivery 
system 
Health 
care 
Category 
Number of health 
facilities (HFs) per 
category 
Average 
catchment 
area 
population 
National: 
(MoH, etc.) 
 
1 
 
National referral & 
Teaching hospitals 
 
Tertiary 
 
8 
 
≈ 12 millions 
Province & Kigali 5 Provincial hosp. 4 - 
District  30 - District hospitals 
- District Pharmacies 
Secondary  36 
30 
≈ 255,000 
Sector  416 Health centers Primary  499 ≈ 23,000 
Cell 2,148 Health posts 
(
*
)
 476 - 
Village  14,837 CHWs First aid 45,516 ≈ 250 
Household  - Family aid Beneficiary  - - 
Other structures: 
SAMU services 
Private HFs 
 
- 
- 
 
Ambulances 
Private sector  
 
Emergency 
- 
 
225 ambulances 
250 registered 
 
- 
- 
 
I.2.3 Description of the Rwandan medicines quality assurance system based on the 
national pharmacy policy  
 
I.2.3.1 Introduction 
 
In Rwanda, availing safe, effective and high quality medicines, health commodities, and 
technologies that are accessible to the population has always been a concern of the 
Government. Thus, since 1996, the Government of Rwanda has undertaken a series of quality 
improvement interventions and has held numerous discussions on how to meet and uphold the 
standards to make essential, high-quality health commodities and technologies accessible to 
all residents, in accordance with the national Pharmacy, and Health Sector policies [28-29]. 
 
Then, to fulfil its mission to provide quality healthcare for all its population, the Government 
of Rwanda has always taken bold steps in its health policy, such as the Alma Ata Declaration 
of 1978 on “expressing the need for urgent action by all governments, all health and 
development workers, and the world community to protect and promote the health of all the 
people of the world” and the Bamako initiative of 1987 sought to accelerate and strengthen 
the implementation of primary healthcare, with the goal of achieving universal accessibility to 
these services. It was an initiative that African Ministers of Health introduced in 1987 to 
reorganize and strengthen primary healthcare with emphasis on maternal and child health.  
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Hence, by adopting the National List of Essential Medicines, creating a Pharmaceutical 
Service Unit within the Ministry of Health, and establishing a Central Medical Store for 
essential medicines, commodities, and technologies and allowing Exemption from entry duties 
on these items, Rwanda is boldly moving forward to develop its pharmaceutical sector so that 
quality healthcare can be available to its population. 
 
I.2.3.2 Situation of the Pharmaceutical sector  
 
The status of key components of the Rwandan pharmaceutical sector is presented below 
according to the national Pharmacy, and Health Sector policies referred to above.  
 
 A) Quality assurance 
 
Quality assurance of medicines refers to all the necessary measures taken to ensure that 
products quality is maintained from the point of production to the point of use. Rwanda has 
established quality assurance systems to ensure that health commodities and technologies 
circulating in the supply chain meet national and international standards of quality, safety and 
efficacy.  
 
However, despite all these efforts, the quality assurance framework has limited capacity in 
terms of infrastructure, human and financial resources. 
 
B) Legislation 
 
Pharmaceutical laws and Ministerial orders have been initiated, developed and gazetted to 
ensure that pharmaceutical services are properly regulated. The following documents have 
been put in place: 
 
1. Law determining “The Art of Healing”; 
2. Law relating to the regulation and inspection of food and pharmaceutical products; 
3. Law governing narcotic drugs, psychotropic substances and precursors in Rwanda;  
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4. Law establishing Rwanda Food and Medicines Authority and determining its mission, 
organization and functioning; 
5. Law on organization, functioning and competence of the Council of Pharmacists. 
 
These laws have to be harmonized with East African Communities. 
 
C) Regulation  
 
The Rwanda Pharmacy sector is regulated at two levels: (i) Medicines, other health 
commodities and technologies and (ii) Pharmacy professionals. 
 
o Currently, the Pharmacy Department in the Ministry of health combines both the 
responsibilities of Policy formulation and Regulatory activities to provide minimum 
services related to product evaluation and registration, import and export control, 
licensing and inspection of pharmaceutical establishment, supply chain monitoring, 
pharmacovigilance and post-market surveillance, pharmaceutical products 
advertisement and promotion. 
 
o A National Pharmacy Council was established by the law no 45/2012 of 14/01/2013 to 
regulate the pharmacy profession.  
 
These need to be reinforced with quality control system (suitable and reliable analytical 
methods) while waiting for strong national FDA system.  
 
D) Rational use of Medicines, Health commodities and technologies 
 
Rwanda has established various mechanisms to promote medicines information, prescribing 
and dispensing; including the development of treatment guidelines and protocols, the national 
formulary and a national essential medicine list with their subsequent periodic reviews. In 
addition, pharmacovigilance systems have been established at different levels. 
 
However, despite of these initiatives, Rwanda faces a number of challenges, including limited 
adherence to good prescribing and dispensing practices, and low reporting of adverse 
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reactions. Also, there is inadequate awareness among the community on the rational use of 
medicines, and inadequate reference materials at the health facilities. 
 
E) Selection of medicines 
 
It is a process of identifying medicines to satisfy the health care needs of the majority of 
population. 
 
Indeed, the choice of medicines depends on many factors such as the prevailing diseases, 
treatments guidelines, level of health care delivery and financial resources. 
 
However, Rwanda encounters challenges in medicines and therapeutic committees not 
performing optimally due to limited capacity and competences in pharmaceutical 
management. 
 
F) Procurement, storage and distribution of health commodities 
 
These are key pillars of an effective health care system. In Rwanda, procurement functions 
are mainly fulfilled by the Central Medical Store currently Medical Procurement and 
Production Division (MPPD), Referral Hospitals, BUFMAR (Bureau des Formations 
Médicales Agréées du Rwanda, a faith-based organization) and private pharmacy wholesalers. 
 
The Coordinated Procurement and Distribution System (CPDS) has improved the availability 
of HIV related health commodities and technologies. 
 
For public procurement of health commodities and technologies, an international competitive 
bidding is used; and the national procurement regulation law and stringent regulation adopted 
by partners are used for the procurement processes. 
 
However, the overall storage infrastructure and equipment for health commodities and 
technologies need improvement in terms of capacity, design, maintenance and security, 
transport and information management systems. 
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G) Local Manufacturers of Medicines  
 
Despite difficulties in the development of local capacity for the production of essential 
medicines, Rwanda has made some efforts to create a comprehensive environmental for 
investment. Rwanda must continue to work through the national investment authorities in 
providing guidance and incentives to create manufacturing capacity for specific investment in 
the pharmaceutical industry.  
 
So far, the country has only one pharmaceutical factory (former LABOPHAR) that produces 
some essential medicines covering less than 2% of the needs of the country, and this puts the 
country on a high risk of procuring counterfeit medicines from illegal manufacturers. 
 
H) Affordability  
 
Currently there is no Pharmaceutical Pricing Policy both in public and private sector; hence 
this may render the prices of health commodities and technologies to be generally high and 
less affordable to the majority of the population. However, in the absence of the pricing 
policy, the Ministry of Health in collaboration with stakeholders established tariffs of services 
rendered in public health facilities. 
 
In this situation, the risk of having very cheap and poor quality medicines is high when prices 
on the market are not well regulated and controlled. Hence, there is need to establish an 
efficient quality control system to regularly assess the quality of different vital medicines at 
reception in customs and after distribution to the community (post market surveillance). 
 
I) Health product financing 
 
The Government guarantee and commitment to an appropriate level of sustainable financing 
is an essential element in the success of the entire health sector and in particular, the 
pharmaceutical sub sector. 
 
In Rwanda health commodities and technologies are financed through fiscal budgetary 
allocations, development partners, insurance schemes, private sector and out of pocket 
expenditure. 
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The population covered by any health insurance scheme is 96% (Rwanda health insurance 
indicators: progress 2010). 
 
J) Pharmaceutical Research and Development 
 
Research and development plays a major role in industrial transformation and economic 
growth, as well as in health care delivery. Pharmaceutical R&D is driven by current 
developments in disease control and treatment, in particular the need for enhanced use of 
diagnostics; early onset of treatment and use of newer, safe, more efficacious and age-
appropriate medicines. 
 
The pharmaceutical services in the Ministry of Health regulate clinical trials, in collaboration 
with the Rwanda Ethic committee (RNEC). 
 
The School of pharmacy at the University of Rwanda and other research institutes have been 
undertaking various forms of research on medicines and treatment, including clinical trials 
and product development. 
 
However, despite Rwanda is endowed with many medicinal flora and fauna there is very 
limited investment to exploit this endowment in making products for use in health care. In 
case where research has shown the presence of pharmacological activity in plants, the 
research ends in only publications but not in products development. 
 
Hence, there is a need to increase and prioritize funding for pharmaceutical research and 
development activities that address local needs and attract investment. 
 
K) Information and communication Technology (ICT) 
 
There have been numerous advances in the field of ICT, and many of these have been 
embraced in various facets of the pharmaceutical sector. ICT use in pharmaceutical includes 
technological advancements in design and automation of processes, including procurement 
and logistics management, dispensing of health commodities, online reporting on medicines 
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safety and quality monitoring, availability and consumption of health commodities and 
technologies. 
 
The country has made significant strides towards narrowing the digital divide within and the 
rest of the world, through infrastructure expansion and upgrading, and through an enabling 
legal and institutional framework. However, there remain some gaps in infrastructural and 
human resource capacity for the full application of ICT in the pharmaceutical sector. 
 
Challenges relating to ICT in the pharmaceutical sector include: 
 
a) Insufficient infrastructure, equipment, and skilled human resource in ICT for improved 
efficiency and effectiveness of pharmaceutical services; 
b) Absence of ICT in regulatory functions (e.g. electronic submission of dossiers for 
registration of medicines, importation licenses, licensing of pharmacies). Currently all 
importation licenses are requested electronically. 
 
To address the challenges of information technology in pharmaceutical sector, the 
Government is investing in ICT infrastructure for effective operation of public pharmaceutical 
services, including procurement (e-procurement), distribution, regulation and quality control. 
This is also evidenced in the regional initiatives for the pharmaceutical regulatory 
harmonization and integration. 
 
On the other hand, there is need to ensure the Data Integrity and compliance with the good 
pharmaceutical practices (GxPs) such as the current good manufacturing practices (cGMPs), 
good distribution practices (GDPs), good clinical practices (GCPs), good auditing practices 
(GAPs), etc. In fact, the role of IT in the health sector has a tremendous positive impact in 
improving quality, safety, and efficiency/productivity. However, such computerized systems 
should be well managed and protected against any misuse, hacking, or dysfunctioning. The 
data integrity should also be assured by ensuring that they are updated, attributable to the 
authorized staff (or officers) for recording or editing, legible, contemporaneously recorded, 
original or true copy, and accurate.  
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L) Human Resource for the pharmaceutical sector   
 
Rwanda recognizes the insufficient numbers of appropriately trained human resources in the 
pharmaceutical sector, and the existing gaps are increasing as demand increases.  
 
In fact, the pharmaceutical work force in Rwanda includes pharmacists and pharmacy 
technicians and of the available 500 pharmacists, only 39% (i.e. around 200 pharmacists) are 
serving in the public sector, and 40% of those in the public sector (i.e. around 80 pharmacists) 
are employed in Kigali City while 60% are in other provinces. On the other hand pharmacists 
employed in the private sector (i.e. around 300 pharmacists), 75% are in Kigali City (i.e. 
around 230) while 25% are in other provinces. These figures show a disproportionate 
repartition of pharmacists in Kigali City, where more than 60% of the working pharmacists 
are concentrated and other parts of the country that share the remaining number of working 
pharmacists.  
 
M) Pharmaceutical human resource development 
 
The current training content and mechanisms for deployment of pharmaceutical personnel 
have been identified as major constraints to their utilization. Pharmacy training is largely 
oriented towards clinical practice and general theoretical knowledge, with minimal emphasis 
on other skills like procurement and supply, manufacturing and trade, etc. that are required to 
handle the wide pharmaceutical sector functions. 
 
There is need to ensure their continuous training and capacity building in different 
pharmaceutical domains including QC and QA. 
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I.3 Description of the project – Analytical strategies against poor quality 
medicines 
 
The analytical strategies against poor quality medicines takes into account the lifecycle of 
method as shown in Figure 7. 
 
 
 
Figure 7 Analytical method lifecycle  
 
The first step in this study included the “Method selection” based on the existing analytical 
techniques and according to the need. However, in the frame of poor-quality medicines 
(PQM), the challenge is that the real composition in active and inactive ingredients is never 
known both qualitatively and quantitatively. 
 
The liquid chromatography (LC) technique coupled with UV detector or DAD is usually 
considered as reference analytical technique for chemical separation, quantification and 
identification of compounds in samples. It is very used in pharmaceutical analysis due to its 
sensitivity and accuracy, and gives results in relatively reasonable time, generally between 10 
and 60 minutes depending on the method. Another advantage is its great capacity of 
automation [30-31]. Therefore, the LC is a technique of choice in the frame of detecting 
PQM. 
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Different laboratories in Rwanda such as the LADAMET, RBC/MPPD, RBC/NRL, RSB, 
NQCL, etc. have recently acquired HPLC systems and the new methods shall be transferred 
to those laboratories.  
 
In the second step, “Methods development” needs an approach that focuses on well-known 
active ingredient(s) and excipients of pharmaceutical classes. Generally, in the frame of 
detecting PQM, the most appropriate approach is to develop generic analytical methods for 
simultaneous analysis of several compounds that can be found in fixed-dose combinations 
thanks to design of experiments (DoE) and design space (DS) methodology. The DoE-DS 
methodology investigates the impact of chromatographic parameters variations and their 
interactions on the final separation, and determines the optimal analytical conditions and 
related ranges of robustness within the studied experimental domain [32-33]. This is 
important as the purpose of analytical methods is for routine analysis of various medicines at 
a large scale either in their original forms as brand products or in generic forms. However, in 
the frame of PQM, method development is challenged by the lack of information on the true 
composition of the products. The DoE-DS methodology presents another big advantage of 
creating a useful database during the realization the experimental matrix on different 
chromatographic conditions; this database can be exploited latter in predicting optimal 
analytical conditions for the analysis of any further combination of compounds involved in 
the previous DoE-DS based method development. Moreover, the development of methods can 
be done by “Adjustments or adaptation” of other existing methods without passing through 
several experimental tests of a full DoE, but simply by fitting the methods to the formulations 
that have almost same composition as that of the products analyzed with the first methods.  
 
However, although there is HPLC equipment in Rwanda, the development of new methods is 
not widely known or applied.  
 
In the third step, “Method validation” is a requirement to guarantee the reliability of future 
analytical results. The validation procedure applies to newly developed methods or to the 
modified/adapted methods from preexisting ones such as compendial monographs and other 
earlier developed methods that have been amended. 
 
In the pharmaceutical analysis framework, the recommendations on analytical methods 
validation are based on the guidelines of the International Conference on Harmonization of 
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Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The 
document “Validation of Analytical Procedures: Text and Methodology (ICH-Q2R1)” is the 
core document on analytical methods validation [34]. 
 
The validation process which should demonstrate that an analytical procedure is suitable for 
its intended purposes consists of a series of performance characteristics shown in Table 3 
depending on the type of analysis to be performed. 
 
Table 3 Typical analytical methods validation characteristics 
 
Type of Analytical Procedure: Identification  Testing for impurities Assay:  
- Dissolution 
- Content/potency Characteristics  Quantitative  Limit  
Accuracy 
Precision 
Repeatability 
Intermediate precision 
Specificity 
(2)
 
Detection limit 
Quantitation limit 
Linearity 
Range 
- 
 
- 
- 
+ 
- 
- 
- 
- 
+ 
 
+ 
   + 
(1)
 
+ 
    - 
(3)
 
+ 
+ 
+ 
- 
 
- 
- 
+ 
+ 
- 
- 
- 
+ 
 
+ 
    + 
(1)
 
+ 
- 
- 
+ 
+ 
 
Legend: 
- : characteristic not normally evaluated  
+: characteristic normally evaluated  
(1): reproducibility (i.e. inter-laboratory assessment) performed, intermediate precision is not 
needed  
(2)
: specificity of one analytical procedure compensated by other supporting analytical 
procedure(s)  
(3)
: may be needed in some cases (e.g.: analysis of subdegradation products, impurity profiles, etc.) 
 
 
Together with the ICH guidelines, there is another innovative methodological approach 
developed by the SFSTP (French Society of Pharmaceutical Science and Technology) 
Commission. These guidelines apply the concept of the total error strategy (i.e. systematic and 
random errors) expressed as “bias + standard deviation” or “trueness + precision” 
illustrated by accuracy profiles as decision tool on the fitness of the methods for their 
intended use [35].  
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In Rwanda the QC laboratories use conventional methods such as pharmacopoeias, which 
once applied on unusual products such as PQM become limited in terms of results reliability 
due to lack of suitability on the new types of samples. Then, other analytical methods can be 
applied in the analysis of non-monographed products, or of PQM suspected to contain 
unusual compounds (APIs and/or excipients) that need to be elucidated. Thus, in the absence 
of appropriate internal methods, those laboratories can use other methods developed and 
validated elsewhere by transferring them into their procedures. 
 
Transfer of analytical procedures to host laboratories for routine analysis:  
 
When a new method is validated in the developer laboratory that is skilled and accredited, it 
can be transferred to the receiver laboratories for routine analyses. In fact, method transfer is a 
fundamental step in ensuring that the analytical results that will be generated by the receiver 
(or host) laboratories will be of the same quality as those provided by the developer 
laboratory. 
 
Another advantage of analytical methods transfer is to qualify the receiving laboratory(s) for 
using the analytical procedures that are originated from the developer laboratories, thus 
ensuring that the receiving laboratories have the procedural knowledge and ability to perform 
the transferred analytical procedures as intended [36-37]. Then, the transfer of analytical 
procedure must be properly documented according to the quality assurance requirements, and 
ensuring the reproducibility. 
 
The United States pharmacopoeia (USP) - General Chapter <1224> describes different types 
of analytical methods transfer:  
 
 Comparative testing that requires the analysis of a predetermined number of samples 
of the homogeneous and same lot by both the sending and the receiving units. 
 
 Co-validation between laboratories that is a validation process involving the receiving 
unit as part of the validation team, and thereby its data is being part of the whole 
validation data as the assessment of reproducibility.  
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 Revalidation is a partial validation of the analytical procedures by the receiving unit, in 
which the validation characteristics which are anticipated to be affected by the transfer 
should be addressed. 
 
 Transfer waiver that is an appropriately justified omission of the transfer process under 
certain circumstances such as : 
 
 The new product’s composition is comparable to that of an existing product and/or 
the concentration of active ingredient is similar to that of an existing product and is 
analyzed by procedures with which the receiving unit already has sufficient 
experience. 
 The analytical procedure being transferred is described in the standardized 
compendial monographs and is unchanged.  
 The analytical procedure transferred is the same as or very similar to a procedure 
already in use.  
 The personnel in charge of the method development, validation, or routine analysis at 
the transferring unit are moved to the receiving unit.  
 
If eligible for transfer waiver, the receiving unit should document it with appropriate 
justifications. 
 
By considering these different types of transfer of analytical procedures, all of them are 
applicable in Rwanda, but they need to be well understood and introduced in different 
laboratories for efficient use whenever needed. So far, comparative testing is applied in the 
frame of East African Community State members under EAC – Pharmaceutical Proficiency 
Testing (PT) project organized and sponsored by PTB (National Metrology Institute of 
Germany) and EAC Secretariat. The Rwandan laboratories participating in the EAC 
Proficiency Testing are the RBC/MPPD, RSB/NQCL, and the UR/LADAMET. 
 
Application of the method in routine is the step that is quite critical since a laboratory has to 
demonstrate that the results obtained are not a fact of chance but deserved authenticity. On the 
other hand, the clients receive laboratory results (as certificate of analysis) without giving 
details on statistical calculations and reliability (validation) of applied analytical methods. The 
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requirement is not easy to fulfill since in routine, some variations may appear in 
pharmaceutical composition (qualitative and quantitative) either without or with intention i.e. 
unknown compounds to detect in PQM. Therefore efficient analytical techniques in the 
identification of unknown components in counterfeit medicines have to be used such as [38-
39]: 
 
 Raman spectroscopy: It is a vibrational spectroscopy technique based on the inelastic 
scattering of a monochromatic light when interacting with the material to be analyzed. 
Raman spectra provide qualitative and quantitative information on the active 
pharmaceutical ingredients (APIs) as well as on the composition of the sample 
matrices (excipients) that can be present in a variety of pharmaceutical formulations. 
Moreover, this technique has advantages of being non-destructive, fast, requiring little 
or no sample preparation, and it is environmental friendly [40-42]. 
 
 Mass spectrometry: Mass spectrometry measures the mass-to-charge ratio (m/z) of 
molecules and molecular fragments. The sample is vaporized and then ionized and 
finally its constituents are separated by an electromagnetic field before reaching a 
detector. This qualitative and quantitative technique allows the mass of individual 
molecules or fragments to be determined quickly and accurately [30; 39].  
 
Coupled with various front-end sample preparation techniques, MS can provide 
unambiguous fingerprints of complex pharmaceutical samples and therefore enabling 
counterfeit products being readily identified. Especially useful in this regard are 
techniques such as DART (direct analysis in real time), which allow much easier MS 
analysis without extensive sample preparation. Mass spectrometry can be used as a 
standalone technique or can be coupled with a preceding sample separation stage such 
as gas chromatography, liquid chromatography, or capillary electrophoresis for better 
analytical results in particular cases. 
 
 Nuclear magnetic resonance spectroscopy that is most known as NMR 
spectroscopy was selected as very powerful analytical technique for the 
characterization of the structure of drug related substances presented as raw materials 
or finished products.  
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This technique excels in the identification of unknown compounds such as metabolites 
or drug degradation products. It is also used for impurity profiling or determination of 
the drug's optical purity, and increasingly has a crucial role to play in fighting against 
poor quality medicines in general by enabling advanced analysis (qualitatively and 
quantitatively) of unknown compounds in their formulations [30; 43-46]. 
 
The targeted applications of the NMR technique in pharmaceutical analysis are mostly 
based on the following [46]: 
 
 Structure elucidation 
 Chemical composition determination 
 Formulations investigation 
 Raw materials fingerprinting 
 Mixture analysis 
 Sample purity determination 
 Quality assurance and quality control 
 Quantitative analysis 
 Compound identification and confirmation 
 Analysis of inter- and intramolecular exchange processes 
 Molecular characterisation 
 Reaction kinetics examination 
 Reaction mechanism investigation 
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PART II - OBJECTIVES 
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II.1 General objective 
 
The main objective of this thesis is to contribute to the protection of public health in Rwanda 
by means of setting up efficient generic analytical methods using liquid chromatography (LC) 
that have to be robust, fast and affordable to fight against poor quality medicines. 
 
II.2 Specific objectives 
 
This general objective is subdivided into four specific objectives that would lead to the 
achievement of the overall goal of the present thesis.  
 
(i) Development of efficient and reliable generic analytical methods for the screening of 
antimalarial and Antiretroviral medicines used in Rwanda, or specific methods for the 
analysis of alone or combined active ingredients; 
 
(ii) Validation of those new analytical methods using the total error strategy combined 
with accuracy profiles as decision tool to fit for purpose; 
 
(iii) Transfer of those methods from the University of Liège (Belgium) to Rwanda for their 
further use in routine analysis; 
 
(iv) Utilization of those new methods in routine for analysis of antimalarial and ARV 
medicines especially when detecting counterfeits, but also in regular quality control of 
those medicines throughout the distribution chain. That is, use on samples taken 
before shipment, at the time of delivery and after distribution to ensure that the 
considered medicines meet quality standards. 
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PART III - MATERIALS AND METHODOLOGY 
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III.1 Generality on Materials and Methodology 
 
Liquid chromatography (LC) coupled with simple UV detector or diode array detector (DAD) 
was selected as conventional analytical technique for simultaneous analysis of several 
compounds in one sample. This technique is suitable in detecting unknown or known 
compounds in counterfeit/falsified, substandard and degraded samples. 
 
The selected mobile phases are classical composed with affordable solvents and chemicals 
which are easily to procure. They are composed of methanol and volatile buffer solutions 
mainly prepared with ammonium formate salt, but also with ammonium acetate and 
ammonium dihydrogenophosphate when needed. The advantage of choosing volatile 
buffering solutions is that they do not precipitate in the mobile phase flow as can do other 
salts if not very well prepared, and this can obstruate the system causing overpressures, and 
stopping the system until maintained or repaired. Another reason is the transfer of the method 
to mass spectrometry (MS) detection for further investigations. 
 
The selected analytical columns are octyl (C8) and octadecyl (C18) silica based stationary 
phases that are very classical too and widely used in the analysis of organic compounds with 
pharmacopoeia monographs or other officially approved compendia. Then, both gradient and 
isocratic elution of mobile phases were used depending on the type/nature and number of 
analytes in the samples. Gradient mode was selected to separate compounds that have almost 
similar chromatographic behaviors and isocratic mode for easily separable compounds as per 
their physicochemical properties and number of expected analytes in the samples. Logically, 
there is no need to develop gradient methods for the separation of one or two analytes unless 
other scientific reasons are exist.   
 
The methods with gradient mode were developed considering the DoE-DS approach while 
those based on simple isocratic mode not requiring long experimental runs were developed by 
adaptation or adjustment of other existing methods on similar or comparable analytes.  
 
On the other hand, other analytical techniques such as Raman spectroscopy, Mass 
spectrometry and NMR spectroscopy were found useful to complete or to confirm HPLC 
results especially for advanced analysis of detected counterfeit medicines in order to elucidate 
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their real composition, identify any unusual excipients or unknown compounds and therefore 
prevent the users from any dangers.  
 
In our study, both geometric and geographic transfers were planned in order to reduce the 
global cost analysis. Geometric transfer is related to methods transfer from long to short 
analytical columns that will allow to reduce the analysis time and solvents consumption, 
whereas geographic transfer is about transferring the methods from the developer laboratory 
in Belgium to Rwanda that will allow the analysis locally; noted that time is very important in 
the detection of PQM as soon as possible in order to allow health systems using quality 
checked medicines and avoid using inadequate or harmful ones.  
 
III.2 Methodology on sampling countrywide  
 
Our sampling strategy is based on targeting suspected or risky places where PQM can be 
found. They can be towns, suburbs, and country borders for both public and private drug 
distribution points mainly pharmacies and hospitals. Any possible informal channels of 
medicines are also targeted. Then, the targeted medicines were antimalarial and antiretroviral 
medicines officially used in Rwanda.  
 
As illustrated in Figure 8, sampling sites include: 
 
 Areas with intensive pharmaceutical commercial activities, 
 Border areas with other countries (Burundi in South, Tanzania in East, Uganda in 
North, and D.R. Congo in West) where the risk of illegal trade of goods including 
medicines from one country to another is relatively high and therefore the possibility 
of poor quality medicines especially counterfeit/falsified ones in circulation.  
 
All samples were randomly selected by considering batch numbers, manufacturers, strength, 
and dosage forms (tablets, capsules, injectables, suspensions, suppositories, etc.).  
 
On the other hand, there are other samples that were received from partners networking in 
Kinshasa (D.R. of Congo), in Cotonou (Benin) and locally (Rwanda) in the framework of 
scientific collaboration between those partnerships that includes the University of Liège 
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(Belgium), the University of Kinshasa (DRC) and the University of Abomey Calavi (Benin) 
as well as the University of Rwanda. Samples of antimalarial medicines were concerned since 
malaria is endemic in these countries generally having the same suppliers of generic or brand 
medicines, and therefore the same type counterfeiting could be found.  
 
 
 
Figure 8 Strategic sampling sites on the map of Rwanda (Western Province: (1) Bugarama, 
(2) Kamembe, (3) Karongi/Kibuye, (4) Rubavu/Gisenyi; Northern Province: (5) 
Musanze/Ruhengeri, (6) Gicumbi/Byumba, (7) Gatuna; Eastern Province: (8) Nyagatare, (9) 
Kagitumba, (10) Rwamagana, (11) Ngoma/Kibungo, (12) Nyamata/Bugesera, (13) 
Ruhuha/Ngenda; Southern Province: (14) Muhanga/Gitarama, (15) Huye/Butare, (16) 
Nyamagabe/Gikongoro; and Kigali City: (17) The Capital). 
 
The sampling for ARV medicines was done at the RBC/MPPD (national drug store based at 
Kigali the capital of Rwanda), CHUB (Butare teaching university hospital in Southern 
Province), and Nyamasheke Pharmacy District in the Western Province. We selected few 
sampling places for ARVs unlike for antimalarial medicines because they are mostly 
dispensed in public health institutions, and are strictly regulated by the Ministry of Health and 
the international partner donors who procure them from WHO prequalified manufacturers.  
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46 
 
 
 
  
47 
 
 
 
IV.1 SECTION 1: Application of Design Space Optimization strategy to the 
Development of LC methods for simultaneous analysis of 18 antiretroviral 
medicines and 4 major excipients used in various pharmaceutical 
formulations 
 
Journal of Pharmaceutical and Biomedical Analysis 139 (2017) 8-21 
         https://doi.org/10.1016/j.jpba.2017.02.040 
 
IV.1.1 Preamble to Article 1 
 
The last Joint United Nations Programme report on HIV and AIDS (UNAIDS, 2016) on 
Rwanda presented alarming figures as following 
[1]
: 
 
- The number of adults and children living with HIV was around 220 000 [210 000 – 
250 000], the figures in […] represent lower and upper estimates; 
- The prevalence rate of HIV among adults aged 15 to 49 years was 3.1% [2.6 % – 
3.5%]; 
- The people living with HIV who knew their status were 200 000;  
- The people who were on antiretroviral therapy (ART) 180 000; and 
- Death to adults and children due to AIDS was approx. 3 300 [2 500 – 4 200]. 
 
Antiretroviral medicines are new molecules in relation with Figure 8 (p.12) that classified 
HIV/AIDS among the top 10 causes of death and disability combined (DALYs) in Rwanda. 
The country is also benefiting from new ARV molecules that are under constant 
pharmaceutical development and innovation to make them more effective. Beside this effort, 
there is need of having suitable analytical methods to support the Government’s initiatives 
and international organizations engaged in fighting against that terrible disease, such as the 
Global Fund, UNAIDS (Joint United Nations Programme on HIV/AIDS), PEPFAR (United 
States President’s Emergency Plan for AIDS Relief), Bill & Melinda Gates Foundation, etc. 
through reliable quality control of pharmaceutical products at different stages of the supply 
chain (pre-shipment, at delivery, and post-market inspections), in routine analysis, and 
particularly in counterfeiting detection.  
 
                                                          
[1]
 Source: UNAIDS | AIDSinfo, Country factsheets RWANDA | 2016. Retrieved May 23, 2018 from 
http://www.unaids.org/en/regionscountries/countries/rwanda      
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In this context, the first part of our results tries to answer to the needs that become a challenge 
towards therapeutic changes due to the existence of different fixed-dose combinations in 
several active ingredients, substitution of those APIs by others that are more effective, and 
modification of dosage forms for adults and pediatrics. In anticipation of this challenge, a 
design of experiments and design space methodology (DoE-DS) was necessary for the 
development of HPLC methods for simultaneous analysis of 15 antiretroviral active 
ingredients and 4 major excipients that we selected. 
 
At first, the experiments were planned on the basis of D-optimal experimental design 
conducted separately on four subgroups of the selected analytes. This step is critical due to 
potential errors that may occur while collecting chromatographic data that may be biased by 
peak overlapping. To avoid this situation, the analytes were regrouped by considering their 
pKa(s) and molecular weights. Then, predictions of retention times (tR) of all peaks were 
made for a mixture solution containing the selected molecules, allowing to define a design 
space where the separation criterion (S) was ≥ 0 min. Three Design Spaces were defined: one 
for the screening of all the 15 ARVs; one for the analysis of liquid dosage forms containing 4 
preservatives; and one for solid dosage forms. 
 
After methods optimization, one fixed-dose combination composed by emtricitabine (FTC), 
tenofovir disoproxil fumarate (TDF) and efavirenz (EFV) was fully validated according to the 
ICH Q2(R1) guidelines and Total Error strategy using the accuracy profiles as decision tool. 
The same method was tested to 3 other ARV active ingredients which were initially not 
considered, as being introduced latter in 2015 in the national list of essential medicines by the 
Government of Rwanda, while our experiments were started in 2014. 
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IV.1.2 Article 1 
 
 
 
ABSTRACT 
 
As one of the world's most significant public health challenges in low- and middle-income 
countries, HIV/AIDS deserves to be treated with appropriate medicines, however which are 
not spared from counterfeiting. For that, we developed screening and specific HPLC methods 
that can analyze 18 antiretroviral medicines (ARV) and 4 major excipients. Design of 
experiments and design space methodology were initially applied for 15 ARV and the 4 
excipients with prediction thanks to Monte Carlo simulations and focusing on rapidity and 
affordability thus using short column and low cost organic solvent (methanol) in gradient 
mode with 10 mM buffer solutions of ammonium hydrogen carbonate. Two other specific 
methods dedicated to ARV in liquid and in solid dosage formulations were also predicted and 
optimized. We checked the ability of one method for the analysis of a fixed-dose combination 
composed by emtricitabine/tenofovir/efavirenz in tablet formulations. Satisfying validation 
results were obtained by applying the total error approach taking into account the accuracy 
profile as decision tool. Then, the validated method was applied to test two samples coded A 
and B, and claimed to contain the tested ARV. Assay results were satisfying only for sample 
B. 
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1. INTRODUCTION 
 
HIV/AIDS remains one of the world's most significant public health challenges. The World 
Health Organization (WHO) reports that at the end of 2015, there were approximately 36.7 
million people living with HIV, with 2.1 million people becoming newly infected in the same 
year globally. Low- and middle-income countries and particularly in Sub-Saharan Africa are 
the most affected with 25.6 million people (i.e. around 70% worldwide) living with HIV [1, 
2]. 
 
On the other hand, antiretroviral (ARVs) medicines are not spared from counterfeiting, 
especially for their substantial high unit costs, long term medical treatment and sustained 
demand. For example, in 2003 the WHO issued an alert that a product called 'Ginovir 3D', 
marketed in Ivory Coast as a combination of triple ARV was counterfeit containing only one 
of the active ingredients and another non-declared ARV agent [3]. In 2004 “Médecins Sans 
Frontières” discovered counterfeit ARVs on the market in the Democratic Republic of Congo 
that contained an antidepressant and a muscle relaxant [4]. In 2011 the Government of Kenya 
removed thousands of batches of ARVs from circulation after patients and health workers 
reported irregularities in the appearance and texture of a widely used antiretroviral Zidolam - 
N [5, 6].  
 
Furthermore, as the antiretroviral therapy (ART) constitutes a growing pharmaceutical 
research field that necessitates combining several ARV molecules to maximally suppress HIV 
and stop the progression of HIV disease, there is need of disposing rapid and efficient 
analytical methods that can serve in different stages of drug development lifecycle, to ensure 
quality and guarantee safety and efficacy. There are also few monographs dedicated to the 
analysis of multiple ARV combinations already on the market, for example there is no 
monograph yet for the analysis of efavirenz/lamivudine/tenofovir in the three most popular 
pharmacopoeias i.e. International Pharmacopoeia (Ph. Int.), British Pharmacopoeia (BP) and 
United States Pharmacopoeia and the National Formulary (USP-NF).  
 
In the frame of fighting against poor quality antiretroviral medicines especially 
counterfeit/falsified ones, we aimed to develop effective, rapid and affordable methods. In this 
context HPLC methods were preferred considering classical and short analytical columns and 
low cost mobile phase such as methanol with classic buffer solutions. Three types of methods 
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were targeted depending on the situation that will be faced : (i) the screening methods for 
which the interest will be the analysis of suspected counterfeit ARV medicines or complex 
samples that contain several ARV molecules, (ii) the generic method(s) that are expected for 
the analysis of specific cases for example of different fixed-dose combinations (FDC) in 
liquid dosage forms containing generally preservatives and/or anti-oxidants, and (iii) the 
generic method(s) applicable to different FDCs in solid dosage forms not generally containing 
preservatives or anti-oxidants.  
 
This study focused on 18 antiretroviral medicines widely used in HIV/AIDS treatment, and 4 
major preservatives and anti-oxidants generally used in liquid dosage formulations. Their 
chemical structures are given in Fig. 1.  
 
 
 
Fig. 1 Molecular structures and pKa(s) of the 18 antiretroviral medicines 
Legend: 
ABC: Abacavir, ATZ : atazanavir, ddI : didanosine, DRV : darunavir, d4T : stavudine, EFV : 
efavirenz, ETV : etravirine, FTC : emtricitabine, IDV : indinavir, LPV : lopinavir, NFV : nelfinavir, 
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NVP : nevirapine, RAL : raltegravir, RTV : ritonavir, SQV : saquinavir, TDF : tenofovir, ZDV or 
AZT : zidovudine, 3TC : lamivudine 
 
A strategic approach based on design of experiments (DoE) and design space (DS) 
methodology was followed during the development of methods. It presents advantages of 
allowing the exploration of different chromatographic factors effects and the interactions 
between them. On the other hand, DS defined as “multidimensional combination and 
interaction of input variables that have been demonstrated to provide assurance of quality” is 
suitable to predict optimal analytical conditions within the experimental domain [7-10]. Then 
in order to ensure its fit-for-purpose, one of the candidate methods was submitted to 
validation prior to its use in routine analysis and its proposal to sustain monographs. We 
privileged the concept of total error strategy using accuracy profiles as decision tool while 
considering the ICH Q2 (R1) guidelines about the validation of analytical procedures [11-15]. 
 
2. EXPERIMENTATION 
 
2.1. Materials and Methods 
 
2.1.1. Chemicals 
 
Abacavir sulfate (99.4%), atazanavir sulfate (99.6%), nelfinavir mesylate (98.3%), ritonavir 
(99.4%), saquinavir mesylate (99.4%), tenofovir disoproxil fumarate (99.1%), and zidovudine 
(99.0%) were purchased from the United States Pharmacopeial Convention (Rockville, USA), 
darunavir ethanolate (100.0%), didanosine (> 99%), efavirenz (> 99%), emtricitabine (> 
99%), etravirine (97.1%), lopinavir (> 99%), nevirapine (> 99%) and raltegravir potassium 
salt (> 99%) from Alsachim (Strasbourg, France), indinavir (97.2%), lamivudine (99.7) and 
stavudine (99.6%) from the European Directorate for the Quality of Medicines “EDQM” 
(Strasbourg, France). The four preservatives used in this study were obtained from the 
following suppliers: butylated hydroxyanisol “BHA” (96%) and methyl paraben “nipagin“ 
(99%) from Alfa Aesar GmbH & Co KG (Karlsruhe, Germany), butylated hydroxytoluene 
“BHT“ (≥ 99%) from Merck Schuchardt OHG (Hohenbrun, Germany), and propyl paraben 
“nipasol“ (101.9%) from Fagron N.V. (Waregem, Belgium). Ammonium formate (99%) was 
purchased from Alfa Aesar (Karlsruhe, Germany), methanol (HPLC gradient grade) and 
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hydrochloric acid (37%) from Merck (Darmstadt, Germany). The ultrapure water was 
produced with a Milli-Q Plus 185 water purification system (Millipore, Billerica, MA, USA). 
 
2.2. Sample preparation  
 
2.2.1. Sample solutions for methods development 
 
Three types of solution were concerned: 
 
2.2.1.1 Individual sample solutions for preliminary data information 
 
Fifteen individual sample solutions at 100 µg mL
-1
 
 
of ABC, ddI, EFV, FTC, IDV, 3TC, LPV, 
NFV, NVP, RAL, RTV, SQV, TDF, d4T, and AZT were prepared in methanol by dissolving 
approximately 10.0 mg of each individual analyte in 100.0 mL volumetric flasks, and 
completing to volume with the same solvent. For non-easily soluble compounds in methanol, 
10 minutes of ultrasonic bath were necessary to allow total dissolution. 
 
These solutions served in collecting preliminary data information on respective UV spectra 
and retention times at apex (tR). The individual sample solutions for BHA, BHT, NpG and 
NpS were not prepared as the needed preliminary information was already known and 
available.  Collecting the retention time of the single compounds prior to optimization was 
useful in order to divide the compounds into subgroups and avoid peak overlapping that 
would be observed when testing all the compounds together. Indeed, in order to properly 
compute a DS, all peaks should be fully monitored for the whole range of experimental 
conditions. 
 
2.2.1.2 Sub-group solutions for design of experiments (DoE) 
 
The 15 ARV compounds and the 4 excipients were split into four sub-groups differing from 
one to another by respective molecular weights and dissociation constants “pKa(s)” as shown 
in Table 1. We tried as much as possible to have sub-groups containing molecules with 
different analytical data to easy the experimental design. 
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Stock solutions per sub-group were prepared at 1 mg mL
-1
 of each analyte in methanol, and 
10 minutes of ultrasonic bath were necessary to allow total dissolution of non-easily soluble 
compounds. Then, aliquots from sub-group stock solutions were diluted with the same solvent 
to have final working solutions at 200 µg mL
-1
 for design of experiments. 
 
Table 1 
Grouping of analytes per pKa(s) and molecular weights in different sub-group solutions for 
DoE 
     Sub-group Analytes pKa(s) Molecular weight (g/mol) 
Sub-group 1 ABC 5.01 335.37 
BHA 8.9 180.25 
ddI 9.12 236.23 
d4T 9.95 224.21 
EFV 10.2 315.67 
Sub-group 2 NVP 2.8 266.30 
IDV 3.8; 6.2 711.87 
RAL 6.3 444.42 
AZT 9.68 267.24 
BHT 12.23 220.36 
Sub-group 3 FTC 2.65 247.25 
TDF 3.75 635.51 
3TC 4.3 229.26 
NFV 6.00; 11.06 663.90 
NpG 8.4 152.15 
Sub-group 4 SQV 1.1; 7.1 670.84 
LPV 2.8 628.81 
RTV 3.48 720.94 
NpS 7.91 180.20 
 
2.2.1.3 Overall solution for the screening method 
 
A mixture of aliquots was prepared by mixing together 2.0 mL from each sub-group stock 
solution in a 10.0 mL volumetric flask in order to have a final solution of 200 µg mL
-1
  of 
each analyte. This overall working solution was used for testing the optimal analytical 
conditions of the screening method and also for assessing other predicted methods to check 
their capability in separating the analytes in the overall mixture solution. 
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2.2.1.4 Additional sub-group of other ARV compounds after design of experiments   
 
Another sub-group i.e. Sub-group 5 composed by three additional ARV agents namely ATZ 
(pKa 4.42; 11.92), DAR (pKa 2.39; 13.59) and ETV (pKa 3.75) was prepared in the same 
conditions as done for the four previous sub-groups in order to have final working solutions at 
200 µg mL
-1
  (see section ii). In fact, the present study including the planed DoE was initially 
based on 15 ARV medicines used in Rwanda by 2013 and inventoried from the national list of 
essential medicines published at that period [16]; After having constructed the DoE, we were 
informed that in 2015 the Government of Rwanda that served us as a model of developing 
country using ARV medicines at a large scale  has updated its national list of essential 
medicines by introducing the three ARV above mentioned in the ART for adult and pediatric 
patients [17-18]. This new sub-group was used to check whether the analytical method for the 
analysis of solid dosage forms will be suitable to detect the three compounds which are 
among the most used in pharmaceutical solid dosage forms.  
 
2.2.2. Sample solutions for calibration and validation  
 
Two sets of solutions, one for calibration standards (CS) and another for validation standards 
(VS) were prepared, by dissolving in methanol approximately 7.0 mg of FTC, 10.0 mg of 
TDF, and 20.0 mg of EFV in each volumetric flask of 20.0 mL and completed to volume with 
the same solvent to obtain stock solutions at the concentration of 350 µg mL
-1
, 500 µg mL
-1
 
and 1000 µg mL
-1
 of FTC, TDF and EFV, respectively. 
 
Then, appropriate and subsequent dilutions were performed using methanol in order to obtain 
three final calibration standards (CS) at three different concentration levels, and three 
validation standards (VS) at five concentration levels daily.  
 
A) Calibration standards 
 
The corresponding concentration levels for CS were as following: 
 
Level 1 (50%): 42 µg mL
-1
 (FTC), 60 µg mL
-1
 (TDF) and 120 µg mL
-1
 (EFV); 
Level 3 (100%): 84 µg mL
-1
 (FTC), 120 µg mL
-1
 (TDF) and 240 µg mL
-1
 (EFV);  
Level 5 (150%): 126 µg mL
-1
 (FTC), 180 µg mL
-1
 (TDF) and 360 µg mL
-1
 (EFV). 
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 B) Validation standards 
 
The validation standards (VS) were prepared considering the tablets matrix in order to 
simulate as much as possible the drug formulation and evaluate the matrix effect on the 
analytes. A matrix stock solution composed by major excipients of the studied medicine 
was prepared by dissolving titanium dioxide, talc, croscarmellose sodium, magnesium 
stearate, microcrystalline cellulose, sodium laurylsulfate and hyprolose in methanol in order 
to obtain 0,1 mg mL
-1
, 0,1 mg mL
-1
, 5 mg mL
-1
, 0,5 mg mL
-1
, 25 mg mL
-1
, 1 mg mL
-1
 and 
0,5 mg mL
-1 
respectively. This solution contains an equivalent amount of the major 
excipients as compared to the real galenic formulation for which the analytical method is 
validated for. 
 
For VS, one stock solution containing FTC at 350 µg mL
-1
, TDF at 500 µg mL
-1
 and EFV at 
1000 µg mL
-1
 was prepared in methanol as done for CS. To this stock solution was added 
545 µL of the matrix stock solution in a volumetric 20.0 mL flask and completed to volume 
with methanol. This solution was filtered through 0.45 µm PTFE syringe filtration disks 
before diluting the aliquots for experiments. 
 
Appropriate dilutions were performed with methanol in order to obtain final validation 
standard solutions at five different concentration levels, and three independent solutions per 
concentration level:  
 
Level 1 (50%): 42 µg mL
-1
 (FTC) - 60 µg mL
-1
 (TDF) and 120 µg mL
-1
 (EFV); 
Level 2 (75%): 63 µg mL
-1
 (FTC) - 90 µg mL
-1
 (TDF) and 180 µg mL
-1
 (EFV); 
Level 3 (100%): 84 µg mL
-1
 (FTC) - 120 µg mL
-1
 (TDF) and 240 µg mL
-1
 (EFV);  
Level 4 (125%): 105 µg mL
-1
 (FTC) - 150 µg mL
-1
 (TDF) and 300 µg mL
-1
 (EFV);  
Level 5 (150%): 126 µg mL
-1
 (FTC) - 180 µg mL
-1
 (TDF) and 360 µg mL
-1
 (EFV). 
 
In final, three independent solutions (n = 3) were prepared for each concentration level (m = 
3 for CS, m = 5 for VS), and all these preparations were repeated for three days 
corresponding to three series (p = 3). 
 
For the analyses of medicine samples, the concentrations of reference standard solutions 
were identical to Level 3 (100%) of the VS: 84 µg mL
-1
 of FTC, 120 µg mL
-1
 of TDF and 
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240 µg mL
-1
 for EFV. For the sample to be analyzed, powdered portions of the tablets were 
taken and treated in the same way as reference solutions to give theoretically final expected 
concentrations of 84 µg mL
-1
 (FTC), 120 µg mL
-1 
(TDF) and 240 µg mL
-1
 (EFV). The 
solutions were freshly prepared, and they were filtered through 0.45 μm PTFE syringe 
filtration disks prior to their analysis onto the liquid chromatographic system. 
 
2.2.3 Sample preparation for FTC/TDF/EFV tablets 
 
20 tablets from each sample batch were weighed and finely powdered. Then, three portions 
containing approximately 80.0 mg of FTC, 120.0 mg of TDF, and 240.0 mg of EFV for the 
sample containing FTC/TDF/EFV were accurately weighed and dissolved in 100.0 mL 
volumetric flasks with methanol. One minute of mechanical shaking with vortex was enough 
to dissolve the studied analytes; and further appropriate dilutions were done with the same 
solvent to have final working solutions containing 80/120/240 µg mL
-1
 of the three active 
ingredients respectively in sample A, and 80/120 µg mL
-1
 in sample B containing only FTC 
and TDF. But before injecting the sample solutions in the chromatographic system, they were 
filtered through 0.45 µm PTFE syringe filtration disks. 
 
In parallel, two independent standard solutions were prepared at the same concentration levels 
(i.e. 80/120/240 µg mL
-1
) of FTC, TDF, and EFV reference substances prepared in methanol 
too. 
 
2.3. Instrumentation and chromatographic conditions 
 
The optimization of the methods was performed on a HPLC system comprising a Waters 
2695 separation module coupled to a Waters 2996 photodiode array detector from Waters 
Corporation (Eschborn, Germany). The analytical column was XBridge Shield (100 mm × 4.6 
mm ID), packed with C18 stationary phase (3.5µm, dp) from Waters Corporation.  
 
The analytes were monitored photometrically at a wavelength of 210 nm while 
chromatographic data of experimental conditions were recorded from 200 to 400 nm. The 
collected chromatographic data were basically the UV spectra of the analytes, retention times 
(at the beginning, apex and end), peaks’ areas and peaks’ heights. The injection volume was 
10 µL and the mobile phase flow rate was 1 mL min
-1
, the temperature of the column 
58 
 
 
 
compartment was fixed at values between 25°C and 35°C depending on the DoE value to be 
tested or optimized method. The temperature of sample compartment was fixed at 15°C. 
 
Measurements of pH were performed with a SevenEasy S20 pH meter (Mettler Toledo, 
Columbus, OH, USA). The buffer solutions of the mobile phase consisted of ammonium 
formate with pH adjusted between 2.7 and 4.8, of ammonium acetate with pH adjusted 
between 4.8 and 6.0, and of ammonium hydrogen carbonate with pH adjusted between pH 6.0 
and 10.0. The adjustment depended on the values to test for DoE and for the optimal 
analytical conditions. The pH was adjusted with 6N hydrochloric acid or with ammonium 
hydroxide 27% while the concentration of the buffers was 10 mM.  
 
2.4. Software 
 
Empower 2.0 software (Waters Corporation, MA, USA) for Windows was used to control the 
HPLC system, to record the signals from the detector and to interpret the generated 
chromatograms. The gradient steps were calculated using a freeware HPLC Calculator v3.0 
developed by Guillarme et al. (2008) [19]. JMP 12.2.0 (SAS Institute Inc., NC, USA) and R 
3.2.2 (GNU project / Free Software Foundation, MA, USA) softwares were used for 
generating the DoE trials and experimental data treatment. The accuracy profiles as well as 
the statistical calculations including the validation results and uncertainty estimates were 
obtained thanks to e-noval
®
 V3.0 software (Arlenda, Belgium). 
 
3. RESULTS AND DISCUSSIONS 
 
3.1. Design of experiments 
 
The strategy of design of experiments (DoE) was applied to collect data through laboratory 
tests and to define design spaces (DS) related to different optimal analytical conditions for the 
screening method or specific methods for the analysis of ARV compounds and the studied 
excipients in different dosage forms. In this study, a D-Optimal design was used to allow 
simultaneous optimization of the methods in few experimental runs. Each experiment was 
performed in duplicate considering the mean of the results.  
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The pH of the aqueous part of mobile phase, the gradient time (TG) and the column 
temperature (T
o
) were selected as the factors to investigate the appropriate analytical 
conditions within the selected levels of those factors as shown in Table 2. All the factor levels 
were symmetrical. For pH, the symmetry was between values 2 and 8, with 5 the central level 
and additional points between that central and the extreme points. Since the majority of the 
compounds to test are basic another point (pH 10) was added to further investigate the 
separation of those compounds. Because the chromatographic column was able to support that 
pH level, it was assessed and treated as an augmented level of the initial DoE. Volatile salts 
were preferred for potential further transfer to LC-MS in case of investigation of potential 
“abnormal peak”, i.e. in counterfeit medicines. A total of 19 experimental conditions were 
randomly generated with R 3.2.2 software (see Table 3). For each trial run, three retention 
times (tR), at the beginning, the apex and the end of each peak analyte were recorded as 
analytical responses from the chromatogram; Retention time at apex was used for peak 
identification while retention times at the beginning and at end were used to model the 
responses and express the separation (S). The sample solutions of each sub-group were 
analyzed throughout these 19 experimental trials. 
 
Table 2 
Factors and corresponding levels selected for the D-Optimal Design  
Factors Levels 
pH 2.70 4.53 5.85 6.35 8.18 10.00 
Gradient time (TG, min.) 7.25 15.25 23.25 
Temperature (T°, °C) 25.0 30.0 35.0 
 
Prior to run the experimental trials, preliminary tests were carried out at pH 2.7 and pH 10.0, 
TG = 7.25 min. and T° = 35°C on individual sample solution of each compound. This allowed 
recording the information on UV-Vis spectra and tR of each peak analyte useful for easy 
identification and information on the chromatographic behavior in terms of elution speed.  
 
To prevent any co-elution of the peak analytes during the experiments, we took the precaution 
of dispatching the analytes according to their differences on pKa(s) of at least 1 unit pKa and 
molecular weight of 10 g mol
-1
. This allowed good chromatographic separation of the 
compounds and therefore allowed recording precise data on respective three retention times 
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(beginning, apex and end) of each peak analyte since with co-eluting peaks this would not be 
possible.    
 
Table 3 
Experimental matrix of D-Optimal design for the investigation of analytical factors  
 
3.2. Influence of the analytical factors on the chromatographic behavior of the analytes 
 
The responses (retention times at beginning, apex and end) from the experimental data were 
modeled by the following multivariate multiple linear model with quadratic for factors other 
than pH and interactions between factors as shown by the following equation:  
 
Y = βo + β1.pH + β2.pH
2
 + β3.pH
3+ β4.TG + β5.TG
2+ β6.T°+ β7.T°
2+ β8.pH.TG + β9.pH. T° + 
β10.T°.TG + β11.pH.T°.TG + E 
 
Y = XB + E 
 
With βo, … β11, the model parameters and E the estimated error. 
 
Trial Experimental set up 
T° (°C) TG (min) pH 
1 35.0 15.25 4.53 
2 30.0 23.25 4.53 
3 35.0 7.25 10.00 
4 25.0 7.25 10.00 
5 35.0 15.25 8.18 
6 30.0 23.25 10.00 
7 30.0 15.25 2.70 
8 25.0 7.25 2.70 
9 35.0 23.25 10.00 
10 25.0 15.25 10.00 
11 35.0 7.25 2.70 
12 25.0 23.25 2.70 
13 30.0 15.25 6.35 
14 25.0 7.25 5.85 
15 30.0 15.25 6.35 
16 30.0 7.25 8.18 
17 30.0 15.25 6.35 
18 25.0 23.25 8.18 
19 35.0 23.25 2.70 
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As can be noticed in Fig. 2, pH and TG have an important influence on the three retention 
times of the compounds: Obviously the decrease of the TG significantly decreases the three 
retention times of the compounds, but often at the expense of peak separation due to peak co-
elution. It was also noticed that pH variation of the mobile phase led to significant changes in 
retention times of some compounds such as 3TC, ABC, NpG, NpS, TDF, RAL, d4T, IDV, 
SQV, and AZT, but also the variation of pH of the mobile phase can cause the inversion of 
peaks and therefore change the elution order of peaks (see Fig. 2.A). For example the elution 
order at pH 2.7 will start with 3TC while at pH 10.0 it will start with ddI. Other compounds 
such as ABC, NpG, RAL, NpS, IDV, etc. will have a change in the elution order upon 
variation of the pH. Moreover, some compounds are subject of co-elution at some pH levels; 
for example NVP/NpS at around pH 10.0, AZT/NpG at around pH 9.7, 3TC/ddI and 
RAL/ABC at around pH 8.5, ddI/3TC/FTC/d4T, NpG/ABC, RAL/NVP, and NpS/TDF at 
around pH 7.0, ddI/FTC/d4T, NpG/ABC, NpS/TDF, and SQV/NFV/LPV at around pH 5.0, 
AZT/ABC and NpG/NVP at around pH 2.7. Therefore there is need of carefulness while 
optimizing the methods involving those compounds in a drug formulation.  
 
Concerning T°, one can noticed that when increasing between 25°C and 35°C, a slight 
retention times decrease of all peak analytes was observed without any co-elution or change 
of peaks elution order.   
 
Based on these observations, the ideal would be to run the chromatographic analysis at higher 
TG for better peaks separation thus their easier identification; however, this becomes a 
compromise with the analysis time that should be reduced in order to obtain the results as 
rapid as possible for allowing taking decision on analyzed batch products especially in case of 
failure (out-of-specifications).   
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Fig. 2. Modelled retention times (tR) of different compounds with respect to factors of 
experimental design: (a) pH, (b) temperature (T
o, o
C), and (c) Gradient time (TG, 
min) 
 
Legend: 
 
 
Table 4 
Optimal analytical conditions and operating range within DS for the separation of the 
molecules 
 
 
Optimal  
P(S > 0) 
pH 
 TG 
(min) 
T° 
 (°C) Screening method for 18 compounds 0.2% 9.09 
(8.70-9.30) 
21.25 
(21.0-21.6) 
35.0 
(34.5-35.0) 
Method for Liquid dosage forms 95% 3.61 
 (3.60-6.00) 
9.25 
 (9.0-23.3) 
25.0 
 (25.0-35.0) 
Method for Solid dosage forms 95% 2.70 
 (2.70-3.70) 
7.25 
(7.0-23.3) 
25.0  
(25.0-35.0) 
 
3.3. Methods optimization  
 
The optimization of the methods was done thanks to R 3.2.2 freeware [20] available for most 
computer systems. It allowed to develop Bayesian models on the prior recorded results of the 
DoE and to predict different optimal analytical conditions for the expected analytical methods 
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using Monte Carlo simulations. To each expected method, the following were computed: 
design spaces, graphs of the tR variation versus T°, pH and TG as well as the corresponding 
predicted chromatogram. Then, the predicted optimal conditions were tested in practice while 
maintaining constant the other analytical conditions: column, flow rate, injection volume and 
detection wavelength as mentioned in the section of materials and methods. As mobile phase, 
classic and affordable solvents were privileged i.e. methanol LC grade and buffers mentioned 
earlier (see section 2.3). 
 
Three kinds of optimization were needed in order to obtain the optimal conditions on T°, pH, 
TG and probability of peaks separation P(S > 0) for the studied analytical methods presented 
in Table 4. 
 
3.3.1 First optimization: Screening method 
 
To sustain the optimization of the screening method through the evaluation of quality 
chromatogram [7; 8], we selected the separation between peaks of the critical pair as a critical 
quality attribute (CQA). Then, as proposed by Lebrun et al. [9], we used in this study the 
separation criterion (S) defined as the difference between the tR at the beginning of a “n” 
th
 
eluting peak (tRB) and the tR of the end of the “n-1” 
th
 eluting peak (tRE) of the critical peak 
pair. The critical pair is defined by min(S), for a given operating condition. In the present 
study, it was not constituted by the same peak pairs; it has changed every time within the 
domain according to the experimental conditions. A screening method able to detecting 15 
ARV and 4 preservatives compounds was optimized. The optimized experimental conditions 
were selected inside the design of experiments by means of the DS and considering the CQA 
defined as S > 0. These were expressed in terms of probability with the optimal conditions 
indicated in Table 4 including the probability surfaces to have S > 0 (see Fig. 3). As can be 
observed over the experimental domain that we investigated, it is noticed that the probability 
of peak separation P(S > 0) is very low (around 0.2%) the range of the optimal conditions is 
narrow to allow separation of all peaks, reversely when the probability is very high (95%), the 
range of the optimal conditions is large (see section 3.3.3.). Such a low probability may 
signify that a full separation (S > 0) among all the compounds is hardly found. The main 
reason over this low probability relies in the “too complex” situation depicted hereby indeed; 
numerous compounds are encompassed in the design space computed. Besides that, another 
explanation is the chromatographic behavior of compounds such as 3TC, ddI, d4T and FTC 
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which are similar and that co-elute around 5 minutes (see Fig. 4.a). Moreover, this probability 
is lessened by the calculated uncertainty of prediction represented by the gray zones around 
all analytes, and therefore allowing to predict a relatively higher risk of having other co-
eluting peaks for compounds that have similar chromatographic behavior especially in case of 
changes of pH and TG as discussed in the previous section about the influence of the studied 
factors (pH, T°, TG). One can notice potential risk of peak co-elution of AZT and NpG at 
around 7 minutes; RAL and ABC at around 10 minutes; and RTV, LPV, NFV and SQV at 
around 19 minutes.    
 
 
Fig. 3. Probability surfaces to reach S ≥ 0: (a) pH versus TG (min.), (b) TG (min.) versus T° 
(°C), (c) pH versus T° (°C) 
 
Despite this very low probability of peak separation, the 19 compounds were sufficiently 
separated to allow their identification from an injected solution containing 15 ARV and the 4 
studied preservatives (cf. Fig. 4.b). As predicted, the compounds with similar 
chromatographic behavior, 3TC, FTC and d4T presented a co-elution at around 3 minutes 
whereas NFV and SQV had an inversion of peaks order while slightly co-elution at around 18 
minutes which correspond to the aforementioned gray zone of uncertainty of prediction. 
 
From the observed results, it can be noticed that the predicted and experimental 
chromatograms are quite comparable in terms of peaks elution order and retention times 
(beginning, apex and end) supported by the calculated coefficient of determination (R
2
 = 
0.9946) between the predicted tR and observed tR that was very good demonstrating the 
accuracy of the prediction of the compounds in the screening method. 
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Fig. 4. (a) Predicted chromatogram for the screening method. (b) Experimental 
chromatogram for the screening method on the overall solution 
  
Legend per elution order in Fig. 4 (b):  
(0) Fumaric acid from tenofovir disoproxil fumarate; (1) ddI; (2) 3TC/FTC; (3) d4T; (4) AZT; (5) 
NpG; (6) RAL; (7) ABC; (8) NVP; (9) NpS; (10) TDF; (11) BHA; (12) IDV; (13) EFV; (14) RTV; 
(15) LPV; (16) SQV; (17) NFV; (18) BHT 
 
Experimental conditions: Column: XBridge Shield (C18), 100 x 4.6 mm, 3.5 µm; Flow: 1 mL min
-1
, 
T°: 35°C, λ = 210 nm, Gradient elution: 
 
 
For 18 compounds  Methanol (%) Buffer (%) Elution phase type 
0.00 5 95 Gradient 
21.25 95 5 
25.25 95 5 Isocratic plate 
25.65 5 95 Rebalancing initial mobile phase 
37.25 5 95 
  
The small changes observed may be explained by the uncertainty of prediction due to the 
variation of the chromatographic conditions especially on pH factor that was found to have a 
significant and different influence on the chromatographic behavior of some compounds by 
relatively changing their tR. Some relationship observed between pH and tR were increasing 
quadratic regression and sigmoid, whereas others were decreasing regression or even no 
regression at all. The compounds concerned were ddI, 3TC, d4T, AZT, NpG, RAL, ABC, 
NpS, IDV and NFV at pH > 9 that is the optimal level of pH for the screening method. As a 
warning to have reproducible results, the analysts should be careful while adjusting the pH of 
the buffer solution in order to minimize the risk of variation in retention times (beginning, 
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apex and end) and/or peaks elution order. Other precaution is to have a sufficient re-
equilibration time of the column after gradient before a next run as indicated in Fig. 5. 
 
We tried also to investigate the probable cause of the fronting peaks observed at 2.86 minutes 
and at 5.10 minutes. For that, we run separately the solutions of the four sub-groups using the 
same analytical conditions of the screening method. As can be seen in overlayed 
chromatograms in Fig. 6 no peak co-elution was observed inside the sub-group or between 
sub-groups and no fronting phenomenon occurred. It was noticed that d4T co-elutes with both 
3TC and FTC when the three compounds are mixed, but 3TC and FTC are well separated 
when they are mixed in one solution. On the other hand, the peak of AZT in the 
chromatogram of sub-group solution 2 was found very good without any fronting peak. We 
understood that the fronting phenomenon on this analyte in the overall mixture solution is 
caused by the presence of NpG that co-elutes with AZT in this analytical method. Note that 
the chromatograms of Figs. 4.b and 6 have similar peaks elution order and very closer 
retention times (at apex).  
  
67 
 
 
 
 
 
Fig. 5. Gradient profiles for the screening method of 18 compounds, liquid dosage forms, and 
solid dosage forms methods 
 
For 18 compounds  Methanol (%) Buffer (%) Elution phase type 
0.00 5 95 Gradient 
 
Isocratic plate 
Rebalancing initial mobile phase 
21.25 95 5 
25.25 95 5 
25.65 5 95 
37.25 5 95 
For liquid dosage forms  Methanol (%) Buffer (%) Elution phase type 
0.00 5 95 Gradient 
 
Isocratic plate 
Rebalancing initial mobile phase 
9.25 95 5 
13.25 95 5 
13.65 5 95 
25.25 5 95 
For solid dosage forms  Methanol (%) Buffer (%) Elution phase type 
0.00 5 95 Gradient 
 
Isocratic plate 
Rebalancing initial mobile phase 
7.25 95 5 
11.25 95 5 
11.65 5 95 
23.25 5 95 
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Fig. 6. Overlaying chromatograms of the 4 sub-groups containing the studied 15 ARV agents 
and 4 excipients, analysed with the screening method  
 
Legend per elution order:  
Blue peaks belong to the ARV sub-group 2 solution (AZT, RAL, NVP, IDV, BHT);  
Green peaks to sub-group 3 (fumaric acid, 3TC, FTC, NpG, TDF, NFV);  
Cyan peaks to sub-group 4 (NpS, RTV, LPV, SQV),  
Red and Black peaks to sub-group 1 (ddI, d4T, ABC, BHA, EFV)   
 
Experimental conditions: the same as for Fig. 4 
 
3.3.2 Second optimization: Generic method dedicated to liquid dosage forms  
 
In a following step, we were interested to the development of methods which are applicable to 
specific dosage forms containing the studied ARVs. A generic method for the analysis of 
ARV medicines in liquid dosage forms was optimized at the predicted optimal conditions 
given in Table 4. It was developed on the basis of earlier DoE/DS database on the 3 ARV 
(3TC, FTC and NFV) and the 4 studied preservatives (BHA, BHT, NpG, NpS) generally used 
in liquid dosage formulations. These ARV were selected on the basis of their medical 
prescription in pediatric formulations that are susceptible of containing NpG and NpS as 
antimicrobial preservatives and/or BHA, BHT as antioxidants, the latter being generally used 
in the manufacture of medicines that contain fatty compounds or oils to prevent their 
oxidation. 
 
For this method we focused on the analysis of different liquid dosage forms either in single or 
combined active ingredients, and on monitoring the content of the four studied excipients in 
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pediatric formulations such as EPIVIR® (3TC), ZERIT® (d4T), Mezivir® (AZT), 
VIRAMUNE® (NVP), Ziagen® (ABC), Emtriva® (FTC), and various other ARV medicines 
containing among others NpG and NpS [21-26]. On the other hand, a recent reflection paper 
by the European Medicines Agency (EMA) on the use of NpG and NpS as excipients in 
human medicinal products for oral use stipulated that in oral pharmaceutical formulations, 
association of those excipients are used with concentrations generally ranging from the 
authorized content from 0.015 % to 0.2% for NpG and from 0.02% to 0.06% for NpS. Based 
on the current posology of medicines containing these conservatives, concentrations of 0.2% 
and 0.06% would correspond to maximal intakes of approximately 140 mg/day and 50 
mg/day, respectively [27]. These can serve as acceptable limits of the two antimicrobial 
preservatives in various formulations. Thus far, to allow monitoring the BHA and BHT 
excipients in medicines, we considered as specification the acceptable daily intake (ADI) 
limits fixed by the Joint FAO/WHO Expert Committee on Food Additives. The ADI for BHA 
was: 0 – 0.5 mg/kg body weight/day, and for BHT: 0 – 0.3 mg/kg body weight/day [28-30] 
which would be compared to the posology of medicines and the medical prescriptions in order 
to avoid consuming more than the recommended ADIs. In this way our interest was also to 
fulfill the above requirements at least by detecting these conservatives. As can be seen in 
Table 5 and in Fig. 7, the peaks of the ARV are resolved as well of the 4 preservatives in 12 
min. The predicted and experimental results were found comparable in terms of peaks elution 
order except BHA and NFV for which an inversion of peak elution was observed. We noticed 
a change of more than 1 minute in retention time (at apex) of NpG, NpS and BHA mainly due 
to the prediction uncertainty and sensitivity of the compounds on slight changes of pH of the 
aqueous mobile phase. 
 
All ARV components among the most found in liquid dosage forms can be quantified without 
any interference with the 4 studied excipients. The method for liquid dosage forms is able to 
detect also the presence of the latter. 
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Fig. 7. Predicted and experimental chromatograms of the method for the analysis of liquid 
dosage forms 
 
Experimental conditions: Column: XBridge Shield (C18), 100 x 4.6 mm, 3.5 µm; Flow: 1 mL 
min
-1, T°: 25°C, λ = 210 nm, Gradient elution:  
 
For liquid dosage forms  Methanol (%) Buffer (%) Elution phase type 
0.0 5 95 Gradient 
9.25 95 5 
13.25 95 5 Isocratic plate 
13.65 5 95 Rebalancing initial mobile phase 
25.25 5 95 
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Table 5 
Predicted and observed retention times (tR at apex) on the method for the analysis of liquid 
dosage forms 
Compound Predicted tR (min.) Observed tR (min.) Difference (min.) 
3TC 3.17 2.77 -0.40 
FTC 3.68 3.75 0.07 
NpG 6.44 8.05 1.61 
NpS 8.09 9.48 1.39 
BHA 8.97 10.05 1.08 
NFV 9.48 9.78 -0.30 
BHT 10.62 11.38 0.76 
 
3.3.3 Third optimization: Generic method dedicated to solid dosage forms 
 
Solid dosage forms are very often used in combination of several ARVs at fixed-dose 
combinations “FDC” among which are listed 3TC/d4T/NVP, 3TC/AZT/NVP, FTC/TDF/EFV 
and 3TC/TDF/EFV. In this context, we oriented our third optimization for a generic method 
starting from the same database previously constructed for all the 19 compounds. The 
predicted optimal conditions (see Table 4) allowed to obtaining the predicted chromatograms 
for the 4 FDCs (see Fig. 8). We tested in practice the conditions of one FDC (i.e. 
FTC/TDF/EFV) and we obtained the experimental results quite similar in terms of peaks 
elution order and retention times (at apex) as illustrated in Fig. 9.  
 
We noticed that the variation in tR was less than 0.6 minute, and all peaks were separated, 
very sharp and symmetric allowing to identify even the fumaric acid at 2.74 minutes. This 
analyte is released from tenofovir disoproxil fumarate (TDF). 
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Fig. 8. Predicted chromatograms of the 4 fixed-dose combinations of 3TC, AZT, d4T, EFV, 
FTC, NVP, and TDF in solid dosage forms  
 
Experimental conditions: Column: XBridge Shield (C18), 100 x 4.6 mm, 3.5 µm; Flow: 1 mL 
min
-1, T°: 25°C, λ = 210 nm, Gradient elution:  
 
For solid dosage forms  Methanol (%) Buffer (%) Elution phase type 
0.0 5 95 Gradient 
7.25 95 5 
11.25 95 5 Isocratic plate 
11.65 5 95 Rebalancing initial mobile phase 
23.25 5 95 
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Fig. 9. Predicted and experimental chromatograms of FTC/TDF/EFV combination. 
Resolutions are 6 (between fumarate and FTC), 27 (between FTC and TDF), and 
24 (between TDF and EFV) 
 
Experimental conditions: the same as for Fig. 8 
 
3.4. Method validation 
 
After the optimization process, it was necessary to demonstrate that the developed analytical 
methods provide accurate assay results. In this study, we choose the method dedicated to the 
assay of one FDC composed by Emtricitabine (FTC), Tenofovir (TDF) and Efavirenz (EFV) 
in tablets formulations. These three molecules were selected for validation since they are used 
alone or in combination to avoid HIV resistance due to different action mechanisms. In 
addition, their chemical structures are different and representative of the most popular 
pharmaco-chemical groups available among the ARV. Emtricitabine belongs to analog of 
cytidine, tenofovir to analog of nucleotide of adenine and efavirenz is a non-nucleoside of 4-
benzyl and 4-benzoyl-3 dimethylamine pyridinones. Indeed, the action of these three 
compounds is strongly related to their specific structures. Thus it was very interesting to 
evaluate the ability of method to quantify these compounds through validation. The validation 
criteria commonly found in the document Q2(R1) of the International Conference on 
Harmonization (ICH) [15] were considered namely: selectivity, trueness, precision 
(repeatability and intermediate precision), accuracy, linearity, limit of detection (LOD) / limit 
of quantitation (LOQ), and dosing range. 
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At first, we ensured that the selectivity of the method was suitable. Since no interference was 
observed at the tR of the peaks of interest here FTC, TDF and EFV, and the resolution 
between peaks was largely well above 1.5, one can conclude that this validation criteria was 
fulfilled. 
 
At second, we applied the concept of total error strategy represented by accuracy profiles as 
decision tool on the fit-for-purpose of the method for its intended use [11-14]. 
 
By using the data of CS, the linear regression model was constructed and allowed obtaining 
the calculated result from VS. The residual sum of square (RSS) values were 4844, 408.5 and 
1288 for EFV, FTC and TDF, respectively. Then, accuracy profiles for the three ARV 
compounds were drawn as can be seen in Fig. 10 with the results of validation criteria 
summarized in Table 6. The acceptance limits were set at ±10% according to the International 
Pharmacopoeia which is among the most used pharmacopoeias in Rwanda in the analysis of 
medicines [31].  
 
From the back-calculated results of VS that are the experimental ones, trueness of the method 
was assessed as it is the closeness of agreement between a conventionally accepted value or 
reference value that correspond to the introduced concentrations of the 3 ARV and a mean 
experimental one. We were able to get information on systematic error that was found 
acceptable since the relative biases were between - 1.64% and 7.09% for EFV; - 1.38% and 
4.02% for FTC; - 4.21% and 4.53% for TDF, all in respect with the acceptable limit of ± 10%.  
 
Method precision was also found acceptable since there was a closeness of agreement among 
measurements here the back-calculated results of VS obtained from multiple sampling of 
homogeneous samples of the three ARV. The relative standard deviation values for 
repeatability and for intermediate precision at the target 100% concentration level were 
acceptable with a maximum of 1.72 % for EFV, of 2.28% for FTC and of 1.74% for TDF. 
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Fig. 10. Accuracy profiles for quantitative methods validation of EFV, FTC and TDF in tablet 
formulations. The plain red line represents the relative bias, the dashed lines the 
95% β-expectation tolerance limits and the dotted lines the 10% acceptance limits. 
The dots express the relative error of the back-calculated concentrations plotted with 
respect to their targeted concentration.    
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Table 6 
Summary of the validation results  
Validation criteria Conc.  
(µg mL-1) 
EFV Conc. 
(µg mL-1) 
FTC Conc. 
(µg mL-1) 
TDF 
Trueness: 
Absolute bias  
(µg mL
-1
) 
& 
(Relative bias) (%) 
120 5.23 (4.36) 42 1.70 (4.02) 60 -1.83 (-3.07) 
180 12.77 (7.09) 63 -0.88 (-1.38) 89 4.06 (4.53) 
240 -3.95 (-1.64) 85 0.99 (1.17) 119 0.19 (0.16) 
300 -1.51 (-0.50) 106 2.57 (2.43) 149 -6.31 (-4.21) 
360 -1.58 (-0.44) 127 3.79 (2.99) 179 -0.84 (0.47) 
Precision: 
 
Repeatability  
(RSD %)  
/ 
Intermediate 
precision  
(RSD %) 
120 3.82/4.03 42 3.15 / 3.15 60 3.17 / 3.17 
180 4.08/4.08 63 2.72 / 2.72 89 1.63 / 1.94 
240 1.52/1.72 85 2.28 / 2.28 119 1.74 / 1.74 
300 0.97/1.93 106 1.75 / 1.75 149 0.92 / 0.92 
360 1.82/2.04 127 1.82 / 1.82 179 1.50 / 2.04 
Accuracy: 
95% βE  
(µg mL
-1
) 
 
& 
 
(Relative 95%βE) 
(%) 
 
120 114.5−136.1 
(-4.62−13.33) 
42 41.1−46.9 
(-2.82−10.85) 
60 53.7−61.9 
(-9.95−3.81) 
180 176.9−208.8 
(-1.77−15.95) 
63 58.8−66.3 
(-7.29−4.53) 
89 89.4−97.7 
(-0.12−9.18) 
240 226.6−245.8 
(-5.64−2.36) 
85 81.4−89.8 
(-3.78−6.13) 
119 115.0−124.0 
(-3.62−3.94) 
300 278.6−318.7 
(-7.19−6.18) 
106 104.3−112.3 
(-1.38−6.24) 
149 139.8−145.8 
(-6.23−2.24) 
360 341.6−375.6 
(-5.16−4.28) 
127 125.7−135.7 
(-0.96−6.93) 
179 168.4−187.8 
(-5.87−4.94) 
Linearity : 
 
Slope 0.9535 Slope 1.036 Slope 0.972 
Intercept 13.35 Intercept 1.42 Intercept 2.41 
R² 0.992 R² 0.995  R² 0.992 
Dosing range : 
Lower LOQ (µg mL
-1
) 
Upper LOQ (µg mL
-1
) 
 
206.4 
 
LLOQ 
 
45.14 
 
LLOQ 
 
59.64 
360.2 ULOQ 126.9 ULOQ 178.9 
 
βE= β-Expectation Tolerance Interval 
 
In fact, between-run variance equaling or almost equaling to zero means that the intermediate 
precision equals to repeatability. 
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Then, to demonstrate the method linearity, we assessed the relationship between the back-
calculated results of VS (experimental ones) against the introduced concentrations of the 3 
ARV in the samples. The linear regression model was fitted on the two types of 
concentrations, with a good linearity of the results illustrated (cf. Table 6) by the slopes close 
to 1. 
 
Method accuracy taking into account the total error, i.e. systematic and random errors, was 
assessed from the accuracy profile shown in Fig. 10. In addition, as shown in Table 6, the 
relative β-expectation tolerance intervals are in general within a range of [−9.95, 9.18%] 
except level 1 of FTC, and level 1 and 2 of EFV. As the lower and upper tolerance bounds are 
included within the acceptance limits for all the targeted concentration levels (except the one 
mentioned i.e. Level 1 for FTC; level 1 and 2 for EFV), one can ensure that each future result 
will fall within the acceptable limits with a probability of at least 95% [32]. 
 
We estimated also the limit of detection (LOD) that is the smallest quantity of the targeted 
substance that can be detected, but not accurately quantified in the sample. The reported 
values were: 6.30; 10.63 and 19.74 µg mL
-1
 for FTC, TDF, and EFV respectively. 
 
The lower limit of quantification (LLOQ) is the smallest quantity of the targeted substance in 
the sample that can be assayed under experimental conditions with well-defined accuracy 
meaning in the range of the specified acceptable limits of ±10%. The definition can also be 
applicable to the upper limit of quantitation (ULOQ) which is the highest quantity of the 
targeted substance in the sample that can be assayed under experimental conditions with well-
defined accuracy in the range of the considered acceptable limits. The limits of quantitation 
were obtained by calculating the smallest and highest concentrations beyond which the 
accuracy limits or β-expectation limits go outside the acceptance limits. The intervals between 
the lower and the upper limits where the procedure achieves adequate accuracy allowed us to 
set the dosing ranges that were 45.14 - 126.9 µg mL
-1
 for FTC;  59.64 – 178.9 µg mL-1 for 
TDF and 206.4  - 360.2  µg mL
-1
 for EFV. 
 
The uncertainty is a parameter associated with the result of a measurement that characterizes 
the dispersion of the values that could reasonably be attributed to the measurand. In this study 
the relative expanded uncertainly (%) have been found less than 8%. 
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3.5. Application of the method 
 
As the last step of the method lifecycle, the developed and validated method dedicated to 
solid dosage form was applied in routine for quality control of tablets samples. Two different 
brand pharmaceutical drugs were tested. They were sampled in Benin and in Rwanda, and 
claimed to contain FTC, TDF and EFV (sample A) and only FTC and TDF (sample B). The 
analytical results presented in Table 7 consisted in the mean percentages of the claimed 
nominal contents in each medicine and the relative standard deviations calculated on 3 
independent samples preparations. Only Brand B satisfied to the acceptable content limits 
90.0% - 110.0%. For Brand A, only EFV content was found within these limits whereas the 
other active ingredients were present but out of the specifications. We can also notice the 
good precision of the method since the RSD are below 1.74%. 
 
Table 7 
Assay results of two ARV medicines coded A and B from Benin and Rwanda. Results consist in the 
mean percentage of claimed nominal content and the relative standard deviation calculated on 3 
independent samples. Specifications are set to 90.0% - 110.0% of the claimed nominal content (mg) 
 
   Drug EFV FTC TDF 
A Claimed 600 mg 200 mg 300 mg 
Assay in % 100.3 ± 1.04 % 80.2 ± 0.78 % 84.8 ± 1.17 % 
B Claimed 0 mg 200 mg 300 mg 
Assay in % - 93.1 ± 1.74 % 91.5 ± 1.40 % 
 
4. CONCLUSION 
 
The main objective of the present study was to develop generic LC methods for qualitative 
and/or quantitative analysis of 18 ARV namely ABC, ddI, EFV, FTC, IDV, 3TC, LPV, NFV, 
NVP, RTV, SQV, d4T, TDF, AZT, RAL, ATZ, DRV, ETV and 4 major excipients (NpG, 
NpS, BHA and BHT) by applying DoE/DS methodology.  
 
Firstly, 15 ARV and the excipients were selected for optimization using D-optimal design 
based on Gradient time, column temperature and pH of buffer solution selected as analytical 
factors, the experiments showed that the Gradient time and pH had significant effects on peak 
separations within the explored experimental domain.  
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By exploiting the generated DoE database, a screening method was predicted thanks to Monte 
Carlo simulations for simultaneous analysis of 15+4 compounds using low cost mobile phase 
composed by methanol and 10 mM ammonium hydrogen carbonate buffer. This method was 
found useful in the detection of suspected counterfeit/falsified or a mix up of the ARV 
studied.  
 
Secondly, other methods for the analysis of solid and liquid dosage forms were optimized. For 
oral solutions or suspensions, a generic method using methanol and 10 mM ammonium 
formate buffer pH 3.61 was optimized for the analysis of 3DT, AZT, ABC, EFV, FTC, 
LPV/RTV, etc. together with at least one of the four studied excipients. 
 
Thirdly, for the analysis of solid dosage forms another method was optimized to analyze four 
tablet fixed-dose combinations. The one for FTC/TDF/EFV was successfully applied in 2 
cases: validation and application on real samples. The build DoE/DS database can serve in the 
prediction of other optimal analytical conditions for the analysis of any other fixed-dose 
combination or mono-component active ingredient with one or more of the four studied major 
excipients. 
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IV.2 SECTION 2 - Optimization of LC Methods using DoE-DS Database and 
Geometric Transfer of the methods for Rapid Screening of poor quality 
antimalarial medicines in Rwanda 
 
(Under submission for publication) 
 
IV.2.1 Preamble to Article 2 
 
Malaria is a major public health concern and one of infant mortality causes in most of 
developing countries. It is among the top ten causes of death and disability combined in 
Rwanda. According to the U.S. President’s Malaria Initiative (PMI) Malaria Operational Plan 
for Rwanda, the entire population is at risk of malaria; including an estimated 1.8 million 
children under five and 443,000 pregnant women (data of 2017). According to the Rwanda 
Biomedical Center - Malaria and Other Parasitic Diseases Division (RBC/MOPDD data from 
June 2015), 19 districts out of 30 were classified as high-burden of malaria disease in the 
country. In 2015, 2,662,706 cases of malaria were reported, and 11 endemic districts 
accounted for 76% of the cases. On the other hand, the number of related reported annual case 
fatalities continued to remain relatively unchanged (1.8% - 3.5%, deaths / hospitalized 
patients) between 2009 and 2015 corresponding to 809, 670, 380, 459, 419, 499, and 489 
annual reported deaths respectively [1].  
 
Face to this unhappy situation, the Government of Rwanda has set the management of malaria 
as key priority in protecting its population. This encouraging initiative is unfortunately 
confronted to the dramatic battle of medicines counterfeiting for which malaria medications 
are highly targeted by counterfeiters. Hence, there is need to have rapid and efficient 
analytical methods that can be used in detecting counterfeit formulations as well as in routine 
analysis to check the  conformity with the required quality specifications.  
 
Instead of building a new DoE-DS database as done for ARVs in the previous section, we 
exploited an earlier DoE-DS database developed in the Laboratory of Pharmaceutical 
Analytical Chemistry (ULg, Pharmacy Department) for 19 active ingredients and 4 major 
                                                          
[1]
 Source: USAID - U.S. President’s Malaria Initiative (PMI) Malaria Operational Plan FY 2017 Rwanda. 
Retrieved May 24, 2018 from https://www.pmi.gov/docs/default-source/default-document-
library/malaria-operational-plans/fy17/fy-2017-rwanda-malaria-operational-plan.pdf?sfvrsn=6 
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excipients. The optimal analytical conditions were predicted for the analysis of 8 active 
ingredients and 4 major excipients used in Rwanda. Then, after methods optimization, we 
focused on reducing the analysis time by doing geometric transfer of the methods from long 
analytical columns to short ones that will enable us increasing the number of samples to be 
analyzed.  
  
85 
 
 
 
IV.2.2 Article 2  
 
ABSTRACT 
 
An earlier developed design of experiments and design space (DoE-DS) database was 
exploited to predict and optimize rapid screening methods for the analysis of suspected poor 
quality antimalarial medicines in Rwanda. The developed methods are specific for the analysis of 
arteether, artemether, artesunate, lumefantrine and quinine in all dosage forms used in curative 
treatment, and atovaquone, mefloquine, proguanil used in preventive malaria treatment 
(chemoprophylaxis), plus four major preservative agents (BHA, BHT, nipagine, and nipasol) 
generally found in liquid dosage forms. 
 
Optimal analytical conditions and related chromatograms were computed thanks to Monte 
Carlo simulations and experimented in laboratory to check their fitness for their intended use, and 
eventually perform some little modifications to obtain better chromatographic results when 
needed. Then, after optimizing the methods, they were geometrically transferred from long to 
short analytical columns in order to reduce the analysis time, increase the sample analysis 
throughput, reduce the mobile phase consumption and budget, and decrease the volume of 
solvents wastes. 
 
Moreover, the overall screening method was applied to other types of molecules that can be 
used by counterfeiters and the method showed the ability of detecting several other compounds 
among other types of antimalarial medicines not officially used in Rwanda, non-steroidal anti-
inflammatories (NSAIs), and antibiotics. This test was performed as counterfeiters can use among 
others wrong active ingredients from classical pharmaceutical compounds in the intention of 
cheating health professionals and patients, and regulatory officials.    
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1. INTRODUCTION 
 
Malaria is still a major health concern to tropical countries, especially in the sub-Saharan 
Africa. Then, antimalarial medicines are fundamental to any strategy for effective reduction 
of morbidity and mortality caused by that disease. According to the latest estimates of the 
World Health Organization (WHO), released in end of 2016, there were 212 million cases of 
malaria in 2015, and 429,000 deaths. Moreover, according to other WHO estimates, most of 
cases in 2015 were in the WHO African Region (90%), followed by the WHO South-East 
Asia Region (7%) and the WHO Eastern Mediterranean Region (2%) [1-2].  
 
On the other hand, before placing any medicine on the market, National Medicines 
Regulatory Authorities (NMRA) check its compliance to the compulsory requirements for 
safety, efficacy and quality. That control normally involves the assessment of related 
documentation supported by inspections on compliance with Good Manufacturing Practices 
(GMP). Then, adherence to GMP requirements during product manufacture ensures that each 
distributed batch will constantly comply with the required specifications.  
 
However, the illicit trade of poor quality medicines constitutes a very serious threat to the 
public health worldwide, and particularly in developing countries where drug regulatory 
systems are weak and controls very limited [3-4]. On the other hand, the quality of genuine 
medicines may be easily deteriorated through improper handling and poor storage conditions; 
therefore, there is need of having efficient analytical methods that can serve in routine 
analysis of different pharmaceutical products especially when analyzing suspected poor 
quality products that may contain no active ingredients, wrong ingredients, sub-degradation 
products and impurities, etc.  
 
In this context, we have developed a set of simple and rapid HPLC methods for the 
screening of antimalarial medicines used in Rwanda by exploiting an earlier developed design 
of experiments and design space (DoE-DS) database created by Debrus et al. (2011) [5], and 
we performed geometric transfers from long to shorter analytical columns in order to reduce 
the analysis time, increase the sample analysis throughput, and reduce the mobile phase 
consumption as well as saving cost of the later. The same methods could be applied by other 
countries in the analysis of similar antimalarial medicines whenever needed.  
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Design of experiments (DoE) is a powerful research methodological approach used in 
various industrial fields including the pharmaceutical sector while conducting different types 
of experiments to develop new products and processes, and to improve existing products and 
processes faster. In pharmaceutical analysis, it presents advantages of allowing efficient 
exploration of different chromatographic factors effects and interactions between them; and 
when applying it correctly, DoE will allow to reduce the development and production costs, 
and to improve quality and reliability. DoE is much more rigorous and advantageous than 
traditional methods of experimentation such as one-factor-at-a-time and expert trial-and-error. 
That proficient approach allows practitioners to explicitly model the relationship among the 
studied variables in any system, and to ultimately arrive at better solutions in short time [6 - 
9].  
 
On the other hand, design space (DS) deﬁned as a “multidimensional combination and 
interaction of input variables that have been demonstrated to provide assurance of quality” 
[9], is suitable for the prediction of optimal analytical conditions within the experimental 
domain. Therefore, in the framework of separation methods development, DS can be clearly 
considered as a zone of theoretical robustness since modifications of the method parameters 
will not significantly affect the separation quality. Consequently, the combination of design of 
experiments and design space methodologies (DoE-DS) is highly important while optimizing 
the operating conditions governing a separation process [10]. 
 
The liquid chromatography (LC) has been privileged as a conventional analytical 
technique widely used in pharmaceutical analysis and pharmacopoeias, but also by its 
capacity to analyze several components simultaneously. Moreover, the number of HPLC 
equipment is increasing in Rwanda, especially in university laboratories and Government 
institutions dealing with medicines.  
 
Hence, the targeted medicines are those manufactured in one or combined active 
ingredients among those illustrated in Fig. 1: arteether (AE), artemether (AM), artesunate 
(AS), atovaquone (AT), lumefantrine (LF), mefloquine (MF), proguanil (PG), and quinine 
(QN), plus four commonly used excipients as antioxidants or antimicrobial preservatives : 
butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), nipagine (NpG), and 
nipasol (NpS) mostly found in liquid dosage formulations.  
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Fig. 1 Molecular structures of the 8 antimalarial medicines and 4 major excipients 
 
Furthermore, the developed methods will be tested to other pharmaceutical substances in 
order to assess their ability in detecting other pharmaceutical compounds than the studied 
ones, and therefore ensure that the methods can detect undeclared active and/or inactive 
ingredients in poor quality medicines. Hence, the following substances were tested with the 
screening method for that purpose: (i) other antimalarial medicines not considered during 
methods development and not officially used in malaria treatment in Rwanda: amodiaquine, 
artemisinine, chloroquine, cinchonine, dihydroartemisinine, halofantrine, piperaquine, 
primaquine, pyrimethamine, sulfadoxine, and sulfalene; (ii) anti-inflammatories and 
associated drugs: aspirin, atenolol, caffeine, codeine, dexamethazone, diazepam, diclofenac, 
furosemide, ibuprofen, metamisole (dipyrone), methylpredinizolone, naproxen, paracetamol, 
and prednizolone; (iii) antibiotics: albendazole, amoxicillin, ampicillin, cefotaxime, 
chloramphenicol, clindamycin, levofloxacin, penicillin-V, sulbactam, tazobactam, and 
trimethoprim; and (iv) finally metronidazole, sodium benzoate, and lidocaine.  
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2. MATERIALS AND METHODS  
 
2.1 Materials 
 
2.1.1 Chemicals and drug samples used during methods development and application 
 
Arteether (100%), Artemether (100%), Artesunate (> 97%), and Lumefantrine (100%) 
were purchased from SensaPharm (Lanchester, UK), Atovaquone (> 99%) and Mefloquine 
hydrochloride (98.8%) from Alsachim (Illkirch, France), Butylated hydroxyanisole (BHA) 
(96%) and Nipagine (Methyl paraben) (99%) from Alfa Aesar GmbH & Co KG (Karlsruhe, 
Germany), Butylated hydroxytoluene (BHT) (≥ 99%) from Merck Schuchardt OHG 
(Hohenbrunn, Germany), Nipasol (Propyl paraben) (101.9%) and quinine sulfate (99.0%) 
from Fagron N.V. (Waregem, Belgium), quinine dihydrochloride (100.8%) from Molekula 
Limited (Dorset, UK), Proguanil hydrochloride (99.8%), Hydrochloric acid (37%) and 
ammonium formate (98.1%) from VWR International BVBA (Leuven, Belgium), Methanol 
LC grade from Avantor Performance Materials B.V. (Deventer, The Netherlands), the 
Ultrapure Water was produced with a Milli-Q Plus 185 water purification system (Millipore, 
Billerica, MA, USA), and various samples of quinine tablets 300 mg, quinine for injection 
300 mg/mL and 600 mg/mL as labelled on the marketed products, artemether-lumefantrine 
tablets 20 mg / 120 mg, artesunate powder for injection 60 mg, mefloquine 250 mg tablets, 
and atovaquone-proguanil 62.5 mg / 25 mg were purchased from different pharmacies in 
Rwanda. 
 
2.1.2 Chemicals used in the assessment of the capacity of the screening method in 
detecting other components  
 
On the other hand, other commonly used pharmaceutical ingredients were selected and 
involved in the study to check the ability of the new LC methods in detecting other medicines 
rather than the principal 12 analytes considered during methods development, and therefore 
evaluate the capacity of the methods to screen other substances in case of counterfeiting. 
Hence, eleven (11) analytes among the category of antimalarial medicines not used in 
Rwanda and related substances were checked with the methods. Those are amodiaquine 
hydrochloride (99%), chloroquine diphosphate (98%), cinchonine (99.9%), pyrimethamine 
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(99.0%), and sulfadoxine (99.9%) purchased from Sigma Aldrich (St. Louis, MO, USA), 
artemisinine (99.6%) and dihydroartemisinine (100.0%) from Apoteket AB (Stockholm, 
Sweden), halofantrine was gratefully provided by GlaxoSmithKline (Genval, Belgium), 
piperaquine was extracted from the P-Gvaxin formulation from Bliss GVS Pharma (Mumbai, 
India), primaquine diphosphate (98%) and sulfalene “Ph.Eur” from Fagron N.V. (Waregem, 
Belgium); then, were also checked fifteen (15) anti-inflammatories and associated molecules 
which are acetylsalicylic acid (99.9%), caffeine (100.1%), ibuprofen (99.6%), furosemide 
(100.5%), metamizole sodium i.e. dipyrone “Ph.Eur“, methylprednisolone “Ph.Eur“, 
prednisolone (100.7%), and paracetamol (99.5%) purchased from Fagron N.V. (Waregem, 
Belgium), atenolol “Ph.Eur“, codeine phosphate “Ph.Eur“, dexamethasone “Ph.Eur“, 
diazepam “Ph.Eur“, diclofenac (99.7%), naproxen (> 98%), and sodium benzoate (99.9%) 
from Sigma Aldrich (Bornem, Belgium); thirteen (13) antibiotics and antiparasitics: 
amoxicillin (99.1%), clindamycin (95.8%), chloramphenicol “Ph.Eur“, ciprofloxacin (99.6%), 
metronidazole (99.9%), phenoxymethylpenicillin (or Penicillin V) (100.2%), sulbactam 
(91.5%), tazobactam (99.2%), tetracycline (96.6%), and trimethoprim (99.2%) purchased 
from Fagron N.V. (Waregem, Belgium), ampicillin (98.0%) from AppliChemBiomedica 
(Darmstadt, Germany), cefotaxime (94.3%), Ceftriaxone (93.9%), and levofloxacin (99.0%) 
from Molekula Limited (Dorset, UK).  
 
2.2 Methods development strategy and validation  
 
The screening and sub-screening methods in gradient mode were developed thanks to an 
existing DoE/DS database created by Debrus et al. (2011). These methods were developed 
through different steps illustrated in Fig. 2, and to each method were computed the optimum 
analytical conditions and related chromatograms thanks to Monte Carlo simulations. 
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Fig. 2 Key steps applied in developing new methods  
 
Indeed, the 12 analytes were split into four subgroup categories of compounds that can be 
analyzed together as illustrated in Fig. 3. Then, to each subgroup was computed a generic 
method for the analysis of all its compounds when detecting suspected counterfeit drugs. 
 
 
Fig. 3 Chronological optimization process 
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Moreover, to check the ability of the overall screening method in detecting other 
compounds that can be used by counterfeiters instead of genuine medicines we analyzed other 
compounds that are widely available on the market.  
 
2.3 Instrumental and software 
 
2.3.1 HPLC equipment 
 
The methods were developed in Belgium on a Waters 2695 Alliance HPLC Separation 
Module coupled to Waters 2996 photodiode array (PDA) detector from Waters Corporation 
(Milford, MA, USA) piloted with Empower 2.0 software (Waters Corporation), and 
transferred to Rwanda on three different LC systems namely Prominence UFLC equipped 
with a UV detector from Shimadzu South Africa (Pty) Ltd (Johannesburg, SA), Agilent 1200 
series equipped with a diode array detector (DAD) from Agilent Technologies (Böblingen, 
Germany), and Cecil HPLC Adept Series equipped with a UV detector from CECIL 
Instruments Limited (Cambridge, UK), but in this paper we are going to limit on reporting the 
different strategies and results obtained in the originator laboratory.  
 
Then, different chromatographic columns packed with C18 stationary phase, in different 
dimensions (L: 250 mm to 50 mm, ID: 4.6 mm; dp: 5 µm and 3.5 µm) were used during the 
methods development and geometric transfer as described in the experimental section.  
 
2.3.2 Softwares 
 
Empower 2.0 software (Waters Corporation, MA, USA) for Windows was used to 
control the Waters Alliance HPLC system, to record the signals from the detector and 
interpret the generated chromatograms. Different gradients for the geometric transfer from 
columns to others were calculated using HPLC Calculator v3.0 developed by Guillarme et al. 
[11].  
 
Then, JMP 12.2.0 (SAS Institute Inc., NC, USA) and R 3.2.2 (GNU project / Free 
Software Foundation, MA, USA) softwares were used for generating the DoE trials and 
experimental data treatment.  
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2.4 Preparation of sample solutions 
 
2.4.1 Sample solutions for the screening and sub-screening methods 
 
A) Solution S12: Sample solution for overall screening method of 12 analytes 
 
A mixture of 12 analytes (8 active ingredients and 4 excipients) was used and prepared as 
follows: In the first step approximately 10.0 mg of atovaquone, lumefantrine, mefloquine, 
proguanil, quinine sulfate, BHA, BHT, nipagin, and nipasol were weighed in 100.0 mL 
volumetric flask and dissolved in methanol under 10 minutes of ultrasonic bath for non-easily 
soluble, then completed to volume with the same solvent. This solution was annotated 
“Solution S9” containing about 100 µg mL-1 of each analyte. In the second step, 
approximately 10.0 mg of each of the arteether, artemether and artesunate were weighed in 
2.0 mL volumetric flask, and dissolved with Solution S9. This was the final solution annotated 
“Solution S12” to be injected in the chromatographic system. It contained around 100 µg mL-
1
 of the first nine analytes, and 5,000 µg mL
-1
 of the last three analytes. 
 
B) Solution S7: Sample preparation for the screening method of quinine, and 
artemether/lumefantrine in oral liquid formulations with BHA, BHT, NpG and NpS 
 
A mixture of 7 analytes (3 active ingredients and 4 excipients) was used and prepared as 
follows: In the first step approximately 10.0 mg of lumefantrine, quinine sulfate, BHA, BHT, 
nipagin and nipasol were weighed in 100.0 mL volumetric flask and dissolved in methanol 
under 10 minutes of ultrasonic bath, and then completed to volume with the same solvent. 
This solution was annotated “Solution S6” containing about 100 µg mL-1 of each analyte. 
Then, in the second step, approximately 10.0 mg of artemether were weighed in a 2.0 mL 
volumetric flask and dissolved with Solution 6. This was the final solution annotated 
“Solution S7” to be injected in the chromatographic system. It contained around 100 µg mL-1 
of the first six analytes, and 5,000 µg mL
-1
 of artemether. 
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C) Solution Q3A: Sample preparation for the screening method of arteether, artemether, 
artesunate, and quinine injectable formulations 
 
In the first step, 10.0 mg of quinine base in quinine dihydrochloride were dissolved with 
methanol in 100.0 mL volumetric flask; and in the second step, this solution was used to 
dissolve and dilute 10.0 mg of each of the arteether, artemether and artesunate weighed in a 
2.0 mL volumetric flask. This was the final solution annotated “Solution Q3A” to be injected 
in the chromatographic system. It contained around 100 µg mL
-1
 of quinine, and 5,000 µg 
mL
-1
 of the three artemisinin compounds. 
 
D) Solution 3/QAL: Sample preparation for the screening method of quinine, and 
artemether/lumefantrine in tablets formulations 
 
In the first step, a quantity containing 10.0 mg of quinine base in quinine sulfate, and 10.0 
mg of lumefantrine were weighed in 100.0 mL volumetric flask and dissolved in methanol 
under 10 minutes of ultrasonic bath, and then completed to volume with the same solvent. In 
the second step, this solution was used to dissolve 10.0 mg of artemether weighed in 2.0 mL 
volumetric flask. This was the final solution annotated “Solution 3/QAL” to be injected in the 
chromatographic system. It contained about 100 µg mL
-1
 of the first two analytes, and 5,000 
µg mL
-1
 of artemether. 
 
E) Solution 3/MPA: Sample preparation for the screening method of mefloquine, 
proguanil/atovaquone in tablets formulations 
 
10.0 mg of mefloquine, proguanil and atovaquone were weighed in 100.0 mL volumetric 
flask and dissolved in methanol under 10 minutes of ultrasonic bath, then completed to 
volume with the same solvent. This solution was annotated “Solution MPA” to be injected in 
the chromatographic system. It contained about 100 µg mL
-1
 of each analyte.  
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2.4.2 Preparation of miscellaneous sample solutions to check the ability of the methods 
in detecting other compounds 
 
A) Other antimalarial medicines 
 
The following sample solutions of other antimalarial active ingredients not used in 
Rwanda were prepared to assess the ability of the screening method in detecting them in case 
they were fraudulently used by counterfeiters or accidently (but rarely) by authentic 
manufacturers as sub-standards. Methanol was used as unique solvent as done in the previous 
section. 
 
(i) Solution ART: Composed by artemisinine solution at around 5,000 µg mL-1 by 
dissolving approximately 10.0 mg in 2.0 mL volumetric flask; 
(ii) Solution DHA: Composed by dihydroartemisinine solution at around 5,000 µg mL-1 
prepared in the same conditions as for artemisinine; 
(iii) Solution ACP: Composed by amodiaquine, chloroquine, and piperaquine at around 250 
µg mL
-1 
by dissolving approximately 5.0 mg of each analyte in 20.0 mL volumetric flask; 
(iv) Solution CPS: Composed by cinchonine, pyrimethamine, and sulfadoxine at around 250 
µg mL
-1 
and prepared in same conditions as for Solution ACP; 
(v) Solution HPS: Composed by halofantrine, primaquine (newly introduced in the list of 
antimalarial essential medicines in Rwanda [12]), and sulfalene at around 250 µg mL
-1
 in 
the same conditions as for Solution CPS. 
 
B) Non-steroidal anti-inflammatory (NSAI) and related compounds 
 
NSAI and related compounds were prepared in methanol too by dissolving 5.0 mg of 
different selected substances in 20.0 mL volumetric flasks as follows:  
 
(i) Solution NSAI 1: Composed by diclofenac, caffeine, acetylsalicylic acid, and 
ibuprofen; 
(ii) Solution NSAI 2: Composed by dexamethasone, atenolol, sodium benzoate, and 
paracetamol; 
(iii) Solution NSAI 3: Composed by codeine, naproxen, prednisolone, and metamisole; 
(iv) Solution NSAI 4: Composed by diazepam, furosemide, and methylprednisolone. 
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C) Antibiotics sample solutions 
 
Antibiotic compounds generally supplied as generic medicines, were also prepared in 
methanol by dissolving 5.0 mg of each selected compound in 20.0 mL volumetric flask and 
diluted with the same solvent as follows: 
 
(i) Solution ANTB 1: Composed by ceftriaxone, cefotaxime, ampicillin, and amoxicillin; 
(ii) Solution ANTB 2: Composed by chloramphenicol, levofloxacin, penicillin V, and 
trimethoprim; 
(iii) Solution ANTB 3: Composed by clindamycin, sulbactam, and tazobactam; 
(iv) Solution ANTB 4: Composed by tetracycline, and ciprofloxacin.  
 
3. EXPERIMENTATION 
 
3.1 Overall screening method   
 
An overall screening method for the analysis of 8 active ingredients and 4 excipients 
was developed by exploiting an earlier created DoE-DS database and computing suitable and 
optimal analytical methods as described in Table 1 dedicated to the studied analytes. Hence, 
this method is applicable to any antimalarial medicine claimed to contain AE, AM, AS, AT, 
BHA, BHT, LF, MF, NpG, NpS, PG, and QN, and can help in detecting any counterfeit 
formulation composed by one or more of these analytes. 
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Table 1 
Predicted and geometric analytical conditions for the screening method applicable to the 
analysis of suspected counterfeit antimalarial medicines claimed to contain one or more of 
the following 12 analytes: AE, AM, AS, AT, BHA, BHT, LF, MF, NpG, NpS, PG, and QN 
 
Columns: (i) XBridge C18, 250 x 4.6 mm, dp: 5µm with a guard column (XBridge 
C18, 5 x 4.6 mm, dp: 5 µm); 
(ii) SunFire C18, 250 x 4.6 mm, dp: 5µm;  
(iii) Zorbax Extend C18, 150 x 4.6 mm, dp: 5 µm 
Mobile phase: a) Methanol LC grade and 10 mM ammonium acetate buffer pH 5.65 
adjusted with 6N HCl or acetic acid. 
 
b) Methanol LC grade and 10 mM ammonium formate buffer pH 2.5 
adjusted with 6N HCl or formic acid. 
Elution mode: Gradient: 
250x4.6 mm 
Time (min) 
150x4.6 mm 
Time (min) 
MeOH 
(%, v/v) 
Buffer  
(%, v/v) 
Test 1 Test 2 Test 1 Test 2 
00.0 
60.0 
70.0 
71.0 
100.0 
00.0 
35.5 
41.5 
42.1 
59.5 
5 
95 
95 
5 
5 
10 
90 
90 
5 
5 
95 
5 
5 
95 
95 
90 
10 
10 
90 
90 
 
Temperature: 35° C 
Flow rate: 1 mL min
-1
 
Wavelength: 230 nm 
Injected volume: 10 µL 
 
3.2 Sub-screening methods 
 
After optimization of the overall screening method for the analysis of 8 active ingredients 
and 4 excipients, we split the 8 active ingredients into sub-group categories as per the existing 
main pharmaceutical forms and treatment mode for both curative and prophylaxis 
medications. Hence, we found four sub-group categories composed by (i) Quinine, artemether 
/ lumefantrine in oral liquid formulations that may contain the four preservatives and 
antioxidants (BHA, BHT, NpG, and NpS), (ii) Quinine, arteether, artemether, and artesunate 
in injectable forms, (iii) quinine, and artemether / lumefantrine in tablet forms, and (iv) 
mefloquine, atovaquone / proguanil which are used as prophylaxis medications and generally 
found in tablet forms. Then, the computed optimal analytical conditions are summarized in 
Tables 2 - 3 for the four sub-group categories.  
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Table 2 
Predicted sub-screening method applicable to the analysis of suspected counterfeit 
antimalarial medicines claimed to contain QN, and AM / LF in oral liquid forms containing 
one or more of the 4 studied excipients (BHA, BHT, NpG, NpS)  
 
Columns: (i) XBridge C18, 250 x 4.6 mm, dp: 5µm with a guard column (XBridge C18, 
5 x 4.6 mm, dp: 5 µm); 
(ii) SunFire C18, 250 x 4.6 mm, dp: 5µm;  
(iii) Zorbax Extend C18, 150 x 4.6 mm, dp: 5 µm 
Mobile phase: Methanol LC grade and 10 mM ammonium formate buffer pH 4.3 adjusted 
with formic acid or 6N HCl 
Elution mode: Gradient: 
250x4.6 mm 
Time (min) 
150x4.6 mm 
Time (min 
MeOH 
(%, v/v) 
Buffer 
(%, v/v) 
00.0 
20.0 
30.0 
31.0 
60.0 
00.0 
11.5 
17.5 
18.1 
35.5 
5 
95 
95 
5 
5 
95 
5 
5 
95 
95 
 
Temperature: 25° C 
Flow rate: 1 mL min
-1
 
Wavelength: 230 nm 
Injected volume: 10 µL 
 
 
Table 3 
Predicted sub-screening method applicable to the analysis of suspected counterfeit 
antimalarial medicines claimed to contain (a) QN, AE, AM and AS in injectable forms, (b) 
QN, and AM / LF in tablet forms, and (c) MF, AT / PG used in prophylaxis treatment 
 
Columns: (i) XBridge Shield RP18, 100 x 4.6 mm, dp: 3.5µm; 
(ii) XTerra RP18, 50 x 4.6 mm, dp: 3.5µm;  
(iii) Zorbax Extend C18, 50 x 4.6 mm, dp: 5 µm 
Mobile phase: Methanol LC grade and 10 mM ammonium formate buffer pH 2.5 adjusted 
with formic acid or 6N HCl 
Elution mode: Gradient: 
100x4.6 mm 
Time (min) 
50x4.6 mm 
Time (min) 
MeOH 
(%, v/v) 
Buffer 
(%, v/v) 
00.0 
23.25 
27.25 
27.65 
39.25 
00.0 
11.0 
13.0 
13.2 
19.0 
5 
95 
95 
5 
5 
95 
5 
5 
95 
95 
 
Temperature: 25° C 
Flow rate: 1 mL min
-1
 
Wavelength: 230 nm 
Injected volume: 10 µL 
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4. RESULTS AND DISCUSSIONS 
 
4.1 Influence of factors on the chromatographic behavior of the analytes 
 
As illustrated in Fig. 4 (A, B, C); from the modelled retention times vs. the studied 
experimental factors (TG, pH, and T°), one can notice that the tR is significantly dependent to 
the variation of the TG and pH of the mobile phase, while the impact of temperature is not 
significant between 25°C and 35°C. Then, as normally known, the smaller the TG is, the 
shorter the analysis time is and consequently the tR of the analytes. Concerning pH variation, 
it was noticed that some compounds such as quinine (QN), artesunate (AS), mefloquine (MF), 
atovaquone (AT), and lumefantrine (LF) are susceptible of sensitive changes of tR at certain 
pH levels while others are relatively stable. For example it was noticed that the tR of QN and 
LF increase with the variation of pH from lower to higher pH levels; and an opposite situation 
was observed for AS and AT where the tR decreases from lower to higher pH levels. On the 
other hand, the tR of MF is stable at pH < 5 and increases at pH > 5. The other compounds i.e. 
nipagine (NpG), nipasol (NpS), proguanil (PG), BHA, artemether (AM), arteether (AE) and 
BHT have a stable tR in comparison with the variation of pH levels within the studied range of 
pH 2.5 – 7.0. One should also notice that at certain pH levels some compounds would co-
elute such as NpG and QN at around pH 2.8; NpS and PG at around pH 2.5; BHA and LF at 
around pH 3.2; MF and AS at around pH 5.2; and BHT, AE, AT at around pH 6.4 depending 
on physicochemical properties of each analyte. 
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Fig. 4 Modelled retention times (tR) of different compounds with respect to factors of 
experimental design: (A) TG; (B) T° (°C); (C) pH 
 
Legend: 
  
 
4.2 DoE/DS prediction and related experimental results 
 
The strategy of design of experiments (DoE) was previously applied by Debrus B. et al. 
(2011) [5], and the database created in that study helped to predict the best analytical 
conditions for (i) Simultaneous separation of arteether (AE), artemether (AM), artesunate 
(AS), atovaquone (AT), lumefantrine (LF), mefloquine (MF), proguanil (PG), quinine (QN), 
BHA, BHT, nipagin (NpG), and nipasol (NpS) for the analysis of these compounds in 
suspected counterfeit antimalarial medicines, (ii) Simultaneous separation of AM, LF, QN, 
BHA, BHT, NpG, and NpS for the analysis of QN or AM / LF in liquid dosage  forms 
generally containing the four excipients, (iii) Simultaneous separation of AE, AM, AS, and QN 
in injectable formulations such as powders for injection or aqueous and oily forms, and (iv) 
Simultaneous separation of AT, MF and PG in tablet forms of the three prophylactic 
antimalarial medicines. In fact, in real life, these methods shall be used generally in the 
analysis of suspected counterfeit medicines, and each method shall be selected according to 
the type of samples to be analyzed.  
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Thus far, the predicted optimal analytical conditions are given in Tables 1-3 for each 
category of analytes, and the Fig. 5 - 6 illustrate the probability surfaces showing the zone(s) 
of robustness (i.e. DS) within which the separation of the studied analytes are optimal for the 
screening and sub-screening methods of the 12 and 7 analytes respectively. The related 
predicted and experimental chromatograms are illustrated in Fig. 7 - 8.  
 
 
Fig. 5 Probability surfaces to reach S ≥ 0: (A) TG vs. Temp.; (B) pH vs. TG; (C) pH vs. 
Temp. for the screening method of 12 analytes 
 
 
Fig. 6 Probability surfaces to reach S ≥ 0: (A) TG vs. Temp.; (B) pH vs. TG; (C) pH vs. 
Temp. for the sub-screening method of 7 analytes 
 
In fact, when the probability of separation P(S > 0) is high, the risk of peak co-elution is 
low for the studied analytes. In this study for example, the optimal conditions for 
simultaneous analysis of QN and AM/LF in liquid dosage forms including the 4 excipients 
has a very good probability of more than 94% to separate well the seven analytes while the 
screening method for the 12 analytes has a lower probability of  around 10% for separating 
the 12 analytes due to compounds such as NpS and PG eluting at around tR = 35-36 minutes, 
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and AE with BHT at around tR = 57 minutes due to their chromatographic behavior which are 
quite comparable in the considered analytical conditions.  
 
 
Fig. 7.a Predicted and experimental chromatograms for the screening method of the 12 
analytes 
 
Experimental conditions: Column: SunFire C18, 250 x 4.6 mm, dp: 5 µm; Flow: 1 mL min-1; 
T°: 35°C; λ = 230 nm; Gradient elution with methanol and 10 mM ammonium acetate buffer pH 
5.65: 
 
Time (min) Methanol Buffer Elution phase type 
00.0 5 95 Gradient  
60.0 95 5  
70.0 95 5 Isocratic plate 
71.0 5 95 Re-equilibration  
100.0 5 95  
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Fig. 7.b Observed chromatogram by the second screening method for the analysis of the 12 
analytes 
 
Experimental conditions: Column: SunFire C18, 250 x 4.6 mm, dp: 5 µm; Flow: 1 mL min-1; 
T°: 35°C; λ = 230 nm; Gradient elution with methanol and 10 mM ammonium formate buffer pH 
2.5: 
 
Time (min) Methanol Buffer Elution phase type 
00.0 10 90 Gradient  
25.0 90 10  
35.0 90 10 Isocratic plate 
36.0 10 90 Re-equilibration  
65.0 10 90  
 
Note that the predicted and experimental chromatograms are quite comparable in terms of 
peaks elution order and retention times which changed at around ± 2 min of the predicted tR in 
general except for QN, AS and PG that changed at + 7 min, + 5 min and + 3 min respectively 
due to the change of the intrinsic nature of the SunFire column used in the experimentation 
vs. the original database created with a XBridge column. Moreover, we calculated the 
relationship between the predicted and observed tR for the screening method, and we found R
2
 
= 0.9697 which indicates the fitness of the method in giving good chromatographic results at 
around 97% of success on a SunFire column. On the other hand, the sub-screening method 
tested on a the same SunFire column gave very satisfactory results in terms of peak 
resolutions where all peaks are perfectly separated and identifiable (cf. Fig. 8). The change of 
elution order in this method is also caused by the intrinsic nature of the SunFire column used 
during the experimentation. 
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Fig. 8 Predicted and experimental chromatograms for the screening method of QN; AM / LF 
and 4 excipients (BHA, BHT, NpG, NpS) in liquid dosage forms. 
 
Experimental conditions: Column: SunFire C18, 250 x 4.6 mm, dp: 5µm; Flow: 1 mL min-1; T°: 
25°C; λ = 230 nm; Gradient elution with methanol and 10 mM ammonium formate buffer pH 4.3: 
 
Time (min) Methanol Buffer Elution phase type 
00.0 5 95 Gradient  
20.0 95 5  
30.0 95 5 Isocratic plate 
31.0 5 95 Re-equilibration  
60.0 5 95  
 
On the other hand, from the modelled retention times of different compounds with 
respect to the DoE factors (i.e. TG, T°, and pH) we deducted a sub-screening method 
applicable to the analysis of QN; AE; AM and AS in injectable forms; and the same method is 
applicable to the screening of QN, and AM / LF in tablet formulations, as well as for MF; PG 
and AT in tablet forms too at pH 2.5, TG: 20 minutes and temperature at 25°C whose 
chromatograms are illustrated in Fig. 10 after geometric transfer of the method on shorter 
analytical columns.   
 
4.3 Geometric transfer of the screening method  
 
To reduce the analysis time, we performed geometric transfer of the methods from long 
to short analytical columns; and the transferred analytical conditions were obtained thanks to 
the HPLC Calculator v3.0 freeware [11]. The Fig. 9 illustrates an example of chromatograms 
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obtained on short columns; and from these results, one can notice an important decrease of the 
run time to 41.5 min on a 150 x 4.6 mm, (dp: 5µm) column, and to 23.3 min on a 100 x 4.6 
mm, (dp: 3.5 µm) compared to 65 min on a 250 x 4.6 mm, (5 µm) column used during the 
method development. In order to further reduce the analysis time of the screening method, a 
shortened gradient profile described in Table 4 was tested and gave interesting results 
presented in the same table, but we suggest to consider this method as a larger sub-screening 
method capable to screen 10 analytes simultaneously within 19 minutes. We recommend to 
use this method on samples not containing Mefloquine and Nipasol together or Arteether and 
Lumefantrine together because the two couples of molecules co-elute at around 7.3 minutes 
and 9.3 minutes of the tR (min.) respectively. All other analytes are perfectly separated with 
this method. Thus far, the screening method can further be transferred to the shortest 
conventional column and therefore allowing to screen individually the four studied sub-
groups within 11 minutes as illustrated in Fig. 10.  
 
Hence, the transfer of these methods to different analytical columns allows the analysts to 
have a wide range of choice among columns available in the laboratory, and therefore apply 
the appropriate analytical conditions during the analysis of suspected counterfeit samples.  
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Fig. 9 Geometric transfer of the screening method from SunFire C18, 250 x 4.6 mm, (5 µm, 
dp) to XBridge C18, 150 x 4.6 mm, (5 µm, dp) and C18, 100 x 4.6 mm, (3.5 µm, dp)  
 
Experimental conditions: 
(A) Idem to Fig. 7.b 
 
(B) Column: XBridge C18, 150 x 4.6 mm, dp: 5µm; Flow: 1 mL/min; T°: 35°C; λ = 230 nm; 
Gradient elution with methanol and 10 mM ammonium formate buffer pH 2.5: 
 
Time (min) Methanol Buffer Elution phase type 
00.0 10 90 Gradient  
17.5 90 10  
23.5 90 10 Isocratic plate 
24.1 10 90 Re-equilibration  
41.5 10 90  
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(C) Column: XBridge C18, 100 x 4.6 mm, dp: 3.5µm; Flow: 1 mL/min; T°: 35°C; λ = 230 nm; 
Gradient elution with methanol and 10 mM ammonium formate buffer pH 2.5: 
 
Time (min) Methanol Buffer Elution phase type 
00.0 10 90 Gradient  
12.1 90 10  
14.9 90 10 Isocratic plate 
15.2 10 90 Re-equilibration  
23.3 10 90  
 
Elution order:  
Chromatogram (A): QN; PG; NpG; MF; NpS; BHA; AS; LF; AM; AE; BHT; AT 
Chromatogram (B): QN; NpG; PG; NpS; MF; BHA; AS; AE; LF; AM; BHT; AT 
Chromatogram (C): QN; NpG; PG; NpS; MF; AS; BHA; AE; AM; LF; BHT; AT 
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Fig. 10 Transfer of the second screening method on the shortest conventional analytical 
column for the screening of the 4 studied sub-group categories of antimalarial medicines 
 
Experimental conditions: Column: XBridge C18, 50 x 4.6 mm, dp: 5µm; Flow: 1 mL/min; T°: 
25°C; λ = 230 nm; Gradient elution with methanol and 10 mM ammonium formate buffer pH 2.5: 
 
Time (min) Methanol Buffer Elution phase type 
0.0 5 95 Gradient  
3.0 95 5  
5.0 95 5 Isocratic plate 
5.2 5 95 Re-equilibration  
11.0 5 95  
 
Elution order:  
Sub-group 1 chromatogram: QN; AS; AM; AE 
Sub-group 2 chromatogram: QN; LF; AM 
Sub-group 3 chromatogram: QN; NpG; NpS; BHA; LF; AM; BHT 
Sub-group 4 chromatogram: PG; MF; AT 
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4.4 Application of the methods on other compounds 
 
As shown in Table 4, the screening method was successively tested on various other 
compounds that can be used by counterfeiters instead of the eight studied antimalarial 
medicines which are AE, AM, AS, AT, LF, MF, PG and QN with four major preservatives 
and antioxidants BHA, BHT, NpG, and NpS. Then, the results revealed that the method can 
easily detect 11 other types of antimalarial medicines not officially used in Rwanda i.e. 
piperaquine, amodiaquine, chloroquine, cinchonine, sulfadoxine, pyrimethamine, sulfalene, 
halofantrine, primaquine, artemisinine and dihydroartemisinine; 14 non-steroidal anti-
inflammatories and related compounds: diclofenac, caffeine, acetylsalicylic acid, ibuprofen, 
atenolol, paracetamol, sodium benzoate, dexamethasone, codeine, prednisolone, naproxen, 
furosemide, methylprednisolone, and diazepam; and 13 antibiotics: amoxicillin, ampicillin, 
trimethoprim, levofloxacin, chloramphenicol, phenoxymethylpenicillin, clindamycin, 
sulbactam, tazobactam, tetracycline, cefotaxime, ceftriazone, and ciprofloxacin. This 
application of the method on other molecules is very useful in the sense of demonstrating the 
high capability of HPLC technique in detecting a wide range of other molecules that can be 
used in counterfeiting.  
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Table 4 
Peak separation by the shortened gradient profile on XBridge C18, 100 x 4.6 mm, dp: 3.5µm; 
Flow: 1 mL/min; T°: 35°C; λ = 230 nm; Gradient elution with methanol and 10 mM 
ammonium formate buffer pH 2.5: 
 
Time (min) Methanol Buffer Elution phase type 
0.0 10 90 Gradient  
7.9 90 10  
10.7 90 10 Isocratic plate 
11.0 10 90 Re-equilibration  
19.0 10 90  
 
 A. Targeted 12 analytes (Rwanda)  B. Other antimalarials 
# Molecule  tR (min) # Molecule  tR (min) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
Quinine 
Nipagin 
Proguanil 
Mefloquine 
Nipasol 
Artesunate 
BHA 
Artemether 
Arteether 
Lumefantrine 
BHT 
Atovaquone 
3.20 
5.70 
5.94 
7.34 
7.37 
7.74 
8.00 
8.83 
9.21 
9.30 
9.74 
10.43 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
- 
Piperaquine 
Cinchonine 
Chloroquine 
Amodiaquine 
Sulfalene 
Sulfadoxine 
Primaquine 
Pyrimethamine 
Dihydroartemisinin 
Artemisinin 
Halofantrine 
- 
1.90 
2.43 
3.32 
3.70 
4.17 
4.48 
4.94 
5.07 
7.40 
7.56 
8.90 
- 
 C. NSAIs and related molecules  D. Antibiotics 
# Molecule  tR (min) # Molecule  tR (min) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
Atenolol 
Metamizole* 
Codeine 
Paracetamol 
Caffeine 
Aspirin 
odium benzoate 
(Unidentified)** 
Furosemide 
Prednisolone 
Dexamethasone 
Methylprednisolone 
Diazepam 
Naproxen 
Ibuprofen 
Diclofenac 
2.07 
2.17 
2.53 
2.70 
3.61 
4.79 
5.37 
6.04 
6.28 
6.57 
7.00 
7.13 
7.33 
7.60 
8.54 
8.63 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
- 
- 
- 
Sulbactam 
Ceftriaxone 
Tazobactam 
Amoxicillin 
Trimethoprim 
Cefotaxime 
Tetracycline 
Ampicillin 
Levofloxacin 
Ciprofloxacin 
Chloramphenicol 
Clindamycin 
Penicillin V 
- 
- 
- 
2.18 
2.23 
2.63 
2.71 
3.43 
3.86 
3.88 
4.00 
4.11 
4.34 
5.40 
5.54 
6.87 
- 
- 
- 
 
Note: * Metamizole was poorly detected; its peak was very negligible nearer to the baseline noise. 
          ** A very significant peak was detected, but not expected. We assume that it is Ibuprofen 
photodegradant    
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Thus, after noticing how much this screening method had sharply detected all those 
molecules, there is a guarantee that several other compounds that can be used by 
counterfeiters will be easily detected too, and therefore be discarded from the supply chain. 
 
5. CONCLUSION 
 
An earlier developed DoE-DS database was exploited during the optimization of: (i) an 
overall screening method for the analysis of eight antimalarial medicines officially used in 
Rwanda with four major excipients (i.e. arteether, artemether, artesunate, atovaquone, 
lumefantrine, mefloquine, proguanil, and quinine with BHA, BHT, nipagin and nipasol); (ii) a 
sub-screening method for the analysis of quinine, artemether and lumefantrine in liquid 
dosage forms containing the four excipients; and (iv) a generic sub-screening method for the 
analysis of quinine, arteether, artemether, and artesunate in injectable forms; mefloquine, 
atovaquone and proguanil in solid dosage forms; quinine, artemether and lumefantrine in 
tablet forms. These methods are mainly useful in the analysis of suspected counterfeit 
antimalarial medicines containing or not any of the four studied preservatives and 
antioxidants.  
 
Then, to reduce the analysis time and increase the sample analysis throughput, the 
methods were geometrically transferred to shorter analytical columns, and another advantage 
is the reduction of the mobile consumption and the inherent liquid wastes.  
 
Moreover, the screening method was applied in testing other types of classical 
compounds in the range of other antimalarial medicines not officially used in Rwanda, non-
steroidal anti-inflammatories and related compounds, and antibiotics in order to assess 
whether the method has the capacity of detecting other components that could be used by 
counterfeiters, and the method was found very effective.      
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IV.3 SECTION 3 - Simple LC isocratic Methods development, Validation, and 
Application in the Analysis of poor quality antimalarial medicines 
 
American Journal of Analytical Chemistry, 2017, 8, 582-603 
http://www.scirp.org/Journal/PaperInformation.aspx?PaperID=79155 
 
IV.3.1 Preamble to Article 3 
 
Very often, in developing countries, we find LC equipment with binary pumps or other ones 
for which the gradient mode cannot be used. It is therefore important to have simple analytical 
methods that are applicable to both systems in order to increase the pool of utilization either 
on one system or another. This is particularly relevant for the analysis of vital and essential 
medicines such as the antimalarials that are highly targeted by counterfeiters and that have to 
be analyzed more rapidly. So in this section we present a methodological approach for the 
development of simple LC methods for routine analysis of antimalarial medicines widely 
marketed in generic forms, and which are most likely to be counterfeit or substandard. To 
fulfill the needs for such methods and context, some technical and economical criteria were 
obvious namely their simplicity, short analysis time, low mobile phase consumption, 
adaptability to LC systems equipped with simple or gradient pumps, large flexibility to 
tolerable changes on the mobile phase organic and aqueous proportions, column dimensions, 
flow rate, etc. without need of revalidation, and of course transferability. 
 
We have also considered the use of methanol as organic modifier that is available compared 
to acetonitrile which is expensive (almost three times more than the cost of methanol), and the 
use of ammonium formate buffer that is volatile without risk of precipitation in the LC 
system. 
 
The following antimalarial medicines were included in this study: 
 
- Quinine with major cinchona alkaloids (cinchonidine and dihydroquinine) in tablet 
forms; 
- Quinine resorcin with major cinchona alkaloids (cinchonine, cinchonidine, quinidine, and 
dihydroquinine) with resorcinol in injectable solutions; 
- Artemether / lumefantrine tablet forms; and 
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- Arteether, artemether, artesunate in injectable forms. 
 
The method for analysis of artesunate powder for injection was successfully validated and 
applied on real samples, and different other samples of artemether / lumefantrine tablets from 
different places in Rwanda, DRC and Benin were also analyzed. Bad results were obtained on 
three samples of artemether / lumefantrine tablets that were found out-of-specifications, and 
very alarming results were found on fake quinine tablets and fake Coartem (artemether / 
lumefantrine) that did not contain any of the declared active ingredients. 
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IV.3.2 Article 3 
 
 
 
ABSTRACT 
 
Liquid chromatographic methods in isocratic mode for the analysis of poor quality medicines 
are privileged due to their simplicity and facility in methods development. They are generally 
fast; do not need to be re-equilibrated between sample injections; have larger flexibility with 
acceptable changes on different column dimensions; and are applicable to LC systems 
equipped with simple or high developed pumps. In this study, we focused on developing 
simple isocratic methods using classical mobile phase composed by methanol and ammonium 
formate buffer for the analysis of most common antimalarial medicines marketed in malaria 
endemic countries and susceptible of being counterfeit/falsified, substandard and degraded.  
 
The selected medicines were quinine and related cinchona alkaloids in tablets and injectable 
forms; artemether/lumefantrine tablets; and artemisinin compounds (arteether, artemether, and 
artesunate) in injectable forms. The current methods were developed thanks to simple 
methodological approach consisting in sequential isocratic runs through adjustment or 
adaptation of existing methods to obtain optimal analytical conditions without complex 
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design of experiments that might be long and costly. Then, the new methods presented shorter 
analysis time; allowed increase of sample analysis throughput; and obviously consumed little 
mobile phase solvents on classical analytical columns: 50 – 250 mm of length (L), 4.6 mm of 
internal diameter (I.D.), and 3.5 - 5.0 μm of particle size (dp). 
 
1. INTRODUCTION 
 
Malaria is a life-threatening disease caused by Plasmodium parasites transmitted to people 
through the bites of infected female Anopheles mosquitoes (called malaria vectors). It is 
usually found in tropical and subtropical climates where the parasites live [1] [2]. According 
to the latest estimates of the World Health Organization (WHO), released in end of 2016, 
there were 212 million cases of malaria in 2015 and 429,000 deaths. The WHO African 
Region is the most affected by that disease and its consequences [1]. Thus far, the prevention 
of malaria involves among others the use of “insecticide-treated mosquito nets” and “indoor 
residual spraying” as effective vector control mechanisms, and the use of “antimalarial 
medicines” in disease treatment or chemoprophylaxis. Concerning medicines, they should 
always meet their quality specifications in order to give guarantee on their safety and efficacy 
during their shelf lives. Otherwise, any failure to the required quality standards may lead to 
serious public health concerns such as failure in disease treatment, development of drug 
resistance, increase of morbidity and mortality, etc. 
 
Indeed, poor quality medicines constitute a harmful threat to the public health worldwide, 
particularly in under-resourced countries [3] [4] [5]. Newton et al. [3] distinguished three 
categories of poor quality medicines: (i) Counterfeit/falsified medicines which are illicit 
products maliciously produced and distributed; (ii) Substandard also called out-of-
specification “OOS” products which are genuine products generally produced in poor 
manufacturing conditions; and (iii) Degraded medicines which are products improperly 
stored, and spoiled. Hence, there is need to develop fast, effective, simple and transferable 
analytical methods to drug quality control laboratories in developing countries, and therefore 
reinforce their capacity in detecting and fighting against the spread of those harmful products. 
In this context, we have developed simple isocratic methods for the analysis of curative 
antimalarial medicines most used in Rwanda i.e. artemether/lumefantrine, artesunate, and 
quinine with related other compounds that should be associated with them in case of 
counterfeiting, substandard, or degradation. This is the case for example of quinine and 
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related cinchona alkaloids such as cinchonine, cinchonidine, quinidine, and dihydroquinine, 
together with resorcinol most found in quinine resorcin formulations, etc. Moreover, we 
added arteether to the group of artemisinin derivatives that should be easily interchanged with 
artemether and artesunate due to their closer chemical structure similarity (see Figure 1). 
 
The technique of Liquid Chromatography (LC) coupled with UV detector or DAD was 
selected as gold standard for chemical separation, quantification and identification of simple 
and complex samples. This technique is highly used in pharmaceutical analysis, very sensitive 
and accurate; it gives results in relatively good-time, generally within approximately 10 and 
15 minutes for isocratic methods, and within less than 60 minutes for gradient methods; and 
has a great capacity of automation [5] [6]. 
 
 
Figure 1 Molecular structures of the studied analytes 
 
The targeted methods were privileged for their simplicity, shorter analysis time, and higher 
analysis sample throughput; they were developed thanks to the adjustment (fine-tuning) or 
adaptation of other existing methods in fewer experimental runs without passing through 
design of experiments that are information fullness however with high cost and relatively long 
time consuming. Then, after optimizing the new methods, they must be validated according to 
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the International Conference on Harmonization “ICH-Q2(R1)” guidelines [7], and we used 
the total error strategy based on random and systematic errors corresponding to the precision 
+ trueness, and using accuracy profiles as decision tool on the fitness of the methods for their 
intended use within given acceptable limits [8] [9] [10] [11]. 
 
Finally, in the frame of reducing the analysis time, we transferred the methods from long to 
shorter analytical columns in the classical range of 250 mm and 50 mm of length (L) × 4.6 
mm of internal diameter (ID), and 5.0 to 3.5 μm of the particle size (dp) before use in routine 
analysis of different medicines especially when detecting counterfeit formulations. 
 
2. MATERIALS AND METHODS  
 
2.1 Materials 
 
Arteether (100%), Artemether (100%), Artesunate (> 97%), and Lumefantrine (100%) were 
purchased from Sensa Pharm (Lanchester, UK), and quinine sulfate (99.0%) from Fagron 
N.V. (Waregem, Belgium), quinine dihydrochloride (100.8%) from Molekula Limited 
(Dorset, UK), Hydrochloric acid (37%) and ammonium formate (98.1%) from VWR 
International BVBA (Leuven, Belgium), Methanol LC grade from Avantor Performance 
Materials B.V. (Deventer, The Netherlands), the Ultrapure Water was produced with a Milli-
Q Plus 185 water purification system (Millipore, Billerica, MA, USA), and various samples 
of quinine tablets (300 mg), quinine for injection (300 mg/mL and 600 mg/mL) as labeled on 
the primary packaging, artemether/lumefantrine tablets (20 mg / 120 mg and 80 mg / 480 
mg), and artesunate powder for injection (60 mg) were randomly collected from Rwanda, 
Democratic Republic of Congo, and Benin. 
 
2.2 Methods development strategy and validation  
 
Methods in isocratic mode were developed by simple systematic approach, and by adaptation 
or adjustment of other methods on similar compounds. These methodologies have an 
advantage of reducing the number of experiments to be carried out without going through 
complex design of experiments (DoEs). The strategy of simple systematic approach was 
based on sequential isocratic runs and optimization of the most promising results, while the 
methods adaptation or adjustment was based on other methods found in literature (scientific 
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publications) on the same analytes, and tested with adequate adaptations or adjustments to 
have the desired chromatographic conditions using our preferred mobile phase composed by 
methanol and ammonium formate buffer. 
 
2.3 Instrumental and software 
 
2.3.1 LC equipments 
 
The methods were developed in Belgium on a Waters 2695 Alliance HPLC Separation 
Module coupled to Waters 2996 photodiode array (PDA) detector from Waters Corporation 
(Milford, MA, USA) piloted with Empower 2.0 software (Waters Corporation). Different 
chromatographic columns packed with C18 or C8 stationary phases, in different dimensions 
(L: 50 mm to 250 mm, ID: 4.6 mm; dp: 3.5 μm and 5 μm) were used during the methods 
development and geometric transfer as described in the experimental part. 
 
2.3.2 Software 
 
Empower 2.0 software (Waters Corporation, MA, USA) for Windows was used to control the 
Waters Alliance HPLC system, to record the signals from the detector and interpret the 
generated chromatograms. Then, different optimum levels for geometric transfer from 
columns to others were calculated using HPLC Calculator v3.0 developed by Guillarme et al. 
[12], and the accuracy profiles as well as the statistical calculations including the validation 
results and uncertainty estimates were obtained thanks to e-noval
®
 V3.0 software (Arlenda, 
Belgium). 
 
2.4 Preparation of sample solutions 
 
2.4.1 Sample solutions for method development for the analysis of arteether, artemether, 
artesunate and quinine in different injectable formulations 
 
In the first step, approximately 10.0 mg of quinine base from quinine dihydrochloride 
chemical reference substance (CRS) were dissolved with methanol in 100.0 mL volumetric 
flask; and in the second step, this solution was used to dissolve and dilute approximately 10.0 
mg of each of the arteether, artemether and artesunate reference substances weighed in a 2.0 
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mL volumetric flask. This was the final working solution annotated “Solution Q3A” to be 
injected in the chromatographic system. It contained approx. 100 μg mL-1 of quinine, and 
5000 μg mL-1 of the three artemisinin derivate compounds. 
 
2.4.2. Sample solutions for method adaptation for the analysis of quinine, resorcinol, 
quinidine, dihydroquinine and other cinchona alkaloids in tablets and injectable 
formulations 
 
The working sample solutions were prepared from two real medicines containing the studied 
analytes (i.e. quinine, dihydroquinine, quinidine, cinchonine, cinchonidine, and resorcinol) 
manufactured by Sanofi-Winthrop Pharma (Senegal) and Wintac Ltd. (India). 
 
Each sample solution was diluted with purified water to have a final working solution 
containing approximately 100 μg mL-1 of quinine alkaloid which is the main active 
ingredient, and the concentrations of other cinchona alkaloids together with resorcinol were 
subsequently reduced according to the product formulation as stated on the labeled 
composition. For example, one sample of ampoule 4 mL was stated to contain per mL: 96.10 
mg of quinine resorcinol dihydrochloride, 2.55 mg of quinidine resorcinol dihydrochloride, 
0.68 mg of cinchonine resorcinol dihydrochloride, 0.67 mg of cinchonidine resorcinol 
dihydrochloride, and water for injection BP q.s. Then, to have final working solutions 
containing approx. 100 μg mL-1 of quinine resorcinol dihydrochloride, 520 μL of quinine 
resorcin injection sample were diluted in 500 mL volumetric flasks before they were injected 
in the chromatographic system for analysis. Note that the content of resorcinol was not 
mentioned on both samples, but the product was well identified as shown later in results. 
Then, to identify all six analytes, we injected separately in the LC system single solutions of 
quinine reference substance (100 μg mL-1 in purified water) containing dihydroquinine 
(<10%), cinchonine CRS (50 μg mL-1 in purified water), cinchonidine CRS (50 μg mL-1 in 
purified water), quinidine CRS (50 μg mL-1 in purified water), and resorcinol CRS (50 μg mL-
1
 in purified water too). 
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2.4.3. Sample solutions for method adjustment for the analysis of artemether / 
lumefantrine in tablet formulations 
 
Reference to the USP, International and European pharmacopoeias allowable adjustments in 
chromatographic systems [13] [14] [15], our previously validated method for the analysis of 
artemether/lumefantrine in tablets forms [16] was adjusted in order to reduce the analysis time 
and increase the sample analysis throughput. The following solutions were prepared: 
 
Standard solutions: 
 
Dissolve accurately weighed quantities of artemether and lumefantrine reference substances 
in appropriate volumetric flask with acidified methanol by phosphoric acid (0.2% phosphoric 
acid in methanol, w/v) to obtain 200 and 1200 μg mL-1 of both analytes respectively. Prepare 
two independent standard solutions for system suitability testing and analysis. 
 
Sample solutions: 
 
Different samples randomly collected using blind sampling techniques from Rwanda (n = 13), 
D.R. Congo (n = 9), and Benin (n = 1 suspected counterfeit) were prepared for analysis in the 
frame of quality assessment of artemisinin-based combination therapy (ACT) medicines 
marketed in the three countries. 
 
The sample solutions were prepared by weighing and powdering 20 tablets; and transferring a 
quantity of each sample powder containing approximately 20 mg of artemether and 120 mg of 
lumefantrine accurately weighed in 100.0 mL volumetric flask, and dissolving the sample 
with the acidified methanolic solution (phosphoric acid 0.2%, w/v) used in the preparation of 
artemether/lumefantrine standard solutions by mechanical shaking on vortex during 1 minute, 
and dilution to volume with the same solvent to obtain approx. 200 and 1200 μg mL-1 of both 
analytes respectively. Prepare three independent sample solutions per batch, and filter each 
solution through 0.45 μm filter before they are injected in the chromatographic system. 
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2.4.4. Sample solutions for method validation and routine analysis for artesunate 
powder for injection 
 
a) Sample solutions for method validation 
 
They consisted of three concentration levels for calibration standards (CS), and five 
concentration levels for validation standards (VS). The required solutions were prepared as 
described in section 3.2.  
 
b) Sample solutions for routine analysis 
 
The samples of artesunate powder for injection were prepared by dissolving with methanol 
LC grade approximately 10.0 mg of the sample in 2.0 mL volumetric flasks and completing to 
volume with the same solvent to obtain around 5000 μg mL-1 final solutions against 
artesunate reference substance prepared at the same concentration level with the same solvent. 
Three independent sample solutions were prepared, and two independent reference solutions 
for system suitability testing and sample analysis. 
 
3. EXPERIMENTATION 
 
3.1. Simple isocratic methods development by adaptation or adjustment and sequential 
isocratic runs with fine-tuning 
 
Simple isocratic methods for the analysis of (i) quinine and artemisinin derivatives (arteether, 
artemether, and artesunate), (ii) quinine resorcin and major cinchona alkaloids (cinchonine, 
cinchonidine, quinidine, and dihydroquinine), and (iii) artemether / lumefantrine in different 
pharmaceutical forms were developed through sequential isocratic runs with optimization 
(fine-tuning), and by simple adaptation or adjustment of other methods in order to reduce the 
analysis time, improve the sample treatments conditions, and use of our preferred mobile 
phase composed by methanol and ammonium formate buffer which is not expensive and that 
can be transferred to LC/MS for advanced analysis whenever needed for the identification of 
unknown compounds. Moreover, isocratic methods have an advantage of flexibility to 
tolerable changes with column dimensions, flow rate of the mobile phase, organic modifier 
proportion, etc. that can be done without need of the methods revalidation [13] [14] [15]. 
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3.1.1. Development of a generic method for the analysis of quinine, arteether, 
artemether and artesunate in injectable formulations 
 
The development of a generic isocratic method for the analysis of quinine, arteether, 
artemether and artesunate was done through a simplified systematic approach based on 
sequential isocratic runs with optimization (fine-tuning) described in Table 1, using classical 
analytical columns and mobile phase composed by methanol and ammonium formate buffer. 
 
The first three experiments helped to know the trend of peak separation of the four analytes 
either at higher or lower proportion of the organic modifier, and therefore have an idea on 
which parameter to make changes in the optimization phase. For example, if the best 
separation of the analytes is at the lower level of methanol (i.e. at Test 1: 25/75% 
MeOH/Buffer, v/v), one can plan for two additional tests at 25% ± 10% of methanol (i.e. Test 
4: 15/85% and Test 5: 35/65% MeOH/Buffer, v/v), and then continue the adjustment of the 
method with the flow rate changes at 0.7 mL min
-1
 or 1.3 mL min
-1
 if needed (Test 6), 
temperature changes at 35˚C (Test 7), or columns dimensions (Test 8: L = 50 - 250 mm; ID: 
4.6 mm; dp: 3.5 or 5 μm) in order to have the desired chromatographic separation within ≤ 10 
minutes of run time generally preferred for isocratic methods. 
 
Table 1 
Simplified sequential isocratic experiments 
Factor  Experiments 
Test (1) Test (2) Test (3) Optimization (± 5 tests) 
Mobile phase : 
     Methanol 
     NH4 formate buffer 
(*)
 
< 50% 
25% 
75% 
50:50% 
50% 
50% 
> 50% 
75% 
25% 
About five more tests are added: 
For example at the Flow of 1.0 
± 0.3 mL min
-1
. (0.7 mL min
-1
 
and 1.3 mL min
-1
); 25 or 75 ± 
10%, v/v of organic modifier 
(15:85%, or 35:65%; 65:35% or 
85:15%) v/v, column 
dimensions, or column 
temperature adaptations, etc.   
Flow rate (mL min
-1
) 1.0 1.0 1.0 
Column temperature (°C) 25 25 25 
Injection volume (µL)  10 10 10 
Detection wavelength (nm)  210 210 210 
(*): The aqueous mobile phase is 10 mM ammonium formate pH 2.8  
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3.1.2. Development of isocratic method for the analysis of quinine, resorcinol, 
dihydroquinine and major cinchona alkaloids 
 
The analysis of quinine in different pharmaceutical forms is generally done with other 
cinchona alkaloids especially dihydroquinine that should not be more than 10% of content, 
cinchonidine not more than 5%, and any other related substance such as cinchonine, 
quinidine, etc. at not more than 2.5% calculated by the area percentage method to quinine 
peak area [17]. 
 
Reference to other existing methods covering almost the same analytes [18] [19], we 
optimized a rapid isocratic method for the analysis of quinine, resorcinol, cinchonine, 
cinchonidine, quinidine, and dihydroquinine by adapting these methods to our analytes and 
changing the earlier mobile phase to methanol and ammonium formate buffer. Resorcinol was 
added to the list of the studied analytes, as being one of the key ingredients in quinine resorcin 
injection solutions widely used in different malaria endemic countries. 
 
The method was optimized on a Zorbax SB-C8 (dp 3.5 μm) column, (150 mm × 4.6 mm ID) 
maintained at 35˚C, applying as mobile phase an isocratic mixture of methanol and 10 mM 
ammonium formate buffer (adjusted to pH 2.8 with formic acid or 6 N hydrochloric acid) 
(40:60, v/v) for the analysis of quinine tablets containing generally quinine sulfate, 
dihydroquinine, and cinchonidine; and (30:70, v/v) for the analysis of quinine resorcin 
injection containing the six analytes (quinine, resorcinol, dihydroquinine, cinchonine, 
cinchonidine, and quinidine), at a flow rate of 1 mL min
-1
. The sample solutions were 
thermostated at 15˚C, introduced in the separation system at 10 μL injection volumes, and 
monitored at 230 nm. 
 
3.1.3. Adjustment of the method for analysis of artemether / lumefantrine in tablet 
formulations 
 
Our former analytical method for the analysis of artemether/lumefantrine in tablet 
formulations [16] was readjusted to improve the analysis time (run time), and sample 
treatment by increasing the capacity of methanol in dissolving lumefantrine. Hence, to 
improve the analysis time, we slightly increased the proportion of methanol in the mobile 
phase and the run time reduced; then, to increase the capacity of methanol in dissolving 
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lumefantrine, we slightly increased the acidity power by using methanol acidified with 
phosphoric acid 0.2% (w/v) instead of 0.1% (w/v) previously used. 
 
The method was adjusted on a Zorbax 80Å Extend-C18, 100 mm × 4.6 mm (ID), (dp: 3.5 μm) 
chromatographic column at a flow rate of 0.7 mL min
-1
 of methanol and 10 mM ammonium 
formate buffer pH 2.8 (85:15%, v/v) maintained at 25˚C, injecting 6 μL of the sample and 
reference solutions, and recording the chromatographic data at 210 nm. The dissolution of 
lumefantrine was improved by slight increases of the phosphoric acid in methanol from the 
original content of 0.1% to 0.2% (w/v) that is enough to dissolve the targeted analyte by hand 
shaking or vortex easily. 
 
3.2. Validation of the method for analysis of artesunate powder for injection 
 
The generic isocratic method for the analysis of quinine and artemisinin derivatives was 
validated for specific analysis of artesunate powder for injection. The calibration and 
validation standard solutions were prepared by dissolving artesunate CRS in methanol in 
order to have the following solutions. 
 
Calibration standards : 
 
Level 1 (60%): 3000 μg mL-1 of artesunate (approx. 15.0 mg in 5.0 mL vol. flask); 
Level 3 (100%): 5000 μg mL-1 of artesunate (approx. 10.0 mg in 2.0 mL vol. flask); 
Level 5 (140%): 7000 μg mL-1 of artesunate (approx. 14.0 mg in 2.0 mL vol. flask). 
 
Validation standards : 
 
The validation standards (VS) were prepared with artesunate CRS and methanol as solvent. 
There is no sample matrix as the studied product is a pure raw material without any excipient, 
and the concentration level is higher due to the weak absorption of the UV light by artesunate. 
The VS were prepared to have five different concentration levels, three series per day, during 
three validation days. 
 
Level 1 (60%): 3000 μg mL-1 of artesunate (approx. 15.0 mg in 5.0 mL vol. flask); 
Level 2 (80%): 4000 μg mL-1 of artesunate (approx. 20.0 mg in 5.0 mL vol. flask); 
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Level 3 (100%): 5000 μg mL-1 of artesunate (approx. 10.0 mg in 2.0 mL vol. flask); 
Level 4 (120%): 6000 μg mL-1 of artesunate (approx. 12.0 mg in 2.0 mL vol. flask); 
Level 5 (140%): 7000 μg mL-1 of artesunate (approx. 14.0 mg in 2.0 mL vol. flask). 
 
To sum up, three independent solutions (n = 3) were prepared per each concentration level (c 
= 3 for CS, c = 5 for VS), and all these preparations were repeated for three days 
corresponding to three series (s = 3). The method was validated on a C18, 150 × 4.6 mm, dp: 
5 μm column in order to allow covering the widest range of classical HPLC columns’ sizes 
and allowable changes. 
 
Then, for routine analyses, two independent reference solutions for system suitability testing 
and sample analysis were prepared at 5000 μg mL-1 i.e. Level 3 (100%) against three 
independent sample solutions per batch was prepared at the same concentration level. 
 
3.3. Sampling and application of the methods on real samples 
 
Seventeen sampling sites mapped in Figure 2 were defined for collecting different 
antimalarial medicines found on the list of national essential medicines for  Rwanda [20] [21] 
[22]. The targeted sampling points were hospitals and pharmacies in public and private 
sectors, and tentatively illicit vendors if available, located in strategic cities, suburbs, and 
Rwanda’s borders. The sampling sites were selected on the basis of areas known to have 
intensive commercial activities, border areas with other countries (Burundi in South, Tanzania 
in East, Uganda in North, and D.R. Congo in West) where the risk of illegal trade of goods 
including medicines is relatively higher and therefore the possibility of entry of poor quality 
medicines especially counterfeit/falsified and substandard. All samples were selected 
randomly by considering batch numbers, manufacturers, strength, and dosage forms (tablets, 
capsules, injectables, etc.). 
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Figure 2 Strategic sampling sites on the map of Rwanda (Western Province: (1) Bugarama, (2) 
Kamembe, (3) Karongi/Kibuye, (4) Rubavu/Gisenyi; Northern Province: (5) Musanze/Ruhengeri, (6) 
Gicumbi/Byumba, (7) Gatuna; Eastern Province: (8) Nyagatare, (9) Kagitumba, (10) Rwamagana, 
(11) Ngoma/Kibungo, (12) Nyamata/Bugesera, (13) Ruhuha/Ngenda; Southern Province: (14) 
Muhanga/Gitarama, (15) Huye/Butare, (16) Nyamagabe/Gikongoro; and Kigali City: (17) The 
Capital). 
 
Moreover, other samples of antimalarial medicines were received from Kinshasa (university 
of Kinshasa, D.R. of Congo) and Cotonou (University of Abomey Calavi, Benin) in the frame 
of scientific collaboration including the University of Liege (Belgium) in the project of 
fighting against counterfeit medicines. 
 
4. RESULTS AND DISCUSSIONS 
 
4.1. Adaptation of the method for the analysis of quinine, resorcinol and major cinchona 
alkaloids in different pharmaceutical forms 
 
A simple isocratic method for the analysis of quinine, resorcinol, and major cinchona 
alkaloids in different pharmaceutical forms was optimized thanks to the adaptation of other 
methods. In fact, from literature search, we identified two interesting references [18] [19] 
from which we did necessary adaptations with our regular mobile phase composed by 
methanol and ammonium formate buffer. Hence, we decided to run some experiments around 
the practical conditions of the two reference methods as summarized in Table 1; and we got 
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satisfactory results at 10 mM ammonium formate buffer pH 2.8 and methanol (60:40, v/v) as 
illustrated in Figure 3 for the analysis of quinine, dihydroquinine and cinchonidine generally 
tested in quinine tablet forms [17]; and for the analysis of quinine, resorcinol, cinchonine, 
cinchonidine, quinidine, and dihydroquinine in injectable forms, the optimum proportions of 
mobile phase was found at 70:30, v/v for 10 mM ammonium formate buffer pH 2.8 and 
methanol, respectively. Figure 4 illustrates the case of simultaneous separation of the six 
analytes in quinine resorcin solutions. 
 
This method was also geometrically transferred to shorter analytical columns in order to 
reduce the analysis time and therefore increase the sample analysis throughput as well as 
reducing the consumption of the mobile phase. 
 
 
Figure 3 Isocratic method for the analysis of quinine and major cinchona alkaloids in tablet 
pharmaceutical forms. Experimental conditions: Column: Zorbax C8, 150 × 4.6 mm, dp: 5 μm; 
Flow: 1 mL min
-1; T˚: 35˚C; λ = 230 nm; Isocratic elution with methanol and 10 mM ammonium 
formate buffer pH 2.8 (40:60, v/v). Elution order: Cinchonidine (≈ 3.274 min.), quinine (≈ 4.140 
min.), dihydroquinine (≈ 5.291 min.). 
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Figure 4 Isocratic method for the analysis of quinine resorcin and major cinchona alkaloids in 
injectable solutions. Experimental conditions: Column: Zorbax C8, 150 × 4.6 mm, dp: 5 μm for 
chromatogram (a), and Zorbax C8, 50 × 4.6 mm, dp: 3.5 μm for chromatogram (b); Flow: 1 mL min-
1; T˚: 35˚C; λ = 230 nm; Isocratic elution with methanol and 10 mM ammonium formate buffer pH 2.8 
(30:70, v/v). Elution order (identic to both chromatograms): i) Chromatogram (a): Resorcinol (≈ 
2.844 min.), cinchonine (≈ 4.513 min.), cinchonidine (≈ 5.504 min.), quinidine (≈ 6.170 min.), quinine 
(≈ 8.095 min.), dihydroquinine (≈ 11.226 min.); ii) Chromatogram (b): Resorcinol (≈ 1.007 min.), 
cinchonine (≈ 1.835 min.), cinchonidine (≈ 2.272 min.), quinidine (≈ 2.615 min.), quinine (≈ 3.452 
min.), dihydroquinine (≈ 4.962 min.). 
 
 
 
 
(a) 
(b) 
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4.2 Adjustment of the method for the analysis of artemether/lumefantrine in tablet 
forms 
 
Our earlier developed method in isocratic mode for the analysis of artemether and 
lumefantrine in tablet forms [16] was adjusted by improving the dissolution capacity of 
methanol on lumefantrine and therefore allowing to speed up the process of sample 
preparation by acidifying methanol at 0.2% w/v with phosphoric acid. Indeed, lumefantrine is 
practically insoluble in water, soluble in dichloromethane and chloroform, and slightly 
soluble in methanol but we privileged to dissolve it with the acidified methanol to avoid the 
use of chloroform or dichloromethane which are very chromophorous and capable of giving 
an additional peak in the chromatogram that would compete with lumefantrine and therefore 
reduce the detection of artemether which does not absorb well the UV light.  
 
Moreover, the amount of lumefantrine is six times the amount of artemether in different 
medicines, and this is another challenge during sample preparation as there is need of having 
an effective solvent for both analytes that cannot compromise the chromatographic results. 
Hence, from the original method that had a run time of 16 minutes, we adapted the mobile 
phase proportions to 85:15, v/v of methanol and ammonium formate buffer pH 2.8 
respectively, 0.7 mL min
-1
 of flow rate, and 25˚C of column oven using a Zorbax-Extend 
C18, 80Å, 100 × 4.6 mm (dp: 3.5 μm) analytical column. This allowed to reduce the analysis 
time from 16 to 6 minutes on a 100 × 4.6 mm column as illustrated in Figure 5, and to 10 
minutes on a 150 × 4.6 mm column with the possibility to reduce the run time by changing 
the flow rate to 1.0 mL min
-1
 with the same mobile phase. 
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Figure 5 Readjusted isocratic method for the analysis of artemether-lumefantrine in tablet forms. 
Experimental conditions: Column: Zorbax-Extend C18, 80Å, 100 × 4.6 mm, dp: 3.5 μm (entire and 
zoomed chromatograms to visualize artemether); Flow: 0.7 mL min
-1; T˚: 25˚C; λ = 210 nm; Isocratic 
elution with methanol and 10 mM ammonium formate buffer pH 2.8 (85:15, v/v). Elution order: 
Lumefantrine (≈ 2.548 min.) and artemether (≈ 4.508 min.) in Full chromatogram (a) and magnified 
chromatogram (b) for low abundant peak. 
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4.3 Simple development and geometric transfer of an isocratic method for the analysis of 
arteether, artemether and artesunate in injectable forms 
 
A simple isocratic method for the analysis of quinine, arteether, artemether and artesunate was 
developed thanks to a simple systematic approach based on sequential isocratic runs described 
in Table 1 using octadecyl silane (ODS or C18) LC columns and the same mobile phase 
composed by methanol and ammonium formate buffer used in the previous methods 
development and optimization. In fact, we added quinine dihydrochloride to the three 
artemisinin compounds as another potential antimalarial medicine used in injectable forms to 
ensure that the method shall detect it in case of analyzing counterfeit medicines composed 
by one of the three artemisinin active ingredients. 
 
Then, by following the planned systematic tests, we found better chromatographic results at 
higher proportions of the organic modifier, and we optimized the method at 90:10, v/v of 
methanol and 10 mM ammonium formate buffer pH 2.8; 0.7 mL min
-1
 to 1.0 mL min
-1
 of 
flow rate; 25˚C of the column oven compartment; and 210 nm of wavelength on a Zorbax 
Extend C18, 150 × 4.6 mm (dp: 5 μm) column; and we transferred the method to XBridge 
Shield RP18, 100 × 4.6 mm (dp: 3.5 μm), and Zorbax Extend C18, 50 × 4.6 mm (dp: 3.5 μm) 
columns to reduce the analysis time and mobile phase consumption, as well as allowing the 
increase of sample analysis throughput. 
 
As illustrated in Figure 6, one can notice that the method has the ability of separating well the 
three artemisinin compounds, and that it can allow detecting any counterfeit of mixing them; 
but also the method was found capable of detecting quinine which is another potential 
injectable medicine from the three compounds. 
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Figure 6 Isocratic method for the analysis of quinine, arteether, artemether and artesunate in 
injectable forms. Experimental conditions: Column: (a) Zorbax Extend C18, 150 × 4.6 mm (dp: 5 
μm); (b) XBridge Shield RP18, 100 × 4.6 mm (dp: 3.5 μm); (c) Zorbax Extend C18, 50 × 4.6 mm (dp: 
3.5 μm); Flow: 1.0 mL min-1 for column (a), and 0.7 mL min-1 for column ((b) and (c)); T˚: 25˚C; λ = 
210 nm; Isocratic elution with methanol and 10 mM ammonium formate buffer pH 2.8 (90:10, v/v). 
Elution order: (identic in in the three chromatograms). 
 i) Chromatogram (a): Quinine (≈ 1.536 min.), artesunate (≈ 3.132 min.), artemether (≈ 5.494 min.), 
arteether (≈ 6.420 min.); ii) Chromatogram (b): Quinine (≈ 1.186 min.), artesunate (≈ 2.161 min.), 
artemether (≈ 4.690 min.), arteether (≈ 5.656 min.); iii) Chromatogram (c): Quinine (≈ 0.637 min.), 
artesunate (≈ 1.144 min.), artemether (≈ 2.423 min.), arteether (≈ 2.907 min.). 
 
4.4. Methods validation 
 
After methods optimization, it is necessary to demonstrate that the new methods are suit-for-
purpose by providing accurate analytical results. In this regards, we have selected the method 
for analysis of artesunate powder for injection as a new antimalarial medicine in Rwanda 
aligned in the national list of essential medicines in 2015 [21] [22]. Moreover, this method 
can also help in detecting other arteminisin compounds such as arteether and artemether 
which are closely related to artesunate and which can be found in counterfeit or substandard 
artesunate medicines. Hence, the validation criteria as required by the International 
Conference on Harmonization (ICH) in its document Q2(R1) were considered namely: 
selectivity, trueness, precision (repeatability and intermediate precision), accuracy, linearity, 
limit of detection (LOD) / limit of quantitation (LOQ), and dosing range [7]. 
 
At first, we checked the selectivity of the method by checking whether there is no peak 
interference at the tR of artesunate especially by other artemisinin compounds widely used in 
(c) 
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pharmaceutical formulations i.e. arteether and artemether, and this criteria was satisfactory as 
illustrated in Figure 7 since all peaks were well resolved. 
 
 
Figure 7 Chromatograms of artesunate with other compounds (a) and artesunate alone in a sample 
solution (b). Experimental conditions: Column: XBridge Shield RP18, 100 × 4.6 mm (dp: 3.5 μm); 
Flow: 0.7 mL min
-1; T˚: 25˚C; λ = 210 nm; Isocratic elution with methanol and 10 mM ammonium 
formate buffer pH 2.8 (90:10, v/v). 
 
At second, we applied the concept of total error strategy represented by accuracy profiles as 
decision tool on the fit-for-purpose of the method for its intended use [8] [9] [10] [11]. By 
using the data of CS, the linear regression model was constructed and allowed obtaining the 
calculated result from VS. Then, an accuracy profile for artesunate was drawn as can be seen 
in Figure 8 with the results of validation criteria summarized in Table 2. The acceptance 
limits were set at ±5.0% according to the European Medicine Agency (EMA) standard for 
finished pharmaceutical products [23], and the analytical results from this method comply 
automatically with the larger specifications of ±10.0% as per the International Pharmacopoeia 
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monograph for artesunate powder for injection [24]. Indeed, we choose the narrower 
acceptable limits to allow the method being suitable to both regional requirements (European 
and International Pharmacopoeias), and the end-user regulatory authority shall choose which 
limit to enforce. 
 
 
Figure 8 Accuracy profile for quantitative method validation of artesunate powder for injection. The 
plain red line represents the relative bias, the blue dashed lines the 95% β-expectation tolerance limits 
and the black dotted lines the 5% acceptance limits. The green dots express the relative error of the 
back-calculated concentrations plotted with respect to their targeted concentrations. (For 
interpretation of the references to color in this figure legend, the reader is referred to the web version 
of this article). 
 
Then after, from the back-calculated results of VS that are the experimental ones, trueness of 
the method was assessed as it is the closeness of agreement between a conventionally 
accepted value (or reference value) that corresponds to the introduced concentrations of the 
analyte and a mean of experimental ones. We were able to get information on the systematic 
error that was found quite acceptable with relative biases between −0.1% and 0.3% compared 
to the two considered acceptable limits. 
 
The method precision was also found acceptable since there was a closeness of agreement 
among measurements; here, the back-calculated results of VS obtained from multiple 
sampling of homogeneous samples of the analyte. The relative standard deviation values for 
repeatability and for intermediate precision at the target of 100% concentration level were 
acceptable with a maximum of 0.3%for repeatability, and 3.2% for intermediate precision. 
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To demonstrate the method linearity, we assessed the relationship between the back-
calculated results of VS (experimental ones) against the introduced concentrations. The linear 
regression model was fitted on the two types of concentrations, with a good linearity of the 
results illustrated in Table 2 by the slope close to 1. 
 
Moreover, method accuracy taking into account the total error, i.e. systematic and random 
errors, was assessed from the accuracy profile shown in Figure 8. In addition, as shown in 
Table 2, the relative β-expectation tolerance intervals are within a range of [−4.8%, 4.0%] 
except level 1 which is between −9.6% and 10.1%. Hence, as the lower and upper tolerance 
bounds are included within the acceptance limits for the targeted concentration level of 5000 
μg mL-1, one can guarantee that at least 95% of future experimental results will fall within the 
acceptance limits [25]. 
 
We estimated also the limit of detection (LOD) that is the smallest quantity of the targeted 
substance that can be detected, but not accurately quantified in the sample. The computed 
value was 124.1 μg mL-1. 
 
The lower limit of quantitation (LLOQ) which is the smallest quantity of the targeted 
substance in the sample that can be assayed under experimental conditions with well-defined 
accuracy was calculated and its value is 3820 μg mL-1 vs. the upper limit of quantitation 
(ULOQ) which is the highest quantity of the targeted substance in the sample that can be 
assayed under the experimental conditions with well-defined accuracy was calculated at 6962 
μg mL-1. In fact, those limits of quantitation were obtained by calculating the smallest and 
highest concentrations beyond which the accuracy limits or β-expectation limits go outside 
the acceptance limits. Hence, the intervals between the lower and the upper limits where the 
procedure achieves adequate accuracy allowed us to set the “Dosing range”, again equivalent 
to [3820 μg mL-1 to 6962 μg mL-1]. 
 
Finally, the uncertainty which is a parameter associated with the result of a measurement that 
characterizes the dispersion of the values that could reasonably be attributed to the measurand 
was calculated, and its relative expanded value (%) was found less than 3.1% on the four 
concentration levels except level 1. 
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Table 2.  
Summary of the validation criteria for artesunate powder for injection 
Validation criteria Conc. (µg mL
-1
) Artesunate 
Trueness: 
Absolute bias (µg mL
-1
) 
(Relative bias (%)) 
 
 
3000.0 7.9 (0.3) 
4000.0 -4.8 (-0.1) 
5000.0 15.0 (0.3) 
6000.0 16.3 (0.3) 
7000.0 -42.0 (-0.6) 
Precision: 
Repeatability (%) /  
Intermediate precision (%) 
 
 
3000.0 0.3 / 3.3 
4000.0 0.2 / 1.3 
5000.0 0.2 / 1.1 
6000.0 0.2 / 1.1 
7000.0 0.2 / 1.4 
Accuracy: 
95% β-expect. tol. int. (µg mL-1) 
[Rel. 95% β-expect. tol. int (%)] 
 
 
 
 
 
 
 
3000.0 
2680 – 3264 
[-9.593, 10.13] 
4000.0 
3870 – 4174 
[-3.9 – 3.7] 
5000.0 
4722 – 5084 
[-3.4 – 4.0] 
6000.0 
5692 – 6060 
[-2.9 – 3.4] 
7000.0 
6628 – 7211 
[-4.8 – 3.6] 
Linearity : 
 
Slope 0.9916 
Intercept 39.49 
R² 0.9975 
Dosing range : Lower LOQ (µg mL
-1
) 3820 
 Upper LOQ (µg mL
-1
) 6962 
 
4.5. Application of the methods 
 
The validated method for analysis of artesunate powder for injection was applied in the 
analysis of 3 different batches found in public hospitals in Rwanda during our sampling, 
whose results are presented in Table 3. The other methods were also applied in the analysis of 
artemether/lumefantrine in different samples of medicines sampled in the D.R. Congo (9 
samples), Rwanda (13 samples) and Benin (1 suspected counterfeit) as reported in another 
article submitted to the Current Drug Safety Journal - Bentham Science Publishers [26], and 
the method for quinine and major cinchona alkaloids was used in the analysis of suspected 
counterfeit quinine tablets as reported in the American Journal of Analytical Chemistry [27]. 
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The methods developed in Belgium on a LC Waters 2695 were successfully tested to Rwanda 
on two other LC systems namely Agilent 1200 series and Agilent 1260 series both equipped 
with diode array detector (DAD) from Agilent Technologies (Boblingen, Germany) and 
Chemetrix (Agilent Technologies authorized distributor, Midrand, South Africa) respectively 
(results not shown). 
 
Table 3. Assay results of the analyzed three batch samples of artesunate powder for injection 
coded A, B and C sampled in Rwanda. The results consist in the mean percentage of claimed 
nominal content and the relative standard deviation calculated on 3 independent sample 
solutions per batch. Specifications are set to 90.0% - 100.0% of the claimed nominal content 
(mg). 
 
Drug sample A B C 
Claimed 60 mg 60 mg 60 mg 
Assay in % 99.4 ± 0.5 % 99.4 ± 0.1 % 100.4 ± 0.4 % 
 
5. Conclusions 
 
Simple isocratic methods were developed thanks to methods adaptation or adjustments 
approach, and sequential systematic tests without passing through long and expensive DoE. 
The isocratic methods were privileged for their simplicity, short analysis time and high 
sample throughput, low mobile phase consumption, and adaptability to LC systems equipped 
with simple or gradient pumps. In this regard, we developed a generic method for the analysis 
of: (i) artesunate, arteether and artemether in injectable forms; (ii) artemether and 
lumefantrine in tablets; and (iii) quinine-resorcin with major cinchona alkaloids (cinchonine, 
cinchonidine, quinidine, and dihydroquinine).  
 
The analytical method for artesunate powder for injection derived from the generic method 
for artesunate, arteether and artemether was fully validated thanks to the strategy of total error 
and accuracy profile approach in accordance with the criteria of ICH Q2 (R1) guidelines; and 
finally, the methods were applied in the analysis of real samples of artemether/lumefantrine 
medicines, artesunate powder for injection, and counterfeit quinine tablets. 
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IV.4 SECTION 4 - Detection of poor quality artemisinin-based combination 
therapy (ACT) medicines marketed in Benin using simple and advanced 
analytical techniques  
 
Current Drug Safety, 2017, Vol. 12, No. 3 
https://doi.org/10.2174/1574886312666170616092457 
 
IV.4.1 Preamble to Article 4 
 
The fight against counterfeit medicines requires among others, a collaboration between 
several sectors working in the pharmaceutical field such as customs services, medicines 
agencies ... The scope of the collaboration can be international, but could be more effective at 
the regional level given the possible similarities of cases of counterfeiting and the proximity 
of interventions. 
 
In this section, we present a case of collaboration among three countries in south, namely the 
Benin, the DRC and Rwanda, and Belgium in north, all with the aim of deploying analytical 
methods to monitor the quality of artemisinin-based combination therapy (ACT). As a 
reminder, these medicines are widely used for the treatment of malaria as first line (as 
mentioned by the WHO). Several trademarks of those ACTs, dosages forms and strengths are 
marketed, and need to be controlled for compliance with the quality specifications. 
 
Various samples were obtained from the three aforementioned countries and analyzed 
according to a decision tree ranging from simple to complex analytical tests. Among the 
results were found out-of-specification cases, and an alarming case of fake Coartem that did 
not contain any of the two expected active ingredients.  
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IV.4.2 Article 4 
 
 
 
ABSTRACT 
 
Background: Poor quality antimalarial medicines still represent a threat to the public health, 
especially in Sub-Saharan Africa who bears a disproportionate share of the global burden of 
malaria. It is essential and urgent to strengthen mechanisms against counterfeit medicines. 
One of the approaches is regular market surveillance through quality controls.  
 
Methods: 12 samples of artemether/lumefantrine were collected from formal and informal 
drug sellers in Cotonou (Benin) as well as additional other similar samples from Rwanda (13 
samples) and from D.R. Congo (9 samples). Thin Layer Chromatography (TLC) as classical 
and simple identification test was applied in Benin while an analytical chemistry laboratory in 
Belgium (ULg, Pharmacy Department) was asked for further analyses with HPLC and Raman 
spectroscopy using a developed and validated HPLC method for rapid analysis of 
artemether/lumefantrine. 
 
Results: The results obtained in Belgium confirmed the lack of the two active ingredients in 
the suspected sample of ACT medicine from Benin whereas some samples from Rwanda and 
D.R. Congo were found to present risk of substandard drugs either for under-dosing or over-
dosing.  
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Conclusions: Counterfeit/falsified of artemisinin-based combination therapy (ACT) 
medicines are really scourge that needs to be fought through strong collaboration between 
public health authorities and appropriate quality control laboratories. 
 
1. INTRODUCTION 
 
Artemether/Lumefantrine (AL) was the first fixed-dose artemisinin-based combination 
therapy recommended and pre-qualified by the World Health Organization (WHO) for the 
treatment of uncomplicated malaria caused by P. falciparum. It is currently recommended as 
first-line treatment for uncomplicated malaria in several countries [1].  
 
The efficacy of AL in Africa and South America remains high, with treatment failure rates 
generally below 10%. Currently, 40 countries in Africa and 6 countries in South America are 
using this combination as first or second-line treatment. In Angola, Burkina Faso, Gambia, 
Ghana, Malawi, Niger, Nigeria and Zimbabwe, isolated studies conducted between 2006 and 
2013 have shown treatment failure rates with AL above 10% [1]. 
 
In 2014, global financing for malaria control increased from an estimated US$ 0.96 billion in 
2005 to US$ 2.5 billion. As far as spending on malaria control commodities (artemisinin-
based combination therapies “ACTs”, insecticide-treated bed nets “ITNs”, insecticides and 
spraying equipment for indoor residual spraying “IRS”, and rapid diagnostic tests “RDTs”) 
are concerned, it is estimated to have increased over the past 11 years, from US$ 0.04 billion 
in 2004 to US$ 1.6 billion in 2014, and accounted for 82% of international malaria spending 
in 2014. ACTs represented 25% of total commodity spending in that year [1].  
 
The therapeutic benefits of ACTs are their high efficacy, rapid action and the reduced 
likelihood of resistance development. In order to make best use of this medicine combination, 
it is very important to address issues of quality. According to the WHO, 200,000 deaths over 
one million that occur from malaria annually would be avoidable if the available medicines 
were effective, of good quality and used correctly [2]. Unfortunately, recent studies report the 
circulation of higher levels of poor quality antimalarial medicines (i.e. counterfeit / falsified, 
substandard, and degraded) in most malaria endemic countries, and therefore highlighting the 
need of strengthening national drug regulatory authorities through quality assurance and 
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quality control (QC) systems, as well as regular market surveillance in order to secure the 
public health [3]. 
 
Analytical chemistry applying separative screening methods, especially with liquid 
chromatography (LC), are suitable in fighting against the spread of counterfeit/falsified and 
other poor quality medicines in this context [4; 5]. 
 
In the framework of fighting against poor quality antimalarial medicines marketed in Benin, 
especially ACTs; we conducted several analyses to assess the quality of suspected samples. 
At first, thin layer chromatography (TLC) was applied as simple identification technique 
allowing to detect the presence or not of the claimed active ingredients prior to their assay. 
Then, further analyses including HPLC and Raman spectroscopy were carried out to gain 
more information on suspected samples and similar samples from Rwanda and DRC in order 
to aware their status. The applied HPLC method was developed and validated in-house during 
our previous study for rapid analysis of AL [5].  
 
2. MATERIALS AND METHOD 
 
2.1. Samples 
 
Drug sampling was done in Cotonou, the economic capital of Benin. This southern city 
concentrates most health facilities (about 45% of medical units installed in urban areas), the 
big markets in the country [6] including the international market Dantokpa. The samples, here 
tablets were collected from formal markets in pharmaceutical establishments (pharmacies 
opened to public) and informal drug sellers. Twelve samples were collected: 3 from 
pharmacies opened to public (formal system) and 9 from informal vendors (informal market 
system). They were submitted to visual inspection and instrumental analyses.  
 
Additional samples were collected from Rwanda (13 samples) and D.R. Congo (9 samples), 
and analyzed at the University of Liège (ULg) / Pharmacy Department - Laboratory of 
analytical chemistry (Belgium). 
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 2.2. Visual Inspection 
 
According to the WHO guidelines for visual inspection of samples [7], we focused on the 
control of packaging, of labeling and of physical appearance of the pharmaceutical forms 
namely the specific size, the shape and the color in order to assess any abnormal presentation 
that can be an indice of potential counterfeiting or deterioration [8]. All samples were further 
submitted to instrumental analyses to check the presence or not of the active ingredients, the 
presence of undeclared compounds in the formulation, impurities or sub-degradation 
compounds when detectable as well. The Figure 1 summarizes the analytical steps that were 
followed during this study. Additional pharmacopoeial tests were done namely uniformity of 
weight and disintegration tests [9, 10]. 
 
 
Figure 1: Flowchart of the analytical and decisional approach 
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 2.3. Instrumental Analysis Methods 
  
2.3.1. Chemical and Reagents 
 
Methanol (HPLC gradient grade), anhydrous acetic acid, toluene, ethyl acetate, concentrated 
sulfuric acid (96%), formic acid (98% - 100%) and orthophosphoric acid European 
Pharmacopoeia grade (85%) were purchased from Merck (Darmstadt, Germany) and 
ammonium formate (99%) was from BDH Prolabo (Almere, Netherlands).  
 
Ultrapure water was obtained from a Milli-Q Plus 185 water purification system from 
Millipore (Billerica, MA, USA). Antimalarial drugs containing AM (20, 40 or 80 mg) and LF 
(120, 240 or 480 mg) were purchased from formal and informal drug sellers. 
 
 2.3.2. Thin Layer Chromatography  
 
We used an adapted standard operating procedures (SOP) provided with the MiniLab®. The 
GPHF-Minilab® is a mini-laboratory used in developing countries by medical stores and 
hospital managers, drug inspectors, and other authorities to detect counterfeit and substandard 
pharmaceuticals to provide basic quality controls. A model is available at the Benin National 
Quality Control Laboratory of Medicines and other Health Commodities, Ministry of Health 
(Cotonou). We have adapted our protocol from this model. Each sample was monitored on 
TLC plates as stationary phase made of silica gel 60F254S (Merck; Germany) while the 
mobile phase was a mixture of (toluene/ethyl acetate/anhydrous acetic acid (9: 2: 1; v/v/v). 
The lamp detection-UV was done at 254 nm for lumefantrine while for artemether, we used a 
spray reagent (methanol/sulfuric acid concentrated (19:1; v/v) followed by 5 minutes heating. 
A stock solution of reference standards of artemether (AM) (2 mg/mL) and lumefantrine (LF) 
(12 mg/mL) was prepared in methanol acidified by anhydrous acetic acid (9:1; v/v). Dilutions 
were performed in methanol in order to obtain solutions at 3 different concentration levels: 
 
Level 1 (60%): 1.2 mg/mL (for AM) – 7.2 mg/mL (for LF); 
Level 2 (80%): 1.6 mg/mL (for AM) – 9.6 mg/mL (for LF); 
Level 3 (100%): 2 mg/mL (for AM) - 12 mg/mL (for LF); 
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For the samples, powdered (n = 10 tablets) or liquid (n = 2 bottles) portions were taken and 
treated in the same way as reference solutions to give final expected concentrations of 2 
mg/mL (for AM) and  12 mg/mL (for LF). The solutions were freshly prepared and protected 
from light. They were centrifuged at 3500 rpm for 5 minutes at 25°C. The supernatant was 
used for TLC analysis. All samples were analyzed in duplicate on the TLC plate. 
 
For identification purposes, we compared the Rf value and the spot intensity of the standard 
reference against those observed with the sample solution. 
 
 2.3.4. Raman Spectroscopy Method 
 
Intact tablet samples vs. intact small quantities of reference materials were used. The samples 
were analyzed with LabRAM HR Evolution (Horiba scientific, Kyoto, Japan) instrument 
equipped with two-dimensional Newton 970 front-illuminated EMCCD detector (1600 × 200 
pixel sensor) (Andor Technology Ltd, Belfast, UK), Leica 50× Fluotar LWD objective and 
785 nm laser with a power of 45 mW (XTRA II single frequency diode laser, Toptica 
Photonics AG, Munich, Germany). A 300 gr/mm grating was used to record the spectra in the 
spectral range of 1853 - 464 cm
-1
. 
 
The confocal slit-hole was fixed at 200 μm; each spectrum results from two acquisitions per 1 
second. The spectra were collected with the LabSpec 6 (Horiba Scientific) software. Once 
acquired, the spectra were baseline corrected using the Asymmetric Least Squares (AsLS) 
algorithm with a λ value of 105 and a p-value of 10−3. The baseline corrected spectra were the 
analyzed by MCR-ALS with non-negativity constraints on both concentration and spectra. 
Two spectra were resolved [11, 12]. The baseline corrected spectra were then scaled between 
1 and 0 and compared to the spectral database. All spectrum processing and correlation 
coefficient computations were performed using Matlab R2013a software (The Matworks, 
Natick, MA, USA) and in-house routine coding. 
 
 2.3.3. HPLC analyses  
 
HPLC analyses were performed according to the methods described in [5] with some few 
adaptations. They were carried out on a Waters 2695 Alliance (Waters, Milford, MA, USA) 
separation module coupled to Waters 2996 photodiode array (PDA) detector (Waters). The 
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system was controlled with Empower 2.0 software (Waters). The chromatographic separation 
was done in a Zorbax SB-C18 (dp 3.5 μm) column (100 mm × 4.6 mm ID) maintained in a 
controlled compartment at 25˚C, applying as mobile phase an isocratic mixture of methanol 
and 10 mM ammonium formate buffer adjusted to pH 2.8 with formic acid (85:15, v/v); the 
pump flow rate was 0.7 mL/min. The sample solutions were maintained in a controlled 
compartment at 15˚C. The injection volume was 6 μL. The UV detection wavelength was 
fixed at 210 nm. However, the UV spectra were recorded online from 210 nm to 400 nm. 
 
3. RESULTS AND DISCUSSIONS 
 
Our sampling (n = 9) took place at the biggest unofficial market “Adjegounlé” (located at the 
international market Dantokpa) with two additional markets in Cotonou: Fifadji and 
Gbegamey. Three (n = 3) samples were collected from official pharmacies.  
 
Visually, none of the samples was expired at the day of purchase; only three inserts were 
written in French (official language in Benin) while all others were written in English. 
Irregularities were observed in the physical appearance of several samples such as small 
brown or black spots leading to suspect contaminants. One batch presented a non-
homogeneous color. Moreover, among the samples from Benin, we noticed a sample not 
containing the indicated quantity of blisters probably due to the bad habit of patients who buy 
incomplete doses for their medication and that the missing blister was already sold earlier. All 
samples (n = 10) met the requirements for the uniformity of weight test (when weighed singly, 
the deviation of the individual masses from the average mass has not exceed 5%) [ 10]. One 
sample failed the disintegration test fixed at 30 minutes for film coated tablets [9], and the 
tablets were not yet disintegrated after 3 hours.  
 
The twelve samples were coded for confidentiality, and were submitted to analysis with TLC. 
Eleven out of twelve samples were found to contain AL. Indeed the Rf value and the spot 
intensity of these two active ingredients were equivalent and similar to those of the standard 
solutions. The remaining sample (Figure 2) failed to that test (i.e. Coartem®; Batch number 
F2261; Manufactured date: 01/2014; Expired date: 02/2018; collected from the market of 
Fifadji). It corresponds to the sample that failed the disintegration test (time over 3 hours), 
thus it was suspected to contain no active ingredient after two tests failures.  
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Figure 2: Suspected Coartem® 20/120 sample (BCF/1507 10-01) having failed TLC and 
disintegration tests 
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In Benin, a pilot study conducted in 2010 on the quality control of some antimalarial drugs 
sold in the same unofficial market Adjégounlè (Dantokpa market), reported that 2/3 of 
artemether- lumefantrine samples failed with the standards of the pharmacopoeia [13]. 
 
Thus we decided to focus on the sample having failed preliminary tests in our study, and 
submitted it to further analyses with advanced analytical techniques such as Raman 
spectroscopy and HPLC available at our partner Laboratory of Analytical Chemistry (GMP 
certified and WHO prequalified) based at the University of Liege (Belgium).  
 
Raman spectroscopic analysis was done to check whether the suspected Coartem® contains a 
known compound, by comparing its spectral characteristic to a spectral database created for 
this purpose to generate candidate products that are likely to be in the composition of the 
suspected medicine. By comparing the sample to earlier AL recorded database, matching 
result are: artemether (r = 0.3343), lumefantrine (r = -0.0680) (see Figure 3). The computer 
system generated a list of compounds with related levels of likeliness to be in the composition 
of the sample (see Figure 4). The two best matches are: calcium carbonate (r =0.9458), potato 
starch (r = 0.9184), which are normally known as inactive pharmaceutical excipients. Some 
components from Raman spectroscopy best matches suspected to be in the sample are usually 
used in that formulation. However, we were not able to identify the coloring agent to yellow 
imitating the color of lumefantrine.  
 
 
155 
 
 
 
 
 
Figure 3: Raman Spectra: (a)- artemether spectrum in blue vs. sample spectrum in red;  (b) - 
Lumefantrin spectrum in blue vs. sample spectrum in red. The spectra were offset for clarity 
 
On the other hand, as illustrated in Figure 5, HPLC results confirmed that none of the two 
active ingredients was detected in the sample. Hence, by considering all previous analyses, we 
concluded that the Coartem® 20/120, batch number F2261, Mfd: 01 2014, Exp: 02 2018 is a 
counterfeit containing no active ingredient.  
 
a 
(a) 
(b) 
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Figure 4: Spectroscopy Raman results. Compounds with related levels of likeliness to the 
sample: (a) for potato starch (r = 0.9184) and (b) calcium carbonate (r= 0.9458). The spectra 
were offset for clarity. 
 
Furthermore, we conducted a literature search on the same batch product to see whether there 
is an alert issued about the same product, or a reported study. We were very interested with an 
article published in Malaria Journal on “Assessing the quality of anti-malarial drugs from 
Gabonese pharmacies using the MiniLab®” [12]. This field study reported 2 samples that 
failed the test, and one of the two samples is the same fake Coartem we sampled in Cotonou 
(Benin). However, even if the two products have a common batch number (i.e. F2261), brand 
name (Coartem
®
), and manufacturer (Novartis), they have totally different manufacture and 
(a) 
(b) 
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expiry dates i.e. Mfd: 01 2012, Exp: 02 2016 (found in Gabon) vs. Mfd: 01 2014, Exp: 02 
2018 (found in Benin).High performance liquid chromatography was used to confirm the 
absence of APIs in the AL sample [14].  
 
 
Figure 5: Chromatograms and UV-Vis spectra of sample BCF/1507 10-01 (Coartem®; Batch 
number F2261; Mfd: 01.2014; Exp: 02.2018; collected from the market of Fifadji; Benin); 
(a)- methanol spectrum;  (b)- lumefantrin spectrum; (c)-artemether spectrum 
 
In early 2013 a batch of falsified Coartem® was discovered in Yaoundé (Cameroon), 
containing no active pharmaceutical ingredients. The product failed the screening by the 
minilab® and was forwarded by an NGO to a WHO pre-qualified laboratory in Nairobi 
(Kenya) for more detailed analysis. Subsequent testing revealed that the product contained 
none of the claimed active pharmaceutical ingredients. The details of the falsified batches of 
Coartem® were: batch number: F1901, Exp: 01.2014 / Mfd: 01.2012; batch number: F2261, 
Mfd: 01.2012/Exp:01.2014. Surprisingly, this second one has the same batch number as the 
counterfeit samples found in Gabon and Benin, but the manufacture and expiry dates are 
totally different in the three cases. These are both genuine Novartis batch numbers which 
have passed their expiry dates. No genuine Coartem® bearing these batch numbers should 
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now be in circulation [15]. The same batch number is also in circulation in Mali [unpublished 
data]. The weakness of drug regulatory authorities in controlling the pharmaceutical supply 
chain is partly responsible of the prevalence of illicit medicines in resource limited countries. 
More efforts are still needed especially in those countries in order to effectively fight against 
the spread of poor quality medicines (counterfeit/falsified, sub-standards, and degraded), and 
therefore protect the public health against the terrible dangers they can cause. Sensitization, 
regular seize and destroy operations, prosecution of counterfeiters, regular market 
surveillance through quality controls, etc. are some urgent recommended actions; but above 
all, there is a real need of strengthening national drug regulatory authorities and set up a 
strong collaborations at national and international levels to overcome the porosity of borders 
in resource limited countries that can explain the easy circulation of fake medicines in those 
countries. In this context, further contacts were established with other research team members 
who are facing the poor quality medicines situation: Rwanda (East Africa); D.R. Congo 
(Central Africa). Similar samples were collected, 13 from Rwanda and 9 from D.R. Congo. 
Those samples were analyzed by the same HPLC method [5]. As can be seen in Table 1, all 
samples from these countries were compliant with the assay test specifications of 90.0% to 
110.0% according to the United States and International Pharmacopoeias for both Artemether 
and Lumefantrine. However, 3 samples from D.R. Congo seemed to present a risk of under 
dose due to result (90.7%) closer to 90% limit and over dose due to results (109.4% and 
108.4%) closer to 110% limits while the standard deviations were somewhat high. When we 
look on the survey study conducted by the WHO in six African countries [16] in which it was 
compared the outcomes of quality control laboratory testing and the GPHF-Minilab® 
screening, it was mentioned that GPHF-Minilab® can reliably detect grossly sub-standard 
samples, but should not be used as an independent testing resource or provide quantitative 
data except in conjunction with more sensitive techniques such as HPLC, etc. [17]. In the 
present study case, we supplemented our adapted TLC method (simple analytical technique, 
robust) by RAMAN spectroscopy and HPLC-UV Vis (advanced analytical techniques) to 
confirm the primary result. In this way, the results of our study support previous reports and 
publications on the issue of counterfeit medicines and drastic consequences they can cause to 
the public health. In fact, the problem is still critical, especially in resource limited countries, 
and there is real need to strengthen National Drug Regulatory Authorities of those countries in 
order to ensure that the distributed medicines are of the required quality, safety and efficacy. 
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Table 1: Results of Artemether (AM) and Lumefantrine (LF) assays in tablets samples from 
D.R. Congo and Rwanda 
 
Samples from D.R. Congo  
(mean in %. ± SD; n=3) 
Specifications 
(USP and Ph. Int)  
90.0 – 110 % 
Conclusion or 
remark for AM 
and LF N° Samples 
codes  
Content of LF (%) Content of AM  (%) 
1. RC001 98.2 ± 1.8 100.2 ± 0.2 OK Compliant 
2. RC002 104.2 ± 1.5 97.7 ± 0.6 OK Compliant 
3. RC003 109.4 ± 1.8 100.9 ± 1.3 OK Risk of overdose 
for LF 
4. RC004 104.1 ± 0.8 96.6 ± 1.2 OK Compliant 
5. RC005 107.8 ± 0.4 96.9 ± 0.6 OK Compliant 
6. RC006 108.4 ± 1.8 100.1 ± 0.8 OK Risk of overdose 
for LF 
7. RC007 94.6 ± 0.2 94.6 ± 0.5 OK Compliant 
8. RC008 101.9 ± 1.2 90.7 ± 1.8 OK Risk of underdose 
for AM  
9. RC009 106.7 ± 0.5 95.5 ± 0.8 OK Compliant 
Rwanda samples 
1. K0904 94.1 ± 0.2 91.9 ± 0.7 OK Compliant 
2. Q40093 97.1 ± 1.8 96.7 ± 0.1 OK Compliant 
3. Q40037/ 
7221596 
92.7 ± 0.1 91.3 ± 1.0 OK Compliant 
4. FA181 96.6 ± 0.8 93.5 ± 0.1 OK Compliant 
5. Q40212 96.5 ± 1.2 98.8 ± 0.7 OK Compliant 
6. Q40125 97.0 ± 0.3 97.7 ± 1.7 OK Compliant 
7. X1684 97.7 ± 0.5 97.2 ± 0.5 OK Compliant 
8. F3266 95.4 ± 1.1 94.0 ± 0.4 OK Compliant 
9. DY11334909 95.9 ± 0.1 101.0 ± 1.4 OK Compliant 
10. Q40353 94.1 ± 0.1 106.1 ± 1.9 OK Compliant 
11. F3262 95.7 ± 0.6 95.8 ± 1.0 OK Compliant 
12. Q30167 97.0 ± 0.1 97.7 ± 0.8 OK Compliant 
13. P04013D 98.7 ± 0.8 107.7 ± 1.2 OK Compliant 
 
4. CONCLUSION 
 
A counterfeit artemether/lumefantrine medicine was detected thanks to simple TLC testing 
adapted from GPHF-Minilab®, and disintegration test. The suspected fake medicine was 
submitted to Raman spectroscopy and HPLC analyses confirming the absence of both active 
ingredients in the sample collected at Fifadji market (Cotonou, Benin). The same fake batch 
of Coartem® was surprisingly found in Gabon, Mali and Cameroun but under different 
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manufacture and expiry dates in the three cases. However, even if the counterfeit ACT was 
found in Benin, Gabon, Mali, and Cameroon, and not found in the analyzed few samples from 
D.R Congo and Rwanda (Central Africa), it does not mean that the fake medicine would not 
be infiltrated to other countries including the Central Africa, and elsewhere where ACTs are 
widely used. Actually, recent reports on the quality of essential medicines keep to highlight 
the need of strengthening national and international strategic measures against the spread of 
poor quality medicines (counterfeit/falsified, substandard, and degraded), especially in 
resource limited countries where national medicine regulatory authorities (NMRA) are weak, 
and not able to fulfill their mission fully and efficiently. 
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IV.5 SECTION 5 - Analytical Tools and Strategic Approach to detect poor 
quality medicines, identify unknown components, and timely alerts for 
appropriate measures: Case study of antimalarial medicines 
 
American Journal of Analytical Chemistry, 2015, 6, 977-994 
http://dx.doi.org/10.4236/ajac.2015.613093 
 
IV.5.1 Preamble to Article 5 
 
As previously mentioned in section 4, international as well as regional collaboration is very 
important to fight counterfeit medicines. It is even more promising at the national level and at 
the local. In this context, this section has been developed with the intention of emphasizing 
the implementation of a strategic approach combined with analytical tools in the frame of 
detecting poor quality medicines, starting from the base (local level) up to top (international 
level). 
 
Local collaboration helps in reporting suspected cases of non-compliance or falsification upon 
the complaints from consumers or medical staff, and international collaboration plays a very 
important role in analyzing the suspected cases with advanced analytical techniques that are 
more oriented to that purpose. 
 
Thus, in this section, two cases of suspected counterfeit quinine tablets were analyzed, and 
advanced analytical techniques helped to identify the harmful nature of counterfeiting in the 
suspected medicines.  
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IV.5.2 Article 5 
 
 
 
ABSTRACT 
 
Nowadays, the circulation of poor quality medicines is becoming an alarming worldwide 
phenomenon with serious public health and socio-economic concerns. The situation is 
particularly critical in developing countries where drug quality assurance and regulatory 
systems for drug manufacturing, importation, distribution and sales are weak. A sustained 
vigilance on poor quality medicines that regroup counterfeit/falsified, substandard and 
degraded medicines is therefore required to ensure patient safety and genuine medicines 
integrity. A case situation is illustrated including a strategic approach and analytical tools that 
were found useful to detect poor quality medicines, identify unknown components, and timely 
alerts for appropriate measures against the spread of those harmful products. Several 
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suspected medicines randomly sampled in several strategic Rwandan areas were firstly check-
controlled by means of visual inspection and then applying several analytical techniques from 
simple to more complex ones. The following medicines were studied: quinine sulfate tablets, 
artemisinin-based combination tablets, and artesunate powders for injection. Taking into 
account the pharmaceutical forms and the chemical characteristics, the following tests were 
applied: uniformity of mass, friability, disintegration, fluorescence, identification and assay. 
They were followed by more complex analytical techniques that allowed more 
comprehension of abnormal findings among which the presence of a wrong active 
pharmaceutical ingredient in quinine sulfate tablets which is mainly discussed in this paper to 
illustrate a strategic approach and various analytical tools that can be used in detecting and 
identifying unknown component in poor quality medicines. 
 
1. INTRODUCTION 
 
Over the past several years, the health of human beings is threatened not only by the old and 
new diseases, but also by the consumption of medicines that are not well known and mostly 
of poor quality. Today, more people than ever put their health in danger by purchasing and 
consuming medicines of doubtful quality. For example, up to 10% of all medicines sold 
worldwide are estimated to be counterfeit and in some parts of Africa and Asia the prevalence 
exceeds 30% as mapped in 2008 by Sanofi-Aventis [1]. The extent of damages caused by 
such drugs requires high collaborative endeavors at national and international levels to 
securize the public health, but also the trade of genuine products which are targeted by 
counterfeiters and deliberately falsified. Counterfeiters have gained access to sophisticated 
technologies that enable them to very closely imitate the packaging and labeling of legitimate 
generic or brand products [2]-[4]. However, in certain cases these products may contain 
unexpected products such as toxic ingredients, be ineffective or cause adverse effects due to 
incorrect concentration of the active ingredients or to the presence of wrong ones. In some 
circumstances, a drug that was initially of good quality may lose it for example by decrease of 
its potency or becoming toxic due to inappropriate storage conditions that lead to the 
appearance of impurities or degraded products. Newton et al. [5] distinguished three 
categories of poor quality medicines: 1) Counterfeit/falsified medicines which are illicit 
products maliciously produced and distributed; 2) Substandard also called out-of-specification 
“OOS” products which are genuine products generally produced in poor manufacturing 
conditions; and 3) Degraded medicines which are products improperly stored, and spoiled. 
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Detecting counterfeit or falsified medicines is a big challenge for healthcare professionals in 
charge of drug quality control. Strategies and specifications have been set up by several 
international organizations such as FDA, WHO, and EMA, defining requirements and 
procedures to follow for drug quality assessment. The first step to detect poor quality is 
usually the “visual inspection” on the physical characteristics of packaging, outer containers’ 
labeling, closures, sealing, as well as the appearance of a medicine itself by its color, smell, 
consistency, etc. [2] [6]. Inspection of the storage conditions at the sampling sites such as the 
temperature, humidity, and exposure to light, is also one of the strategies recommended. 
During visual inspection, critical alterations are easily detected. Spoiled tablets, oral 
suspensions that harden, fluids leaking or containing particles/molds are quite enough signs to 
decide the non-conformity of a product without undergoing further laboratory tests. 
Nevertheless, this inspection needs a minimum and informative training to medicines end 
users for them to detect poor quality suspicions or visual evidences. Furthermore, laboratory 
analysis is of paramount importance during drug quality control for accurate identification 
and/or quantification of the active ingredients, and whenever possible of the excipients or 
impurities. That may necessitate using simple analytical techniques such as colorimetric tests, 
thin layer chromatography (TLC), UV-Vis spectroscopy or more complex techniques such as 
gas chromatography (GC), high performance liquid chromatography (HPLC), vibrational 
spectroscopy (Infrared, Near-infrared, Raman), mass spectroscopy (MS), nuclear magnetic 
resonance (NMR) spectroscopy, etc. [7]- [18]. 
 
The Republic of Rwanda is not spared from trafficking of poor quality medicines. Its 
government, highly aware of this situation, is continuously taking appropriate actions 
whenever feasible. For example, the regulatory system and analytical control laboratories are 
being implemented as well as the establishment of an Anti-Counterfeit Products and Illicit 
Pharmaceuticals Unit in the Rwanda National Police under the Department of Interpol [19] 
[20]. As a contribution to this endeavor, the aim of this study was to describe a strategic 
approach to detect poor quality medicines, identify unknown components, and as much as 
possible to timely communicate alerts to the competent organizations such as the National 
Medicine Regulatory Authorities (NMRAs), Ministry of Health (MoH), Healthcare Non-
Governmental Organizations (NGOs), Manufacturers, Distributors, Health centres, and the 
WHO. For that purpose, several analytical techniques including simple and complex methods 
were involved targeting antimalarial medicines. 
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Figure 1 depicts a step-by-step guide to accomplishing drug quality assessment from 
sampling to instrumental analysis. The main steps are sampling, visual inspection, laboratory 
preparedness, sample preparation, reporting the results, and timely alerts for appropriate 
measures against the use of detected poor quality products. After alerting, there is a need to 
conduct advanced analysis with powerful analytical techniques in order to identify the nature 
and extent of the defective situation in the studied products especially in case of 
counterfeiting. 
 
 
 
Figure 1. Step-by-step guide to drug quality control processing and alerting 
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2. Materials and Methods 
 
2.1. Drug Sampling 
 
As sampling sites, we privileged the countryside areas having intensive commercial activities 
due to border exchanges with Rwanda and neighboring countries namely, Burundi, Tanzania, 
Uganda, and D.R. Congo, and from which deceitful medicines could be infiltrated. For this 
study, we selected quinine and artemisinin-based preparations as most widely used 
antimalarial medicines in Rwanda. Different samples of quinine tablets 300 mg, artemether-
lumefantrine tablets 20 mg/120mg, and artesunate powder for injection 60 mg were randomly 
purchased in retail pharmacies or received free of charges from public institutions operating in 
the selected areas. They were submitted to visual inspection and instrumental analyses. 
 
2.2. Visual Inspection 
 
According to the WHO guidelines [2], we focused on differences in packaging, labeling, and 
physical appearance of the dosage forms characterized by specific size, shape and color in 
order to identify potential counterfeiting or deterioration. Suspected samples were further 
submitted to instrumental analysis to identify non-visual quality issues such as the presence of 
undeclared active ingredients or excipients, impurities and related contents. 
 
2.3. Instrumental Analysis Methods 
 
2.3.1. Reagents and Solutions 
 
1) Reagents 
 
Quinine sulfate (99.0%) and metronidazole (99.9%) reference substances were purchased 
from Fagron NV (Waregem, Belgium); Methanol LC grade from Avantor Performance 
Materials BV (Deventer, The Netherlands); hydrochloric acid (37%) and Ammonium formate 
(98.1%) from VWR International BVBA (Leuven, Belgium); Ultrapure water produced with 
Milli-Q Plus 185 water purification system (Millipore, Billerica, MA, USA); 
Dimethylsulfoxide “DMSO-d6” from Bruker (Billerica, MA, USA); Acetanilide and 
Sulfanilamide standards from ThermoQuest Italia S.p.A (Milan, Italy); Helium 6.0 (=99.9999 
Vol%) and Oxygen 4.5 (=99.995 Vol%) from Alphagaz (Liège, Belgium). 
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2) Sample solutions for HPLC analysis 
 
The test sample solutions for quinine tablets were prepared by dissolving in methanol LC 
grade accurately weighed quantities of the powders obtained from 20 tablets of each sample. 
Several dilutions were done to make final solutions equivalent to 100 µg/mL of quinine as 
analyte. The reference solutions were prepared in the same way to obtain the targeted 100 
µg/mL concentration of the quinine. Two independent reference substances and three 
independent test sample solutions were prepared for the system suitability testing (SST) and 
for assay test. 
 
On the other hand, metronidazole was involved in the analysis as a wrong active ingredient in 
quinine tablets, and preparation of the standard and assay test solutions was done as 
following: 
 
Standard preparation: Dissolve in methanol LC grade an accurately weighed quantity of 
metronidazole CRS to obtain 200 µg/mL, and dilute half with the mixture water/methanol 
(80:20, v/v) to obtain a final standard solution of about 100 µg/mL. Two independent 
reference solutions were prepared. 
 
Assay preparation: Dissolve in methanol LC grade a quantity equivalent to about the average 
weight of one tablet from 20 single dose units finely powdered; make appropriate dilutions in 
methanol to obtain about 200 µg/mL assuming that one tablet may contain 200 mg of 
metronidazole, filter each solution on a microporous membrane (preferably 0.45 µm pore size 
or less) and dilute as done for the standard solutions to have about 100 µg/mL of 
metronidazole. 
 
3) Sample solutions for UV-Visible spectroscopic analysis 
 
A fast UV identification test using a spectrophotometer was done on the following solutions: 
 
Quinine sulfate reference solutions at 50 µg/mL and 100 µg/mL: Dissolve in methanol LC 
grade a quantity of quinine sulfate CRS in order to obtain approximately 200 µg/mL of stock 
solution. Then, make appropriate dilutions with water to obtain 50 and 100 µg/mL solutions. 
 
170 
 
 
 
Test sample solutions at 50 µg/mL and 100 µg/mL: Dissolve in methanol LC grade a portion 
of fine powdered quinine tablets in order to obtain a stock solution containing 200 µg/mL of 
quinine sulfate active ingredient. Then, make appropriate dilutions with water to obtain 
expected concentrations of 50 µg/mL and 100 µg/mL solutions. 
 
Metronidazole reference solutions at 50 µg/mL and 100 µg/mL: Use metronidazole CRS 
and prepare as per quinine sulfate reference solutions. 
 
Blank solutions: Prepare mixtures of methanol-water at two proportion levels (25:75, v/v) 
and (50:50, v/v) to simulate the blank conditions at 50 µg/mL and 100 µg/mL respectively. 
 
2.3.2. HPLC Method 
 
The analyses by HPLC were carried out on a Waters 2695 Alliance (Waters, Milford, MA, 
USA) separation module coupled to Waters 2996 photodiode array (PDA) detector (Waters) 
applying an in-house developed method for quinine analysis and a USP procedure for 
metronidazole in tablets as described below. The system is controlled with Empower 2.0 
software (Waters). 
 
1) HPLC operating conditions for quinine analysis as developed in-house 
 
For quinine analysis, the chromatographic separation was done in a Zorbax SB-C8 (dp 3.5 
µm) column (150 mm × 4.6 mm ID) maintained in a compartment thermostatted at 35°C, 
applying as mobile phase a isocratic mixture of methanol and 10 mM ammonium formate 
buffer adjusted to pH 2.5 with 6 N hydrochloric acid (40:60, v/v) that was pumped at 1 
mL/min. The sample solutions, thermostatted at 15°C in a compartment, were introduced onto 
the separation system at a rate of 10 µL and monitored under the UV detection fixed at 230 
nm. 
 
2) HPLC operating conditions for metronidazole assay as wrong active ingredient in quinine 
tablets 
 
For metronidazole analysis, chromatographic separation was done also with Zorbax SB-C8 
(150 mm × 4.6 mm ID, dp: 3.5 µm) column in isocratic conditions, but using as mobile phase 
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a mixture of methanol and water (80:20, v/v). Flow rate, injection volume and UV detection 
were maintained identical as for quinine except thermostatted sample and column 
compartments that were set at 15°C and 25°C, respectively. 
 
2.3.3. Raman Spectroscopy Method 
 
Intact sample tablets vs. intact small quantities of reference materials were used. The samples 
were analyzed with LabRAM HR Evolution (Horiba scientific, Kyoto, Japan) instrument 
equipped with two-dimensional Newton 970 front-illuminated EMCCD detector (1600 × 200 
pixel sensor) (Andor Technology Ltd.), Leica 50× Fluotar LWD objective and 785 nm laser 
with a power of 45 mW (XTRA II single frequency diode laser, Toptica Photonics AG). A 
300 gr/mm grating was used to record the spectra in the spectral range of 3200 - 100 cm
-1
. 
The confocal slit-hole was fixed at 200 µm. Each spectrum results of two acquisitions of 1 
second. The spectra were collected with the LabSpec 6 (Horiba Scientific) software. Once 
acquired, the spectra were baseline corrected using the Asymmetric Least Squares (AsLS) 
algorithm with a λ value of 105 and a p-value of 10-3. The baseline corrected spectra were then 
scaled between 1 and 0 and compared to the spectral database. All spectrum processing and 
correlation coefficient computations were performed using Matlab R2013a software (The 
Matworks, Natick, MA, USA) and in-house routine coding. 
 
2.3.4. Mass Spectroscopy (ESI-MS) 
 
Four different solutions of the powdered fake quinine tablets (two samples), quinine sulfate 
and metronidazole references were prepared at 10 µg/mL in a mixture of methanol and water 
(90:10, V/V), and analyzed by direct injection in the ES+/MS analytical conditions hereafter 
described. 
 
The mass spectrometry on a triple quadripole instrument from Waters Corporation (Milford, 
MA, USA) was used in a positive electrospray ionization mode (ES+), in MS and MS/MS 
modes. MassLynx 4.1 software (Waters Corporation) was selected for instrument control, 
data acquisition and handling. ES+/MS analytical conditions were set at Capillary Voltage 2.5 
kV, dessolvation temperature 200°C, Source Temperature 115°C, Multiplier 650 V. 
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2.3.5. Nuclear Magnetic Resonance (NMR) Spectroscopy 
 
The 1H NMR spectra were measured on a Bruker Avance (500 MHz) spectrometer 
(Wissembourg, France) equipped with a 5 mm TCI cryoprobe. Tetramethylsilane (TMS) was 
used as an internal standard. Chemical shifts were reported in δ values (ppm) relative to 
internal TMS. The abbreviation s = singlet, d = doublet, t = triplet, m = multiplet and b = 
broad were used throughout, and data were processed using Topspin 2.1 software (Bruker, 
Wissembourg, France). 
 
The reference solutions of quinine sulfate and metronidazole were prepared by dissolving 2 
mg of the compound or equivalent of 2 mg for quinine powdered tablets in 700 µl of DMSO-
d6 and then introduced into a 5 mm tube for analysis. 
 
2.3.6. Elemental Analysis (CHNS) 
 
Elemental analysis CHNS was also used to determine the percent weight of specific atoms of 
carbon (C), hydrogen (H), nitrogen (N) and sulfur (S) in the suspected organic compounds, 
and therefore enabling to verify their empirical formula (C x H y N j S k ). 
 
In this study, elemental analysis (CHNS) was realized on a Thermo Electron Corporation 
Flash EA 1112 CHNS Elemental Analyzer (Interscience sprl, Louvain-la-Neuve, Belgium) 
equipped with a dry sample autosampler on the top of furnace, and under Eager 300 dedicated 
software control for organic elemental analysis in the following analytical conditions: 900°C 
for sample combustion, 130 mL/min of the Carrier Flow, 100 mL/min for Reference Flow, 
250 mL/min for Oxygen Flow, 5 sec for Oxygen Injection End (0 sec for Oxygen analysis), 
12 sec for Sample Delay Time, 10 min for Run time, and 2 - 3 mg for Sample weight. 
 
2.3.7. UV-Vis Spectroscopy 
 
A UV spectrophotometric analysis was done using a CECIL, CE 2501 model (2000 series) 
spectrophotometer (Cecil Instruments Limited, Milton Technical Centre, Cambridge, UK) by 
recording and comparing the reference and sample test solutions’ absorption spectra acquired 
in the range between 200 and 400 nm. 
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3. Results 
 
3.1. Visual Inspection Findings 
 
The pictures in Figure 2 and Figure 3 elucidate several cases of default and suspicious 
information confirming the usefulness of visual inspection at first line in decision making on 
drug quality when the product’s physical appearance presents evident deviations to the quality 
standards. Indeed, various cases of poor quality medicines were detected such as the presence 
of discolored film coated quinine tablets, the packaging of artesunate powder for injection in 
different size boxes, the unlike batch numbers of artesunate powder for injection vials and 
outer packaging boxes, the fake packaging of artemether-lumefantrine blister tablets labelled 
COMBIART (Strides Arcolab Ltd) in LUMARTEM boxes (Quality Chemical Industries 
Ltd.), and infiltrated artemisinine-based combination therapy drug (ACT) from Uganda to 
Rwanda with a specific marginal note stating “Government of Uganda, For Public Use Only, 
Not for Sale”. Note that the declared quinine tablets samples manufactured and/or distributed 
by HOLDEN MEDICAL (WEZEP-THE NETHERLANDS), HOLDEN MEDICAL 
(LELYSTAD-THE NETHERLANDS), and ELYS CHEMICALS (NAIROBI-KENYA) 
seemed to be visually normal. After these findings, the analyses continued following the step-
by-step guide of Figure 1. 
 
3.2. General Pharmacopeial Tests 
 
As simple analytical tests, the following were processed: uniformity of mass, friability, 
disintegration, identification and assay according to the International Pharmacopoeia (4
th 
edition 2014) and United States Pharmacopoeia (USP 37-NF 32). The friability and 
disintegration tests results were within the specifications, but not the uniformity of mass for 
two particular samples manufactured and/or distributed by HOLDEN MEDICAL (WEZEP- 
THE NETHERLANDS), and ELYS CHEMICALS (NAIROBI-KENYA) illustrated in 
Appendix (Figure A1 and Figure A3). The mass of the product supposed to be manufactured 
and/or distributed by HOLDEN MEDICAL (WEZEP-THE NETHERLANDS) was 292.4 ± 
9.1 mg (average and standard deviation, n = 20 tablets). 
 
The second quinine sample said (but not verified) to be manufactured by ELYS 
CHEMICALS (NAIROBI-KENYA) was found with similar average mass of 297.6 ± 6.1 mg 
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per tablet (n = 20 tablets). These results were surprising and not coherent since the two 
samples were declared to contain 300 mg of quinine sulfate. Hence, one can worry about the 
content of the active ingredient if the average weight is less than the declared content per 
tablet regardless the amount of excipients. Then, we decided on the basis of sampling periods 
and the incoherence of weight, to study and present these suspicious samples into two cases, 
one on underweight quinine tablets labelled HOLDEN MEDICAL (WEZEP-THE 
NETHERLANDS) and ELYS CHEMICALS (NAIROBI-KENYA), and another on the 
normal weight tablets of quinine labelled HOLDEN MEDICAL (LELYSTAD-THE 
NETHERLANDS). 
 
 
 
 
Figure 2. Photographs of poor quality quinine tablets and artesunate powder for injection. 
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Figure 3. Photographs of Artemether-Lumefantrine combination medicine illicitly introduced 
to Rwanda. 
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3.3. First Case 
 
3.3.1. Fluorescence Analysis 
 
As a rapid identification test in the laboratory, we performed a visual observation of quinine 
fluorescence in both reference and sample solutions under UV light at 366 nm. It clearly 
showed noticeable difference between quinine sulfate reference at 10 µg/mL that was 
greenish-blue color fluorescence whereas the suspected sample solutions at the same 
concentration level did not present any fluorescence (Figure 4). 
 
 
Figure 4. Quinine identification under UV light at 366 nm for fluorescence 
 
3.3.2. HPLC Analysis 
 
To explore the suspicious and illogical situation noticed above (Section 3.3.1), we carried out 
the most used separative technique in pharmaceutical analysis, namely HPLC. As shown on 
the chromatograms in Figure 5, the retention time of the major peak in the suspected false 
quinine tablets’ solutions was 2.33 minutes, while the one of quinine reference substance 
eluted at 4.14 minutes. In addition, the analytical method was able to reveal two distinctive 
cinchona alkaloids at low concentrations generally present with quinine raw material or 
reference substance. The two alkaloids were identified cinchonidine and dihydroquinine 
eluting at 3.27 minutes and 5.29 minutes, respectively, and were not present in the suspected 
samples. Furthermore, the corresponding UV spectra extracted from PDA for the two 
suspected samples were totally different from the one for quinine reference substance (Figure 
5), and the detected differences in terms of retention times and UV spectra were followed by 
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further analytical investigation to identify the unknown component in the two samples. 
 
 
 
Figure 5. HPLC chromatograms and UV spectra of quinine sulfate CRS vs. Fake samples 
 
3.3.3. Raman Spectroscopy 
 
To pursue with the laboratory investigation, the Raman spectroscopic technique was used 
involving four basic steps to identify unknown components in the counterfeit products: 1) 
data acquisition on the studied samples, 2) instrument library search and update, 3) candidate 
products selection by fitting the experimental spectra to those in the database, and 4) identity 
confirmation of the unknown components by analyzing potential candidate substances vs. the 
samples. 
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The Raman spectra of the suspected quinine samples were found different from that of 
quinine sulfate reference substance. By comparing to Raman spectra database set up in the 
laboratory, it was noticed that the correlation coefficient corresponded very likely to 
metronidazole as potential candidate compound present in the suspected quinine tablets (cf. 
Table 1 and Figure 6 and Figure 7). Considering this new information, further analytical 
techniques were needed to confirm the identity of the unknown component. 
 
Table 1. Raman spectrometry database search results for potential candidate products 
 
Candidate product Correlation coefficient 
Methylprednisolone 
Metronidazole 
Miconazole nitrate 
Microcristalline cellulose 
Naphazoline HCl 
Norfloxacine 
Noscapine HCl 
Oxazepam 
Paracetamol 
Paroxetine HCl. ½ H2O 
PEG 20000 
Phenazone 
Phenoxymethylpenicilline 
Phenylephrine HCl 
Pheniramine maleate 
Piperacillin Na 
Piperaquine  
Povidone 
Prednisolone 
Proguanil HCl 
Propranolol HCl 
Pseudoephedrine HCl 
Quinine 2HCl 
Quinine sulfate 
Saccharinate Na 
-0.064 
0.996 
-0.022 
0.109 
0.161 
0.111 
-0.026 
-0.034 
0.002 
0.074 
-0.074 
-0.074 
-0.084 
-0.003 
0.139 
0.038 
0.390 
-0.022 
-0.045 
-0.015 
0.265 
-0.012 
0.281 
0.140 
-0.066 
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Figure 6. Raman spectra overlay for one of the two fake quinine tablets vs quinine sulfate 
CRS 
 
 
 
Figure 7. Raman spectra overlay for HOLDEN WEZEP fake quinine tablets vs 
metronidazole CRS 
 
(A) 
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Figure 7. Raman spectra overlay for ELYS CHEMICALS fake quinine tablets vs 
metronidazole CRS  
 
3.3.4. Mass Spectrometry 
 
Both the MS and MS/MS were used. Their spectra presented in Figure 8 and Figure 9 
confirmed the presence of metronidazole in the suspected quinine tablets. Indeed, the two 
samples have identical peaks with metronidazole reference substance, fragmentation profiles 
are very similar (172 > 128, 172 > 111) and relative abundance of the 128 and 111 peaks is 
the same in metronidazole CRS and in the two fake quinine samples. 
 
3.3.5. Nuclear Magnetic Resonance (NMR) 
 
By comparing respective 1H NMR spectra, all signals of the “fake quinine tablets” exactly 
matched with the signals of metronidazole CRS but not with quinine sulfate (Figure 10), 
confirming again the presence of metronidazole in the suspected quinine tablets. Based on 
these previous analytical results (HPLC, Raman and MS), one can already confirm the 
absence of the declared active ingredient in the two samples. 
 
(B) 
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Figure 8. Comparison of ES+/MS spectra of metronidazole and the two fake quinine tablets 
(Elys chemicals and Holden Wezep) at 1.35e8, 1.37e8 and 1.12e8 Scan ES+ respectively. 
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Figure 9. Comparison of ES+/MSMS daughters for metronidazole CRS, fake quinine (Elys 
chemicals) and Holden Wezep at 172 ES+1.53e7, 172 ES+1.81e7 and 172 ES+7.42e7 
respectively. 
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Figure 10. NMR spectra of fake quinine tablets and metronidazole reference substance 
 
3.3.6. Elemental Analysis (CHNS) 
 
Finally, the contents in (%) of carbon, hydrogen, nitrous and sulfur elements in the two 
samples were determined by elemental analysis. Considering ±0.4% - ±0.5% for carbon and 
nitrous, ±0.7% - ±0.8% for hydrogen, and ±1% for sulfur as calculated acceptable error limits 
to each considered element, one can notice that the two fake quinine tablets have totally 
different results from that of quinine sulfate CRS as can be seen in Table 2. 
 
Indeed, the experimental % values obtained for N, C, H and S in the suspected quinine 
samples (Holden Wezep, and Elys Chemicals) are very closer among themselves, and closer 
to the experimental % values of metronidazole reference substance. However, they are 
particularly different from quinine sulfate for nitrous (about 3 times higher) and carbon (about 
1.5 lower). 
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In addition, sulfur was not present in the two suspected and fake quinine samples. Such 
findings correspond more to metronidazole than to quinine sulfate. In fact, the absence of 
sulfur is not normal since quinine sulfate is used as raw material in the manufacture of quinine 
tablets and the sulfur content should be found in these samples. 
 
Table 2. FlashEA 1112-CHN/S experimental results for metronidazole, quinine sulfate and 
fake quinine tablets. 
 
 Metronidazole CRS Sample 1: 
Holden Wezep 
Sample 2: 
Elys 
Chemicals 
Quinine sulfate CRS 
Atom Theoritical 
(%) 
Experimental 
(%) (n = 2) 
mean 
Experimental 
(%) (n = 2) 
mean 
Experimental 
(%) (n = 2) 
mean 
Theoritical 
(%) 
Experimental 
(%) (n = 2) 
mean 
N 
C 
H 
S 
24.55 
42.1 
5.3 
0.0 
25.14 
42.11 
5.38 
0.0 
22.21 
 46.00 
5.77 
0.0 
20.59 
41.85 
5.49 
0.0 
7.16 
61.36 
6.95 
4.1 
7.67 
60.89 
6.98 
3.4 
 
3.4. Assay Test Results of Metronidazole in the Two Fake Quinine Tablets 
 
After characterization and identification of the unknown component in the two fake quinine 
tablets, we decided to determine the content of metronidazole in the two particular 
formulations. We used an adapted analytical method to the USP-37/NF-32 (2014) as 
described in Materials and Methods. The content of metronidazole in the first sample 
(HOLDEN MEDICAL, WEZEP-THE NETHERLANDS) was found 81.6%, and in the 
second sample 81.0% (labeled ELYS CHEMICALS NAIROBI-KENYA). 
 
3.5. Second Case 
 
Another case of suspected quinine sulfate tablets was discovered one year later after the first 
study case. The sample was labelled HOLDEN MEDICAL (LELYSTAD-THE 
NETHERLANDS) and immediate suspicion on this product quality was mainly based on the 
fact that the name “HOLDEN MEDICAL (THE NETHERLANDS)” already known from the 
previous analysis on another sample of quinine sulfate tablets labelled HOLDEN MEDICAL 
(WEZEP-THE NETHERLANDS) found containing metronidazole as active ingredient. The 
two types of HOLDEN MEDICAL quinine tablets samples are illustrated in pictures given in 
Appendix (Figure A1 and Figure A2). 
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3.5.1. Visual Inspection and General Pharmacopeial Tests 
 
Visual inspection and general pharmacopeial tests such as the uniformity of mass, friability 
and disintegration tests were processed as done in the first case analysis, but identification 
was done on a UV-Vis spectrophotometer to collect the UV spectra for comparison, and 
therefore confirm similarity with the first case. The assay test was not performed on this 
sample as the main purpose was to see if the product was also counterfeited with 
metronidazole as in the previous Holden sample despite their differences in shape, color, size 
and probably manufacturing sites (WEZEP-THE NETHERLANDS for the previous sample, 
and LELYSTAD-THE NETHERL-ANDS for the new sample). The new suspected quinine 
sulfate tablets 300 mg average weight was found 426.5 ± 3.6 mg which is logical including 
the excipients content. The tests of friability and of disintegration complied with the 
pharmacopeial specifications. 
 
3.5.2. UV-Vis Spectroscopy 
 
This technique was used to rapidly identify the active ingredient in that sample by comparing 
its UV spectrum to those of metronidazole and quinine sulfate reference substances. The UV 
spectrum of the sample did not match with the spectrum of quinine reference solution, 
however and again surprisingly the sample UV spectrum matched very well with 
metronidazole reference standard solution. After confirming that the new sample labelled 
HOLDEN MEDICAL (LELYSTAD-THE NETHERLANDS) contains the same wrong 
ingredient as in the HOLDEN MEDICAL (WEZEP-THE NETHERLANDS) sample, we 
decided to not perform further analysis with advanced analytical techniques as done in the 
first case, because the relevant information on the nature of counterfeiting was already known. 
 
4. Discussion 
 
During this study, careful visual inspection has enabled to detect easily a series of poor 
quality antimalarial medicines such as the presence of 1) discolored film coated quinine 
tablets that may contain toxic substances, impurities and or sub-degradation substances. The 
discoloration should be a result of poor storage conditions and subsequent degradation, poor 
manufacturing or even counterfeiting; 2) Different sized boxes and mixed batch materials of 
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artesunate powder for injection that may also be a result of drug counterfeiting or substandard 
manufacturing conditions; 3) Packed COMBIART blister tablets (Mfd. by Strides Arcolab 
Ltd) in LUMARTEM boxes (Mfd. by Quality Chemical Industries Ltd.) is clearly a result of 
drug counterfeiting because normally no official manufacturer should mix two different 
manufacturers’ products; 4) Artemether-Lumefantrine combination tablets infiltrated to 
Rwanda with a marginal note stating “GOVERNMENT OF UGANDA, FOR PUBLIC USE 
ONLY, NOT FOR SALE” illegally introduced to Rwanda and sold. Another related quality 
issue to the later product, is that some illicit vendors tried to scratch the marginal note in order 
to cheat the vigilance of patients or inspectors. 
 
On the other hand, laboratory testing had revealed surprising results on three different 
samples of tablets declared to contain quinine sulfate 300 mg and labeled HOLDEN 
MEDICAL (WEZEP-THE NETHERLANDS), HOLDEN MEDICAL (LELYSTAD-THE 
NETHERLANDS) and ELYS CHEMICALS (NAIROBI-KENYA). 
 
Normally the average weight of tablets medicines is always greater than the declared content 
of active ingredient(s) due to the presence of excipients, however this was not the case for 
Holden Medical (Wezep-The Netherlands) and Elys Chemicals (Nairobi-Kenya) who have 
lower average weights than the declared active ingredient’s amount. The identification test of 
quinine fluorescence under UV light had also failed on both samples, and further analysis 
with advanced analytical instruments such as HPLC, Raman spectroscopy, Mass 
spectroscopy, NMR and Elemental Analysis revealed that the two types of quinine tablets 
contain metronidazole instead of quinine. For Holden Medical (Lelystad-The Netherlands) 
quinine tablets samples of the second case, the average weight cannot cause suspicion to poor 
quality since it was higher than the declared active ingredient’s amount. However, the UV 
spectrum has confirmed substitution of quinine sulfate by metronidazole. Something 
surprising is that the three fake quinine tablets despite their different shapes, color, and names 
(labelling) have the same wrong ingredient metronidazole which is an antimicrobial, 
antiprotozoal/anti-amoebic. On the other hand, this is very cunning from counterfeiters as 
metronidazole is relatively bitter like quinine, but more than ten times cheaper [21]. 
 
Quantitative analysis of metronidazole in HOLDEN MEDICAL (WEZEP-THE 
NETHERLANDS) and ELYS CHEMICALS (NAIROBI-KENYA) quinine tablets revealed 
that not only counterfeiters have used a wrong active ingredient, but also the products are 
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under-doses. This may refer to thinking about falsification of the active ingredient during 
production or falsification during packaging and labelling. Hence, several public health 
consequences may be possible for consumers such as the failure in malaria treatment, 
development of drug resistance for plasmodium, increase of morbidity and mortality due to 
malaria, etc. 
 
After noticing that the products were counterfeit and therefore dangerous to the public health, 
immediate alerts were sent to the vendors, the Pharmacy Task Force of the Ministry of Health 
(Rwanda), and to the National Procurement and Distribution Center for appropriate measures 
against these products; but also for careful control of other medicines that would be 
circulating in the country from the same manufacturers or distributors. 
 
Concerning the other antimalarial samples, even if visual inspection was not satisfying, the 
declared active ingredients were confirmed to be present at the expected and declared content. 
However, note that each medicine should comply with all required quality specifications for 
safe use. 
 
From this study, one can notice how advanced analytical techniques such as HPLC, Raman 
spectroscopy, mass spectroscopy, NMR, and elemental analysis (CHNS) are complementary 
and efficient in the detection and characterization of unknown components in counterfeit 
medicines. One can also rely on the database of simple analytical technique such as the UV-
Vis spectroscopy that was successfully used to detect the second case of suspected Holden 
quinine sample. 
 
5. Conclusion 
 
A strategic approach to detect poor quality medicines and identify unknown components in 
counterfeit antimalarial medicines has been applied in this study that allowed detection of 
several cases. Some of them were detected by means of simple and affordable tools such as 
visual inspection and tablets weighing, whereas in other cases it was necessary to exploit 
complex tools namely pharmacotechnical and analytical ones. The latter were applied for 
deep analyses in order to evaluate the quality of three quinine sulfate tablets samples that 
were found containing metronidazole instead of quinine. Timely alerts were sent to all 
concerned parties, medical and pharmaceutical, based on scientific evidences found for 
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appropriate measures against the spread of the detected harmful products. In fine, the study 
results illustrated and highlighted the necessity to strengthen National Medicines Regulatory 
Authorities, especially in developing countries in order to ensure among other responsibilities 
that all distributed medicines are of the required quality, safety and efficacy. 
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APPENDIX 
 
 
Figure A1. Picture of HOLDEN MEDICAL (WEZEP-THE NETHERLANDS) fake quinine 
sample. (a) Sample labeling information on a “cubical plastic box”; (b) Packed biconvex 
yellow tablets without a break line; (c) Logo of either the manufacturer or distributor (not 
specified!); (d) Logo of HOLDEN MEDICAL (picked from internet for comparison: 
http://www.holdenmedical.com/web/show/contact), last visited on Sept 12
th
, 2014. 
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Figure A2. Picture of HOLDEN MEDICAL (LELYSTAD-THE NETHERLANDS) fake 
quinine tablets sample. (a) Sample labeling information on a “cylindrical plastic box”; (b) 
Packed white flat-faced bevel-edged bisect tablets; (c) Logo of either the manufacturer or 
distributor (not specified!). 
 
 
 
Figure A3. Picture of ELYS CHEMICALS (NAIROBI-KENYA) fake quinine tablets 
sample. Note: The picture was taken after the friability test. 
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PART V - GENERAL DISCUSSION 
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This thesis was made possible conducted under the methodology described in Chapter III, and 
the following key activities were performed: 
 
V.1 Selection of therapeutic classes for study  
 
Different sources of information on the use and management of medicines mainly in Rwanda 
were exploited to know which therapeutic classes are mostly used and which medicines are 
widely consumed in order to select the ones that our thesis had to focus on.  
 
We consulted the Pharmacy Department of the Ministry of Health, and pharmacists working 
in the private sector and public institutions who kindly shared different lists of medicines they 
use to supply their clients. In addition, other useful information were obtained from different 
reports published in the websites of the Rwandan government and international health-related 
organizations such as the World Health Organization, the Global Fund to fight AIDS, 
tuberculosis and malaria, the Management Sciences for Health, the Bill & Melinda Gates 
Foundation, the Clinton Health Access Initiative, the Médecins Sans Frontières, etc. On this 
basis, antiretroviral and antimalarial medicines were obviously the most appropriate 
candidates for our study due to their wide use and high risk to counterfeiting. The targeted 
molecules are also mentioned in the national lists of essential medicines or other medicines 
officially authorized in Rwanda (cf. [16-18] on p. 78).  
 
V.2 Selection of analytical technique  
 
Normally medicines and related raw materials have dedicated analytical methods. It should be 
noted that in some circumstances there is need to combine several techniques in order to 
assess the identity and assay of a given sample in complicated situations such as complex 
samples, and counterfeit medicines whose real composition is never known either 
qualitatively or quantitatively before testing. 
 
The choice of HPLC technique was very helpful due to its very high sensitivity, selectivity 
and accuracy. It is also a powerful analytical technique for simultaneous analysis of several 
compounds in samples, widely recommended in pharmacopoeias, well known in different 
laboratories across the world, and whose equipment are available in Rwanda. Kovacs et al. 
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[30] (cf. p. 31) have also confirmed that HPLC could be considered as first choice analytical 
technique in drug analysis in our countries.  
 
V.3 Methods development 
 
The new methods were developed thanks to the Design of experiments – Design space (DoE-
DS) methodology explained in Part I.3 (cf. p. 23) for the methods that imply simultaneous 
analysis of several compounds such as the screening methods. 
 
DoE methodology is a systematic approach used to investigate the factors effects and 
interactions between them by modifying multiple factors at time. It is time and cost efficient 
methodology. Then, DSs defined as “multidimensional combination and interaction of input 
variables that have been demonstrated to provide assurance of quality” are computed from the 
collected data of applied experimental designs. It should be noted that DoE is needed to 
define DS and that performing analysis within DS is not considered as a change, thus DoE-DS 
methodology ensures the robustness of the developed methods, that is an another advantage in 
the frame of geographic method transfer. 
 
To realize our DoE, the studied key variables (analytical factors or parameters) were pH of 
the aqueous mobile phase, temperature (T°) and gradient time (TG) as basically having very 
significant impact on the chromatographic behavior and that need to be optimized for better 
chromatographic results.  
 
As mobile phase, methanol and volatile buffer salts (ammonium formate, ammonium acetate, 
and ammonium bicarbonate) were mainly privileged for affordability and effectiveness in 
yielding good chromatographic results. Moreover, the volatile buffering salts present an 
advantage of being transferable to LC/MS systems for further analysis (if needed) after DAD 
detection. Then, classic reversed phase (C8 and C18) analytical columns were also privileged 
for their wide use in LC analysis, and availability on the market. In fact, by applying HPLC 
coupled with UV-Vis detector or DAD, we have assurance to identify a very wide range of 
basic, acidic, and neutral substances that possess chromophoric groups. This was 
demonstrated in Sections 1 and 2 of Results while checking the capability of the screening 
method of antiretroviral and antimalarial medicines, respectively. We extended the 
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methodology application in detecting other substances that are not expected to be in the 
original composition of medicines such as in case of counterfeiting or substandard, or 
withdrawal medicines in Rwanda.   11 antimalarial molecules were concerned as well as 14 
out of 15 NSAIs and 13 antibiotics. They were traced in the developed methods. Two 
counterfeit cases of fake quinine tablets and fake Coartem (artemether/lumefantrine) tablets 
were detected during sample analysis and well described in Sections 4 and 5 of Results.  
 
Sometimes there are useful analytical methods that can be developed without much effort, in 
particular for the analysis of few molecules in a sample. In this case, we used a simple 
methodological approach of simple adjustment or adaptation of preexisting methods related to 
the studied analytes. We were able to optimize and improve the working analytical conditions 
up to their suitability that were observed with desired separation results in few experiments 
without need of long and relatively complex design of experiments. 
  
V.4 Methods validation 
 
As explained in Part I.3 (cf. p. 23-24), methods validation is a requirement to guarantee the 
reliability of future analytical results, and we used the recommended ICH Q2R1 guidelines 
complemented by the Total Error strategy. The latter is a very practical statistical tool that 
helps assessing quickly and visually the fitness or ineptness of the methods to their intended 
use by comparing the experimental results with the required acceptable limits plotted in the 
accuracy profiles drawn from the validation results. 
 
Prior to the validation step, the development was extremely useful through DoE-DS 
methodology to demonstrate the selectivity of the methods considering the separation of 
analytes. Also, the pre-validation was carried out by assessing any interference checked with 
the chromatograms of sample, the reference substances, and the blank solutions. The retention 
times and UV spectra were taken into account. 
 
Method trueness was found very good for the two validated methods with relative bias values 
less than 2% to the targeted sample concentrations (100%) as well as the method precision for 
which the RSD values were less than 2.5% for both repeatability and intermediate precisions. 
These two validation parameters were obtained thanks to the accuracy of results as can be 
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observed in the accuracy profiles illustrated in Sections 1 and 3. Their tolerance intervals were 
included within the predefined acceptance limits of 5% and 10% according to the type of 
sample. The methods presented good linearity (with coefficient of determination (R
2
 > 0.99) 
and adequate slope and intercept. 
 
Method for quantitation of high amount does not need determining the LOD and LOQ. 
However, since we expected low dosage or contamination in the frame of counterfeit, 
falsification or degradation, these two parameters were determined. The LOQ (lower and 
upper) allowed us to fix the dosing range of the validated methods (for artesunate powder 
analysis, and for ARV tri-therapy (emtricitabine / tenofovir disoproxyl fumarate / efavirenz) 
in tablets. 
 
V. 5 Methods transfer 
 
We performed geometric transfers from long to shorter analytical columns in order to 
improve the sample analysis throughput by reducing the analysis time, and the volume of 
rejected wastes. It is also very important not only to keep efficient analytical methods, but to 
have fast ones especially while analyzing poor quality medicines or suspected ones in order to 
know as soon as possible if the analyzed samples comply with the required quality standards 
or not and therefore take appropriate measures as soon as possible in protecting the users.  
  
Then beside those geometric transfers, some methods have been successfully transferred from 
the developer laboratory in Belgium to Rwanda, and currently they are being used in routine 
analysis at the Laboratory of Analysis of Foodstuff, Medicines, Water and Toxicants 
(LADAMET / University of Rwanda) and at Rwanda Biomedical Center / Medical 
procurement and Production Division (RBC/MPPD). An extension of the methods transfer to 
other laboratories such as the National Quality Control Laboratory of medicines based at the 
Rwanda Standards Board (RSB) is also planned. All the developed methods shall serve a lot 
in the analysis of different antimalarial medicines and ARVs used in Rwanda. 
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V.6 Sample collection and application of the methods 
 
Antimalarial medicines were the most concerned by sampling because ARVs are generally 
procured from WHO prequalified manufacturers under strong quality assurance policies set 
by the key international donors that support and control more severely their procurement and 
distribution.  
 
Strategic sampling sites were selected in towns, suburbs, and country borders near Burundi, 
Tanzania, Uganda and the D.R. of Congo in order to collect samples from potential outlets 
such as pharmacies, hospitals, health centers, and tentatively informal supply channels that 
may be found during the sampling.  
 
Actually, the Rwandan Ministry of Health has the reputation to close down any 
pharmaceutical establishment that does not comply with the regulation in force, and in general 
there is no informal market of medicines in Rwanda except rare cases that may pass 
unnoticed. Then, the sampling technique was random sampling by considering different batch 
numbers, manufacturers, strength, and dosage forms (tablets, capsules, injectables, etc.). 
 
On the other hand, there are other samples of antimalarial medicines that were collected from 
Kinshasa (DRC) and Cotonou (Benin) in the frame of scientific collaboration, and they were 
added to the samples from Rwanda in order to assess their quality, and thus know whether 
they present potential public health risks if poor quality is discovered among them. 
 
V.6.1 Antiretroviral medicines 
 
Two fixed-dose combinations of emtricitabine, tenofovir disoproxyl fumarate and efavirenz, 
were collected from Rwanda and Benin. One of the two samples was composed by the three 
APIs, and the second by two.  
 
As presented in Section 1, the developed method helped to identify the three APIs (sample 
coded A), but unfortunately the content for two (emtricitabine and tenofovir disoproxil 
fumarate) failed to comply with the specifications (90.0 % - 110.0 %) at 80 ± 1 % and 85 ± 1 
%, respectively.  However, the content of those APIs in the other sample coded B, were 
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acceptable (93 ± 2% and 91 ± 1%), respectively. We realized that sample A had expired few 
months ago, and assume that this might be in relation with the loss of 15% or more on assay. 
In the other sample, even if results are acceptable, they are also nearer to 90%. 
 
V.6.2 Antimalarial medicines 
 
As presented in Sections 3 to 5, different samples of antimalarial medicines collected from 
Rwanda, DRC and Benin were successfully analyzed thanks to the developed and validated 
methods in this thesis, taking mainly advantage of their character of being simple and fast.  
 
In Section 3, three samples of Artesunate powder for injection sampled in Rwanda gave very 
satisfactory results at the level of 99 to 100% of the claimed nominal content. In Section 4, on 
the analysis of 9 samples of artemether / lumefantrine tablets sampled in the DRC and 13 
samples of the same Artemisinin-based combination therapy medicine sampled in Rwanda in 
very different generic formulations, 3 of the 9 samples from the DRC were found at risk of 
out-of-specifications either for underdose cases where one sample presented a result of 90.7 ± 
1.8% for artemether content, or for overdose cases where two samples presented 108.4 ± 1.8 
% and 109.4 ± 1.8 % for lumefantrine content. The other samples gave very satisfactory 
results comprised between the acceptance limits (90.0 % - 110.0 %), and public health 
authorities should enforce quality assurance and quality control policies to protect the 
population against poor quality medicines dangers. All 13 samples from Rwanda were found 
compliant with the specifications, but always attention and enforcement of QAQC policies are 
highly needed to prevent all medicines from counterfeiting or substandard. On the other hand 
however, the suspected batch of Coartem from Benin for being counterfeit was confirmed not 
containing any of the two expected active ingredients, and this is a very serious concern to the 
public health that needs national and international collaborations in controlling the supply 
chain of medicines and protecting the population against all dangers that may rise from the 
use of poor quality medications. Another successful application of these methods is presented 
in Section 5 where two types of quinine tablets sampled in Rwanda were detected not 
containing the declared active ingredient, but contained another substance that was later 
discovered to be metronidazole thanks to the use of other powerful analytical techniques. This 
case is also very alarming as the one of fake Coartem sampled in Benin, and it reveals the 
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gravity of the phenomenon of drug counterfeiting that must be fought severely by all, 
worldwide and jointly. 
 
V.7 Application of advanced techniques 
 
As aforementioned, among the analyzed samples were two types of Quinine sulfate 300 mg 
sampled in Rwanda whose one of them had a very abnormal average weight inferior to the 
declared content in quinine as active ingredient, and one sample of artemether / lumefantrine 
from Benin suspected to be counterfeit that were submitted to more complex analytical 
techniques in order to identify the nature of unknown compounds in their composition. 
Hence, the Raman spectroscopy, mass spectroscopy, NMR spectroscopy, and elemental 
analysis were used to supplement HPLC results and other basic tests carried out earlier.  
 
As described Chapter I, Raman spectroscopy is a vibrational spectroscopic technique capable 
of providing qualitative and quantitative information on the active pharmaceutical ingredients 
as well as on the composition of the sample matrices (excipients) that can be present in a 
variety of pharmaceutical formulations. This technique has advantages of being non-
destructive, fast, requiring little or no sample preparation, and it is environmental friendly. On 
the other hand, Mass spectrometry (MS) is a powerful analytical technique used to: (i) 
quantify known materials, (ii) identify unknown compounds within a sample, and (iii) 
elucidate the structure and chemical properties of different molecules with very high 
specificity. The complete process involves the conversion of the sample into gaseous ions, 
with or without fragmentation, which are then characterized by their mass-to-charge ratios 
(m/z) and relative abundances. Then, NMR which is another powerful analytical technique 
used in determining chemical molecular structures and capable of providing both qualitative 
and quantitative information on the studied analytes was used to complement the results 
obtained with the other techniques. 
 
These advanced analytical techniques were used to supplement each other, and they gave very 
conclusive results on the type of unknown compound in the two fake quinine samples, as well 
as the absence of the two declared active ingredients in the sample expected to contain 
artemether - lumefantrine.  
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However, note that it is not mandatory to use several advanced analytical techniques as long 
as one or two of them can give satisfactory information to know the real identity of the 
unknown compound(s). Note also that the identification of unknown compounds can be fast if 
there are rich spectral libraries to consult and compare with the unknown sample results, but it 
is always necessary to close the testing with the analysis of the sample vs the reference 
substance of the product revealed to be the unknown analyte, and confirm the similarity.  
 
V.8 Results reporting  
 
Finally, when the quality control is finished and that the results are ready, they should be 
communicated as soon as possible to all concerned persons and to health authorities whenever 
necessary to allow taking appropriate measures timely, especially in case of poor quality 
products that must be recalled for destruction. Normally, the responsible health authorities use 
rapid alerts by media (radio, TV, SMS, internet, etc.) in order to spread the information to the 
largest number of the population.  
 
For example, the detected fake quinine tablets that contained metronidazole instead of quinine 
were communicated to the Pharmacy Department of the Ministry of Health in Rwanda and to 
the national store of medicines (RBC/MPPD) to allow them knowing the problem and do the 
necessary actions accordingly. They were also informed about the fake Coartem product not 
containing any of the declared active ingredients in order to check whether it has not been 
supplied in the country even though the samples was collected from Benin. 
 
Our scientific collaborators in the DRC and Benin, were also informed as soon as the 
alarming results were confirmed on the fake medicines, in order to inform the competent 
authorities in their countries for appropriate measures timely.  
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VI.1 General Conclusion 
 
Since one of the major problems of counterfeit medicines is in direct relationship with the 
health of the population, the main purpose of this thesis was to contribute to the protection of 
public health in Rwanda. 
 
This main objective was split into four specific objectives carried out through our work and 
based on two pharmacological classes of medicines, the antiretroviral (ARV) and 
antimalarials. Those are vital medicines used in developing countries in the treatment of the 
two pandemic diseases, HIV and malaria, for which any lack of active ingredient, below or 
overdoses, substitution or degradation, will have a direct negative impact on health of 
population. 
 
On basis of method lifecycle strategy, the first part of our contribution was devoted to the 
development of reliable generic analytical methods for the screening of the two groups of 
medicines cited above, which for remind are largely used in Rwanda.  
 
In this way, we successfully developed generic LC methods for analysis of 18 ARVs (namely 
the ABC, ddI, EFV, FTC, IDV, 3TC, LPV, NFV, NVP, RTV, SQV, d4T, TDF, AZT, RAL, 
ATZ, DRV, ETV) and 4 major excipients (NpG, NpS, BHA and BHT) by applying DoE/DS 
methodology. At first 15 of them and 4 excipients were selected for optimization using D-
optimal design involving column temperature, gradient time and pH of buffer solution as 
factors under investigation. Only the two later factors had significant effects on peak 
separations within the investigated domain. At the end of Monte Carlo simulations, this 
screening method proved to be able to separate simultaneous analysis of 19 compounds using 
as mobile phase a mixture of methanol and 10 mM ammonium hydrogen carbonate buffer. In 
the same configuration, we developed other methods for the analysis of ARVs in solid and 
liquid dosage forms.  
 
Always in the same context, another of our contribution was the construction of DoE-DS 
knowledge domain for ARVs. Indeed, this tool is very useful since one can use it in the 
prediction of other optimal analytical conditions without performing any other experiments, 
for example the case for the analysis of any other fixed-dose combination or mono-
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component of ARV active ingredient with one or more of the four studied excipients. This 
part is described in the section 1 of Results. 
 
Concerning the antimalarial medicines, we exploited a DoE-DS knowledge domain 
previously elaborated by previous PhD-students in the Laboratory of Pharmaceutical 
Analytical Chemistry. Twelve compounds including eight active ingredients (arteether, 
artemether, artesunate, atovaquone, lumefantrine, mefloquine, proguanil, quinine) and four 
excipients (BHA, BHT, nipagin and nipasol) were able to be separated by an overall 
screening method besides a sub-screening method for the analysis of quinine, artemether and 
lumefantrine in liquid dosage forms containing the four excipients, and a generic sub-
screening method for the analysis of quinine, arteether, artemether, and artesunate in 
injectable forms. This part was developed in the section 2 of Results. 
 
In section 3 of the Results, we also developed simple isocratic methods thanks to methods 
adaptation or adjustments approach. Taking into account the advantages of isocratic methods, 
we were able to set up three generic methods for the analysis of (i) artesunate, arteether and 
artemether in injectable forms; (ii) artemether and lumefantrine in tablets; and (iii) quinine-
resorcin with major cinchona alkaloids (cinchonine, cinchonidine, quinidine, and 
dihydroquinine).  
 
To complete this part of the present thesis, the ability of the developed methods to quantify 
the targeted molecules with accuracy in routine was then demonstrated. By means of the total 
error strategy, we successfully performed the validation of the method for the combination of 
FTC/TDF/EFV in a fixed dose tablet (see section 1 of Results) that was applied in assay of 
those ARVs on real samples. In section 3 of the Results, we also presented the validation of 
the method for analysis of artesunate powder for injection as a new antimalarial medicine. We 
obtained an adequate accuracy profile clearly demonstrating its suitability according to its 
intended use.  
 
The third aspect of our contribution was devoted to the detection of several cases of 
counterfeiting. In the section 4 of Results, we showed how a counterfeit artemether / 
lumefantrine medicine was detected from people complaints after analysis with simple tests, 
namely the thin layer chromatography and disintegration test. Thanks to Raman spectroscopy 
and HPLC, this falsification hypothesis was confirmed. All these tests established the 
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unfortunate case of absence of both active ingredients in the sample collected from Benin, and 
the same batch was found in Gabon, Mali and Cameroun which means infiltration in different 
countries.  
 
Finally, in the section 5, we proposed a strategic approach to detect poor quality medicines. 
Stepwise, again counterfeit antimalarial medicines were detected by means of simple and 
affordable tools such as visual inspection and tablets weighing, followed by complex tools 
namely pharmacotechnique and analytical ones. The quality of three quinine sulfate tablets 
samples were found containing metronidazole instead of quinine. Through the network, 
timely alerts were sent to all concerned parties. 
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VI.2 Perspectives 
 
In future prospects, we plan to: 
 
 Complete the validation of the remaining developed methods before their use in routine 
analysis. We expect to do that locally in Rwanda, that will need to ensure adequacy of 
the obtained validation results through the training of analysts, and the qualification of 
available equipment; 
 
 Complete the transfer of the remaining methods from the University of Liège (Belgium) 
to Rwanda for efficient use in the quality control of antimalarial medicines and 
antiretrovirals (ARVs), especially in the frame of the analysis of suspected 
counterfeit/falsification batches. This will be an extremely important support to the 
health institutions concerned by HIV and malaria treatments; 
 
 Conduct as much as possible a large study on the quality assessment of different 
antimalarial medicines and ARVs used in Rwanda in both public and private sector, 
considering different aspects that can affect the quality of a medicine such as 
manufacturers (generics vs brand products), storage conditions, dosage forms, strength, 
etc. This kind of information is currently lacking in Rwanda and these studies will be 
conducted in close collaboration with the Ministry of Health. 
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English version 
 
This thesis is part of the fight against poor quality medicines and especially their spread in 
developing countries. Its main goal is to contribute to the protection of public health in 
Rwanda and neighboring countries given the danger that this type of medicines represents to 
the health of the population. This contribution focuses on the development of reliable and 
inexpensive analytical methods that can be used in Rwanda. The technique of high 
performance liquid chromatography has been selected driven by the availability of LC 
equipment at the local level. 
 
Two therapeutic classes have been selected, namely antiretrovirals and antimalarials. They are 
among the medicines whose pathologies are classified in the TOP 10 causes of death and 
disability in Rwanda, so very widely used and therefore potentially targeted by counterfeiters. 
Two approaches of methods development have been applied. A first more complex but rich in 
analytical information (retention times, UV-Vis spectra, light absorption and intensity of 
peaks, sensitivity to parameter variations, etc.) that required modeling and statistical 
processing based on the experimental designs whose results make possible to determine the 
design spaces in which the analytical parameters can vary without altering the quality of the 
expected results. Another simple approach was followed for the development of simple 
methods in isocratic mode from other methods that must be adjusted to obtain good results on 
the separation of the targeted analytes. This has been applied for antimalarials. One part of the 
the methods was validated using the total error strategy that includes the accuracy profile as a 
decision tool for compliance. 
 
Moreover, in support of HPLC, other orthogonal analytical techniques were used to confirm 
the cases of counterfeit samples. These are mainly the Raman spectroscopy, mass 
spectroscopy, and nuclear magnetic resonance. 
 
Thus in the Article 1, a general screening method for simultaneous analysis of 15 ARVs and 
4 major excipients was optimized on a C18 column; 100 x 4.6 mm, 3.5 μm (dp); a generic 
screening method for the analysis of ARVs in liquid dosage forms; and another method of 
analysis for solid dosage forms have been developed and optimized. Subsequently, a 
formulation of emtricitabine (FTC), tenofovir disoproxil fumarate (TDF) and efavirenz (EFV) 
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tablets was selected and fully validated under the analytical conditions of the method for solid 
dosage forms. Thanks to these methods, it is easy to detect counterfeits involving one or more 
of the studied analytes, but also other types of non-compliance such as overdoses or 
underdosages can be detected. 
 
In the Article 2, two general screening methods for simultaneous analysis of 8 antimalarial 
medicines used in Rwanda and 4 major excipients were developed and optimized on a C18 
column, 250 x 4.6 mm, 5 μm (dp) at the analysis times of 100 and 65 minutes per injection, 
and we preferred the shorter of the two methods (the one at 65 minutes) which was then 
geometrically transferred to the columns of 150 mm, 100 mm, and 50 mm of length in order 
to obtain shorter analysis times: 41.5 minutes on the 150 mm column, 23.3 minutes on the 
100 mm column, and 11 minutes on the 50 mm long column. 
 
In the Article 3, it is about simple development of methods through the adaptation or 
adjustment of other methods on less complex samples containing few analytes. In addition to 
this approach, another strategy based on sequentially followed experiments according to the 
obtained results has been applied, and we have developed three simple and rapid isocratic 
methods for the analysis of antimalarial medicines in less than 10 minutes by injection, or 
even less than 5 minutes.  
 
The Articles 4 and 5 deal with the applications of already developed methods. The Article 4 
is about an application of the method for analysis of artemether/lumefantrine in various 
generic forms commonly marketed in Benin, the Democratic Republic of Congo and Rwanda 
in tablets forms. The first part of analysis was done in Benin using conventional techniques 
based on thin layer chromatography, disintegration and uniformity of mass tests. 
Subsequently, a sample was suspected to be counterfeit due to lack of characteristic spots of 
both analytes and abnormal disintegration time of more than 3 hours without effect. This 
sample was analyzed with other artemether/lumefantrine tablets collected in the DRC and 
Rwanda, and HPLC test results revealed that the Beninese sample was a fake medicine 
containing neither artemether nor lumefantrine! This counterfeit has been confirmed by 
Raman spectroscopy. As for Article 5, we had a case of samples of quinine tablets whose 
HPLC results revealed the absence of quinine as the declared active ingredient, but the 
substitution with another compound which was later elucidated with advanced spectroscopic 
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techniques namely the Raman, NMR and mass spectrometry. The substituting molecule was 
surprisingly the metronidazole !  
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Version en français 
 
La présente thèse s’inscrit dans le cadre de la lutte contre les médicaments de qualité 
inférieure et plus spécialement leur propagation dans les pays en développement. Elle vise 
comme but principal de contribuer à la protection de la santé publique au Rwanda et les pays 
voisins étant donné le danger que ce genre de médicament représente sur la santé des 
populations. Cette contribution est centrée sur le développement de méthodes analytiques 
fiables, peu coûteuses, utilisables au Rwanda. La technique de la chromatographie liquide à 
haute performance a été sélectionnée vue la disponibilité d’équipements au niveau local.   
 
Deux classes thérapeutiques ont été sélectionnées à savoir les antirétroviraux et les 
antipaludéens. Elles font partie des médicaments dont les pathologies sont classées dans les 
TOP 10 des causes de décès et d’invalidité au Rwanda, donc très largement utilisés et par 
conséquent potentiellement ciblés par les contrefacteurs. Deux approches de développement 
des méthodes ont été appliquées. Une première plus complexe mais riche en information 
analytiques (temps de rétention, spectre UV-Vis, absorption de la lumière et intensité des pics, 
sensibilité des analytes aux variations des paramètres, etc.) qui a nécessité des modélisations 
et traitements statistiques basée sur les plans d’expériences dont les résultats permettent de 
déterminer les espaces de conceptions au seins desquels les paramètres analytiques peuvent 
varier sans altérer la qualité des résultats attendus. Une autre approche simple a été suivie 
pour le développement des méthodes simples en mode isocratique à partir d’autres méthodes 
qu’il faut ajuster pour obtenir de bons résultats sur la séparation des analytes étudiés. Celle-ci 
a été appliquée pour les antipaludéens. Une partie des méthodes a été validée au moyen de la 
stratégie de l’erreur totale qui inclue le profil d’exactitude comme outil de décision quant à la 
conformité.  
 
Par ailleurs, en appui à la CLHP, d’autres techniques analytiques orthogonales ont été mise à 
contribution dans le but de confirmer les cas des échantillons révélés contrefaits. Il s’agit 
principalement de la spectroscopie Raman, la spectroscopie de masse, et la résonance 
magnétique nucléaire. 
 
Ainsi dans l’Article 1, une méthode générale de criblage pour l’analyse simultanée de 15 
ARVs et 4 excipients majeurs a été optimisée sur une colonne de type C18 ; 100 x 4.6 mm, 
3.5 µm (dp) ; une méthode générique de criblage pour l’analyse des ARVs en forme 
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liquide ;  et une autre méthode d’analyse pour les formes solides ont été développées et 
optimisées. Par après, une formulation d’emtricitabine (FTC), tenofovir disoproxil fumarate 
(TDF) et efavirenz (EFV) comprimés a été sélectionnée et entièrement validée dans les 
conditions analytiques de la méthode pour les formes solides. Grâce à ces méthodes, on peut 
facilement détecter des contrefaçons impliquant un ou plusieurs des analytes étudiés, mais 
aussi on peut détecter d’autre types de non-conformité comme les surdosages ou sous-
dosages.  
 
Dans l’Article 2, deux méthodes générales de criblage pour l’analyse simultanée de 8 
antipaludéens utilisés au Rwanda et 4 excipients majeurs ont été mises au point et optimisées 
sur une colonne de type C18, 250 x 4.6 mm, 5 µm (dp) aux temps d’analyse de 100 et 65 
minutes par injection. Nous avons privilégié la plus courte des deux méthodes (celle à 65 
minutes) qui a été ensuite transférée géométriquement aux colonnes de 150 mm, 100 mm, et 
50 mm de longueur afin d’obtenir des temps d’analyse plus courts : 41.5 minutes sur la 
colonne de 150 mm, 23.3 minutes sur la colonne de 100 mm, et 11 minutes sur la colonne de 
50 mm de longueur.  
 
Dans l’Article 3, il s’agissant d’une simple mise au point des méthodes rendues possibles 
grâce l’approche d’adaptation ou ajustement d’autres méthodes sur les échantillons moins 
complexes contenant peu d’analytes. En plus de cette approche, une autre stratégie basée sur 
les tests séquentiellement agencés les uns après les autres selon les résultats obtenus a été 
appliquée, et nous avons développé trois méthodes d’analyse en mode isocratique simples et 
rapides pour l’analyse des médicaments contre la malaria en moins de 10 minutes par 
injection, voire même moins de 5 minutes. 
 
Quant aux Articles 4 et 5, ils portent sur des applications réelles des méthodes déjà 
développées. L’Article 4 est une application de la méthode d’analyse d’artémether – 
luméfantrine dans diverses formes de génériques couramment commercialisés au Bénin, au 
République Démocratique du Congo (RDC) et au Rwanda sous forme des comprimés. Une 
partie des échantillons était d’abord analysée au Bénin à l’aide des techniques classiques 
basée sur la chromatographie sur couche mince, et des tests de désintégration et uniformité de 
masse. Par après, un échantillon a été suspecté contrefait suite au manque des spots 
caractéristiques des deux analytes et au temps de désintégration anormal de plus de 3 heures 
sans effet. Cet échantillon a été analysé avec d’autres échantillons d’artémether – 
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luméfantrine comprimés collectés en RDC et au Rwanda, et les résultats d’analyse par CLHP 
ont révélé que l’échantillon du Bénin était un faux médicament ne contenant ni artémether ni 
luméfantrine !  Cette contrefaçon a été confirmée par la spectroscopie Raman. Quant à 
l'Article 5, nous avions un cas des échantillons de quinine comprimés dont les résultats HPLC 
révélaient l'absence de quinine en tant que principe actif déclaré, mais la substitution avec un 
autre composé qui a été élucidé après à l’aide des techniques spectroscopiques avancées dont 
le Raman, la RMN et la spectrométrie de masse. La molécule de substitution était 
étonnamment le métronidazole ! 
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